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Abstract 
Work presented in this thesis focuses on the application of signal amplification 
by reversible exchange (SABRE) to the hyperpolarisation of small molecules. 
The aim of this work was to develop the technique towards future biologically 
relevant applications through resolution of barriers currently preventing clinical 
relevance. Furthermore, applications to forensics were also investigated. 
SABRE currently almost exclusively utilises iridium-based catalysts, however, 
there are reports of the utilisation of cobalt and one mixed iridium/rhodium 
system. A range of rhodium based complexes, [Rh(IMes)(COD)Cl] (6), 
[Rh(ImNPri2)(COD)Cl] (7), [Rh(ItBu)(COD)Cl] (8) and [Rh(ICy)(COD)Cl] (9), 
were synthesised and evaluated for SABRE activity. Testing demonstrated 
that these species were unable to form stable dihydride species at room 
temperature and therefore the iridium complex [Ir(IMes)(COD)Cl] (4) was 
utilised for the remainder of the work. 
19F SABRE provides a versatile route for measurements in vivo due to the low 
background present within the body. This work assessed the hyperpolarisation 
of 2-, 3-, 4-, 3,5- and pentafluoropyridine (L2 – L6), that have been interrogated 
by SABRE to establish a theoretical understanding of their efficacy with 
respect to polarisation transfer. However, hyperpolarisation of L3, which 
yielded the highest enhancement, resulted in an antiphase signal which may 
lead to internal cancelation within a biological imaging context. Thus, Signal 
Amplification By Reversible Exchange in shield enables alignment transfer to 
heteronuclei (SABRE-SHEATH) was employed to generate an in-phase 
absorptive hyperpolarised signal. 
Recent studies have demonstrated 4 is cytotoxic, therefore the mounting of 
the catalyst on silica or polymer derived supports was evaluated for the 
generation of a HET-SABRE catalyst and hyperpolarisation reported for a 
heterogeneous system. The solids proved effective at scavenging the metal 
from solution, therefore, an evaluation of their potential efficacy for production 
of a biocompatible bolus following homogenous SABRE is presented. 2-(2-
pyridyl)ethyl - functionalised silica gel (S5) is reported to be the most effective 
4 
metal scavenger utilised, with results suggesting ~1g of S5 is capable of 
reducing the iridium content of a bolus from ~1005ppm to below background 
levels within 2 minutes. 
The hyperpolarisation of a range of fentanyl derivatives is F1-F5, including 
Mirfentanil (F5), a derivative with known biological activity. Both F2 and F5 have 
been detected within an excess of heroin. F5 was detected at a concentration 
of 81 μM in ~5 seconds when ~145 mM of heroin was present. Further to this, 
the 19F SABRE of a world health organisation essential medicine, 
voriconazole, is reported at a concentration ~4 times below current dosing 
guidelines.
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1. Introduction 
1.1. NMR 
A wide range of techniques are available in the field of sample analysis, 
however, while techniques such as infrared (IR) and ultraviolet (UV) 
spectrometry are useful for sample identification, these rely on a response 
factor. Therefore, the same concentration of two different samples may elicit 
different integrals. However, nuclear magnetic resonance (NMR), first 
reported in 1938 by Rabi et al.,1 eliminates this response factor meaning 
NMR may be used as a qualitative technique. The first bulk NMR samples 
were run in 1946, followed by the publication of the first spectrum, shown in 
Figure 1, by Arnold et al. in 1951.2, 3 
 
Figure 1. First published NMR spectrum by Arnold et al. showing the 1H 
spectrum of ethanol.2 
Development of NMR in the decades since has led to the discovery of 
chemical shift,4 as well as the ability to interrogate a range of nuclei including 
13C and 19F. However, despite magnet and probe improvements, the main 
limitation of NMR remains the inherent insensitivity of the technique. 
19 
The primary nuclei examined in the course of this work (1H, 13C and 19F) are 
all spin ½ nuclei meaning that, when placed within an external magnetic field, 
two discrete energy levels of +½ and -½ are generated. The population of each 
energy level is defined by the Boltzmann distribution. The number of nuclei 
populating each energy level is influenced by the strength of the external field, 
leading to an overall thermal polarisation level, which may be described 
utilising Equation 1. 
𝑃 =
𝛾ℎ𝐵0
2𝑘𝐵𝑇
 
Equation 1. Expression for calculating thermal polarisation. γ is the 
gyromagnetic ratio, h is Planck’s constant, B0 is the magnetic field to which 
nuclei are exposed to, T is the temperature and kB is the Boltzmann constant. 
In the course of an NMR experiment the populations of these energy levels 
oppose each other, meaning the signal observed is effectively based on the 
small excess in population of one of the energy states. This problem is 
exacerbated in nuclei such as 13C, which have a gyromagnetic ratio 
significantly smaller than that of 1H. Table 1 demonstrates the effect of field, 
gyromagnetic ratio and temperature on overall polarisation of a range of nuclei. 
Table 1. Polarisation values for 1H, 13C, 15N and 19F nuclei at different magnetic 
fields and temperatures.5 
Nucleus 
B0 = 1.4 T, T 
= 273 K 
B0 = 1.4 T, T 
= 298 K 
B0 = 9.4 T, T 
= 273 K 
B0 = 9.4 T, T 
= 298 K 
1H 5.24 x10-6 4.80 x10-6 3.52 x10-5 3.22 x10-5 
13C 1.32 x10-6 1.21 x10-6 8.85 x10-6 8.10 x10-6 
19F 4.93 x10-6 4.51 x10-6 3.31 x10-5 3.03 x10-5 
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1.2. Hyperpolarisation 
Hyperpolarisation methods attempt to overcome the inherent low sensitivity of 
NMR through an increase in the population of one energy state relative to the 
other in order to obtain a greater observed signal. A range of techniques may 
achieve this, which are described herein. 
1.2.1. Brute force 
Brute force, first reported by Abragam et al. in 1958,6 centres around 
manipulating the terms of Equation 1, rather than attempting to create a non-
Boltzmann spin distribution. This technique maximises the Boltzmann 
distribution through low temperature and high field measurement. For 
example, for 1H nuclei at 4 K and 9.4 T the polarisation is 2.4x10-3, which is 
two orders of magnitude larger than at 298 K. Increasing the field strength to 
20 T results in a ~50% increase in polarisation to P = 5.11x10-3. 
Brute force polarisation also takes a long time for polarisation to develop as at 
low temperatures nuclear relaxation is significantly slowed due to the loss of 
molecular motion.7 However, this limitation may be overcome by making use 
of low field thermal mixing in order to transfer polarisation from briskly relaxing 
nuclei such as 1H to slower relaxing nuclei such as 13C. This obstacle may also 
be negated with the addition of relaxing agents into the sample. However, 
there are practical and cost limitations to the application of this technique. For 
example, superconducting magnets required to generate strong fields are 
expensive and low temperatures may not be applied to in vivo magnetic 
resonance imaging (MRI) measurements due to patient wellbeing. Resultantly, 
brute force techniques have largely been superseded by other 
hyperpolarisation techniques that show greater potential for biological 
measurement. 
1.2.2. Dynamic Nuclear Polarisation 
Dynamic Nuclear Polarisation (DNP) was first proposed by Overhauser in 
1953.8 This technique involves the transfer of polarisation from a radical 
species to the substrate of interest via microwave irradiation near the electron 
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paramagnetic resonance (EPR) transition.9 This process takes place at a 
relatively low temperature, typically between 2 K and 100 K, with an efficiently 
vitrified sample ideal for polarisation transfer.10 Following polarisation transfer, 
the sample is briskly thawed and transferred to a suitable measurement field 
where the hyperpolarised state may be interrogated. Care must be taken 
during the dissolution of the vitrified state that the process occurs faster than 
the nuclear relaxation process. Relaxation may be exacerbated by high levels 
of radicals present in the sample, meaning sample design is a trade-off 
between high polarisation levels and longevity of the hyperpolarised state. 
Polarisation transfer takes a significant length of time, traditionally taking 
hours, though recent work has demonstrated polarisation transfer times of 
under an hour.11 
Although very high signal enhancements, in excess of 10,000 times, may be 
attained utilising DNP, the technique is very expensive as it requires 
specialised equipment and high cryogen usage while only allowing low sample 
throughput. In contrast, the more recently discovered parahydrogen 
techniques require less infrastructure and allow for faster sample preparation. 
1.2.3. Parahydrogen techniques 
Parahydrogen techniques are used to create a non-Boltzmann distribution of 
spins in the sample. The two main techniques are parahydrogen induced 
polarisation (PHIP) and the focus of this work, signal amplification by 
reversible exchange (SABRE). Both of these techniques make use of 
polarisation derived from one of the spin isomers of hydrogen, 
parahydrogen.10 
1H is a spin-½ nucleus and has two spin-states, +½ or −½, written as α or β 
respectively. As hydrogen is found as dihydrogen (H2), these states may 
combine in four possible combinations as αα, (αβ - βα), (αβ + βα) and ββ; of 
these states three do not represent a change in the sign of the overall 
wavefunction and can be considered symmetric: these are αα, (αβ + βα) and 
ββ. These symmetric forms of H2 are referred to as orthohydrogen and hence 
this is the triplet spin isomer. This spin isomer can be observed in the NMR 
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experiment. The remaining state, (αβ - βα), is antisymmetric with respect to 
sign change and may be referred to as parahydrogen. Parahydrogen is not 
observable in the NMR experiment. At room temperature roughly 75% of H2 is 
found as orthohydrogen with the remaining 25% being parahydrogen. 
Parahydrogen is the more stable of the spin isomers due to Pauli’s exclusion 
principle stating that the overall wavefunction (Ψ) of H2 must be antisymmetric. 
This wavefunction is a combination of translational, electronic, vibrational, 
rotational and nuclear contributions: 
Ψ =  ψ(translational)ψ(electron)ψ(nuclear)ψ(rotational)ψ(vibration) 
Equation 2. Expression of the wave function of H2. 
The translational, electronic and vibrational elements of this wavefunction are 
always symmetric, therefore, for the overall expression to be antisymmetric 
the nuclear and rotational functions must have different symmetry. Due to its 
symmetrical rotational states orthohydrogen must have an antisymmetric 
nuclear state, J = 1, 3, 5… conversely parahydrogen with its antisymmetric 
rotational function must be found in a symmetrical nuclear state represented 
by J = 0, 2, 4… As parahydrogen may access the more stable J = 0 nuclear 
state, this is demonstrated in Figure 2. 
  
23 
 
Figure 2. The spin combinations of ortho and para hydrogen demonstrating 
that parahydrogen occupies a lower energy.12 
As parahydrogen is more stable it is, therefore, found in a higher proportion 
at lower temperatures, this trend has been evaluated experimentally by 
Duckett et al. and is demonstrated in Figure 3. 
 
Figure 3. The proportion of parahydrogen and orthohydrogen over a range of 
temperatures based on data collected by Duckett et al.13 
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Unfortunately changing two states within the wavefunction is spin forbidden, 
meaning that an interconversion catalyst such as Fe2O3,14 charcoal,15 or 
silica/FeCl3,16 is required in order to generate parahydrogen at low 
temperatures.17 However, this transition being forbidden means once 
parahydrogen is generated it may be stored at room temperature, provided it 
is isolated from any suitable interconversion catalyst.18 
1.2.4. Parahydrogen induced polarisation (PHIP) 
Proposed in 1986 by Bowers et al., PHIP makes use of parahydrogen in a 
hydrogenation reaction targeting an olefin containing substrate to achieve a 
non-Boltzmann hyperpolarised state.19 The same group demonstrated this 
effect the following year making use of Wilkinson’s catalyst ([RhCl(Ph3)3]) with 
parahydrogen added to the sample within the magnetic field used for 
measurement. This approach to PHIP became known as PASADENA 
(Parahydrogen And Synthesis Allow Dramatically Enhanced Nuclear 
Alignment) and generated a mixture of in and out of phase signals in the 
acquired spectra.20 In the same year another report conducted 
parahydrogenation at low field before rapid transport to a higher field for 
measurement; this process resulted in in-phase signals and was therefore 
differentiated from PASADENA and instead termed ALTADENA (Adiabatic 
Longitudinal Transport After Dissociation Engenders Nuclear Alignment). 
PHIP is used as a general term to describe both approaches. 
Despite enhancement levels of several hundred times being demonstrated,21 
the requirement for a suitable hydrogen acceptor presents an important 
limitation of PHIP. This limitation has led to the need to develop a 
parahydrogen technique which could allow substrate polarisation without 
hydrogenation. 
1.2.5. Signal amplification by reversible exchange 
(SABRE) 
First reported by Adams et al. in 2009, SABRE demonstrated that the 
simultaneous reversible binding of parahydrogen and the substrate of interest 
to a metal could facilitate polarisation transfer onto the substrate.22 This 
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hyperpolarisation method means there was no chemical modification of the 
substrate as polarisation is transferred from parahydrogen derived hydrides to 
the analyte via a J-coupling network at low magnetic fields. This effect was 
first demonstrated making use of [Ir(H)2(PCy3)(substrate)3] which is formed 
following the reaction of the pre-catalyst, [Ir(COD)(PCy3)(MeCN)][BF4], where 
COD is 1,5-cyclooctadiene, with parahydrogen in the presence of a suitable 
substrate. As the binding of both hydrides and substrate is reversible, this 
allows a build-up of polarised substrate molecules free in solution as shown in 
Figure 4; this means that for maximum polarisation build-up a commensurate 
hydride/substrate exchange rate with the SABRE active catalyst is ideal.  
 
Figure 4. Mechanism of polarisation transfer from parahydrogen to a metal 
bound substrate molecule when [Ir(IMes)(COD)Cl] is utilised as the pre-
catalyst. Hyperpolarised species are shown in red. 
However, overly fast exchange rates may decrease the observed substrate 
polarisation due to insufficient time for polarisation transfer to occur before the 
substrate dissociates from the active species. SABRE experiments are 
practically undertaken by the bubbling of parahydrogen through the sample or 
the shaking of a Young’s capped NMR tube with an atmosphere of 
parahydrogen. Since this first report, SABRE has been demonstrated on a 
wide range of molecules; a near exhaustive list is provided by Barskiy et al.23 
1.3. SABRE catalyst optimisation 
After the initial report of SABRE, the first generation of pre-catalysts continued 
to make use of iridium phosphine complexes, of these it was discovered that 
the most sterically hindering and electron donating ligand provided the best 
polarisation transfer to pyridine. These pre-catalysts do not themselves 
facilitate polarisation transfer, however, in the presence of a suitable substrate 
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and H2, an active species is formed. For instance [Ir(PCy3)(COD)Cl] forms the 
active species [Ir(PCy3)(substrate)3(H)2]. Having established that sterically 
demanding and electron donating phosphines optimised polarisation transfer, 
the development of catalysts was expanded to examine N-heterocyclic 
carbenes (NHCs) to establish if further polarisation enhancement could be 
gained. 
An NHC containing catalyst, [Ir(IMes)(COD)Cl] (IMes=1,3-bis(2,4,6-
trimethylphenyl) imidazole-2-ylidene) was synthesised.24 The exchange rates 
of both pyridine and hydrides were measured for both the SABRE active 
catalysts [Ir(IMes)(py)3(H)2]+ and [Ir(PCy3)(py)3(H)2][BF4] making use of 
exchange spectroscopy (EXSY). These exchange rates may be 
experimentally investigated making use of a modified nuclear Overhauser 
effect spectrometry (NOESY) pulse sequence known as exchange 
spectroscopy or EXSY.25 This sequence selectively pulses a spin transfer 
catalyst-bound peak, of either the hydride or ligand, then allows magnetisation 
transfer over a range of mixing times into the free species. Modelling the 
relative integrals of the free and bound peaks over a range of known mixing 
times allows the calculation of the rate of exchange for either the substrate or 
hydride (depending on which species was irradiated) for a given temperature. 
Conducting this experiment at a range of temperatures allows the construction 
of an Eyring-Polanyi plot.26, 27 
The use of an Eyring-Polanyi plot allows determination of ΔH, ΔS and ΔG 
values for a given exchange, enabling multiple ligand systems to be directly 
compared in energetic terms, as well as through inspection of the exchange 
rates. 
The exchange rate of pyridine with [Ir(IMes)(py)3(H)2]+ at 300 K was shown to 
be 11.7 s-1 and 9 s-1 for pyridine and hydride ligands respectively.24 This may 
be compared with an analogous pyridine exchange rate making use of PCy3 
as the electron donating ligand of 1.9 s-1.28 An increase in observed 
polarisation, when [Ir(IMes)(COD)Cl] was used as the pre-catalyst, was 
attributed to this faster, yet more commensurate, ligand and hydride exchange. 
This investigation also demonstrated that an increase in pyridine concentration 
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leads to a decrease in hydride exchange, supporting the mechanism of hydride 
loss following pyridine dissociation, as shown in Figure 7. 
In order to further optimise polarisation, a series of pre-catalysts with the 
general formula [Ir(NHC)(COD)Cl] were synthesised making use of the range 
of NHC’s shown in Figure 5.29 
 
 
Figure 5. Carbenes evaluated as potential SABRE pre-catalyst ligands.29 
It was noted that the exchange rates of both pyridine and hydrides increase 
with steric bulk of the NHC due to weaker binding to iridium. In both cases, 
IMes was near the middle of the range of NHCs in terms of exchange rate but 
led to the largest overall signal enhancement for pyridine. This suggests that 
an optimal exchange rate exists. This has led to [Ir(IMes)(COD)Cl] being used 
in the majority of reports since this study.27, 30-32 Additional studies into the 
modification of structures similar to IMes have further examined complexes 
with modification of substituent groups in the ortho, meta and para positions 
of the phenyl rings of the imidazole backbone as shown in Figure 6.33 
Asymmetric carbenes have additionally been examined and demonstrate 
potential for the polarisation of more sterically encumbered substrates.34, 35 
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Figure 6. NHC structures initially evaluated by Rayner et al.33 
Of the structures examined by Rayner et al. in Figure 6, IMes was shown to 
yield the highest polarisation levels when the [Ir(NHC)(COD)Cl] was exposed 
to 4,6-d2-nicotinate as the substrate and 3 bar of parahydrogen. Though 
Rayner et al. went on to demonstrate higher polarisation levels could be 
attained by the deuteration of IMes, this is due to a reduction in ‘dilution’ of 
polarisation with no protons present to potentially be polarised within the 
carbene. 
In general [Ir(IMes)(COD)Cl] is utilised within this work in order to allow 
comparison with the bulk of existing literature. This does, however, mean that 
polarisation levels reported here may be further optimised through the 
utilisation of a deuterated NHC. 
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1.3.1. Exchange Rates 
The mechanism of polarisation transfer to a reversibly bound ligand, typically 
an N-heterocycle such as pyridine, is shown in Figure 7.23 The rate at which 
the parahydrogen derived hydrides and the analyte exchange with the spin 
transfer catalyst have a major impact on polarisation transfer efficiency. Ideally 
these exchange rates would be commensurate, in order to enable the 
formation of a scalar coupling network between each pair of parahydrogen 
derived hydrides and each ligand pair, before dissociation and turnover to 
facilitate efficient build-up of a hyperpolarised bolus in solution. 
 
Figure 7. SABRE mechanism of polarisation exchange to a reversibly bound 
ligand (in this case pyridine (L)). L’ is a carbene, typically IMes. Hyperpolarised 
species are shown in red. Ligands trans to hydrides are shown with cyan 
and/or green bond pairs. 
The ligand trans to the NHC has been reported not to exchange which means 
the ligands trans to parahydrogen derived hydrides are the primary 
contributors to polarisation build-up.36, 37 This is fortunate as polarisation 
transfer is preferential to the ligands trans to a hydride (shown by cyan/green 
bond pairs in Figure 7) due to the scalar couplings present in this case (cis 
couplings are ~0 Hz).38 
Catalyst design may play a major role in the speed of these exchanges – in 
particular the identity of substituent L’, typically an NHC, from Figure 7 has an 
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impact on the speed of exchanges as a L’ with a significant buried volume 
increases steric encumberment, resulting in faster exchange. 
1.4. Metals utilised for the formation of SABRE-based 
catalysts 
As discussed in 1.3 the majority of recent SABRE reports make use of the 
iridium complex [Ir(IMes)(COD)Cl], however, other metals have been used to 
facilitate the SABRE process. 
 
Figure 8. Styrene products identified when the indicated cobalt catalyst, in 
conjunction with parahydrogen, was utilised. R = Ph and Mes = 1,3,6-
trimethylphenyl. 
Cobalt has been used to facilitate simultaneous SABRE and ALTADENA 
polarisation using a [(MesCCC)Co(N2)(PPh3)] (MesCCC = (bis(mesityl-
benzimidazol-2-ylidene)phenyl)) pre-catalyst, as shown in Figure 8.39, 40 The 
bulky strongly electron donating tridentate ligand means the SABRE active 
form of this species has been proposed as [(MesCCC)Co(H2)(substrate)]. 
Therefore, polarisation transfer may occur via a different mechanism when 
compared to the iridium-based complexes. 
Despite its common use in PHIP, there is only a single literature source for the 
use of rhodium in SABRE. This comes from a mixed [Rh(DPPB)(COD)]BF4 
(DPPB = 1,4-bis(diphenylphosphino)butane) and [Ir(PCy3)(COD)(Py)]PF6 pre-
catalyst system used to achieve 31P polarisation.41 However, the authors note 
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that, due to a complex equilibrium of multiple species within the sample, they 
were unable to assign polarisation transfer to a particular species. 
1.5. Nuclei used in SABRE 
SABRE has been applied successfully to a range of spin ½ nuclei utilising a 
range of substrates. Each NMR active nucleus SABRE has currently been 
applied to are discussed within this section. 
1.5.1. Proton 
A focus of extant literature has been the application of SABRE to acquire 1H 
NMR data. One of the key steps for 1H SABRE was the optimisation of the 
polarisation transfer field; for pyridine optimisation, an automated reaction 
setup was used which would conduct a SABRE experiment inside a variable 
field coil.27 This demonstrated optimal polarisation transfer in a field of 65-70 
G as shown in Figure 9. 
 
Figure 9. Field dependency of polarisation transfer to pyridine.27 
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Additional investigation made use of the same experimental setup but instead 
focused on the biologically relevant substrates isoniazid and pyrazinamide. 
Again a 65 G field was found to be optimal for the SABRE process. This study 
also demonstrated that polarisation is temperature and solvent dependent.  
1H polarisation has been successfully applied to a range of applications 
including detection and quantification of analytes at nanomolar 
concentrations.42 This high sensitivity means that SABRE is still highly 
effective at low detection fields (circa 1.4 T) such as those found in benchtop 
NMR instruments. This has been exemplified for 1H NMR reaction monitoring 
and in the acquisition of natural abundance 13C NMR spectra in a single 
scan.43-45 
Recently hyperpolarised signals equating to an overall polarisation of 50% in 
an optimised system have been demonstrated by Rayner et al.46 In order to 
achieve high polarisation levels Rayner et al. have deuterated all sites on IMes 
except the imidazole ring, partially deuterated the substrate (4,6-d2-nicotinate) 
to reduce polarisation acceptors and utilised 5.5 bar of parahydrogen which 
was enriched at 30 K for a very high parahydrogen content. This signal could 
be detected for ~2 mins demonstrating significant steps towards in vivo 
application. 
Work towards the application of SABRE in vivo has explored polarisation of 
amino acids as well as two small peptides.47 This work demonstrated it is 
possible to hyperpolarise all proteinogenic amino acids, in addition to two small 
peptides tested, though the authors note that water soluble catalysts would be 
ideal to undertake studies of amino acid and peptide analytes as they have 
poor solubility in organic solvents such as d4-methanol. This work was 
expanded upon by Ratajczyk et al.48 who have successfully demonstrated the 
hyperpolarisation of a range of SABRE labelled (using nicotinamide or 
isonicotinamide) peptides shown in Figure 10, though hyperpolarised signals 
were only observed for the label rather than the peptide chain. 
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Figure 10. Labelled peptides hyperpolarised by Ratajczyk et al.48 
A small number of low molecular weight drugs have also been polarised, such 
as pyrazinamide and isoniazid.49 Optimisation of the polarisation conditions for 
both drugs supported 1H polarisation being most efficient in a 65 G field with 
the largest enhancements being observed in d4-methanol as opposed to 
methanol, ethanol and DMSO (polarisation was observed to be inversely 
proportional to solvent viscosity). The polarisation was further optimised at 
greater than room temperature, with a temperature of 46.1°C showing optimal 
transfer for both drugs in all solvents tested except pyrazinamide when ethanol 
was used as a solvent which was optimised at 37.5°C. The polarisation 
optimisation at high temperature for these drug molecules, shown in Figure 
11, demonstrates a faster exchange rate is desirable in these systems to 
achieve the build-up of hyperpolarised free substrate in solution. 
  
34 
 
Figure 11. Effects of temperature and solvent on the hyperpolarisation of 
isoniazid.49 
1.5.2. Nitrogen 
15N labelled substrates have been successfully polarised, primarily making use 
of SABRE-SHEATH (SABRE in shield enables alignment transfer to 
heteronuclei). SABRE-SHEATH utilises a μ-magnetic shield to conduct 
SABRE experiments within a microtesla magnetic field.50 This technique 
created ~24% polarisation in metronidazole, an antibiotic.30 Combined with the 
relatively long relaxation times of 15N, this is an attractive approach for 
biological imaging with hyperpolarised signals detectable for over an hour in 
some applications.51 A theoretical basis for the effectiveness of SABRE-
SHEATH has been presented to support the increased 15N polarisation 
generated when SABRE is conducted within a magnetic shield.52  
The application of SABRE-SHEATH has been shown to increase 
enhancements measured for 15N,53-55 though studies have shown that short T1 
values in this field regime may limit the efficiency of polarisation build up when 
traditional iridium-based SABRE pre-catalysts are utilised.56 Despite this, 
SABRE-SHEATH has been shown to provide an efficient mechanism for the 
polarisation of long lived singlet states (13C2) due to the relative size of JCC 
compared to the hydride JHH in a micro-tesla field.57 Therefore, with rational 
substrate design, it seems likely that short relaxation times could be overcome. 
A selection of substrates that SABRE-SHEATH has been reported for is 
demonstrated within Figure 12. 
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Figure 12. Range of molecules hyperpolarised by SABRE-SHEATH.52-54, 57-59 
1.5.3. Carbon 
13C SABRE was included within the first report of SABRE by Duckett et al. in 
2009.22 Though enhancements reported have been lower than those reported 
for heteronuclei such as 15N, with polarisation levels of ~4.4% being reported,60 
13C has still been shown to be an effective tool for the detection of all carbon 
environments within a substrate such as nicotinamide within a single scan.61 
The effectiveness of 13C SABRE for the rapid acquisition of carbon NMR data 
has recently been exemplified for 4-methylpyridine with carbon present at 
natural abundance within a detection field of 1 T as shown in Figure 13.44 
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Figure 13. Spectra of 4-methylpyidine after 256 scans under thermal 
conditions (top) and after a single scan under SABRE conditions (bottom, 
scaled by x8). The SABRE sample is ~70 times less concentrated than the 
sample used for thermal data collection.44 
Duckett et al. have demonstrated that 13C polarisation levels of ~0.5% may be 
observed for T1’s of 186 ± 18 seconds within a ~10 mT field when substrate 
design is utilised in order to integrate 13C spin pairs within the substrate of 
interest.62 
1.5.4. Phosphorus 
31P SABRE was first reported in 2013.36 In this report triphenylphosphine and 
tricyclohexylphosphine were utilised as ligands. The complexes formed with 
these phosphines favoured acetonitrile and pyridine coligands trans to the 
hydrides with the phosphine bound trans to carbene due to the high buried 
volume of the ligand. The ligand being bound trans to the carbene, however, 
appears to have precluded ligand exchange with no exchange rate for PR3 
being reported in the complexes [Ir(IMes)(PR3)(Py)(Acetonitrile)(H)2] where 
PR3= triphenylphosphine or tricyclohexylphosphine. The ligand bound trans to 
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the carbene not exchanging has also been reported for other ligand systems.29 
This led to a relatively modest 31P enhancement of 30-fold when measured at 
a 9.4 T or 11.7 T field. 
A further report by Koptyug et al. did not utilise a carbene in order to enable 
PPh3 binding trans to hydrides.63 Instead, a polarisation transfer species 
[Ir(PPh3)3(H)2Cl] was generated in solution which enabled a 260 times 
enhancement for 31P when measured at 7 T. While this represents a significant 
increase in enhancement due to the enabling of ligand reversible exchange, 
the authors note that EXSY interrogation of the species does not show PPh3 
exchange at sites cis to the parahydrogen derived hydrides within the 
relaxation time of 31P magnetisation. 
Pyridine based ligands with phosphorous containing substituents were tested 
by Duckett et al. and demonstrated a 31P enhancement of up to 860 times at 
a 9.4 T or 11.7 T field for 3,5-bis(diethoxyphosphoryl)pyridine.64 Deuteration 
of the substituent ethyl chains resulted in this enhancement being further 
increased to 3588 times the thermal signal. Notably these substrates were 
characterised to form the traditional SABRE polarisation transfer species of 
[Ir(IMes)(L)3(H)2]. 
1.5.5. Silicon and Tin 
The low gyromagnetic ratios of 29Si and 119Sn, -8.47 and -15.97 MHz T-1 
respectively, compared to 42.58 MHz T-1 for 1H, lead to low sensitivity for these 
nuclei due to polarisation being proportional to γ (Equation 1). This low 
sensitivity is further exacerbated by a low natural abundance of 4.7% and 8.6% 
respectively for 29Si and 119Sn, leading to typical measurement times in the 
tens of hours for high signal-to-noise spectra of these nuclei. 
Olaru et al. have reported an investigation into the applicability of SABRE to 
these spin ½ nuclei.65 This has been conducted through the utilisation of 
pyrimidine labelled with a 29Si or 119Sn heteronucleus in the form of 5-
(tributylstannyl)pyrimidine (LSn) for tin and 5-(trimethylsilyl)pyrimidine (LSi) for 
silicon as shown in Figure 14. 
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Figure 14. Structures of 5-(tributylstannyl)pyrimidine (LSi, left) and 5-
(trimethylsilyl)pyrimidine (LSn, right) utilised for demonstrating the applicability 
of SABRE to 29Si and 119Sn. 
When [Ir(IMes)(COD)Cl] was utilised as the polarisation transfer pre-catalyst 
and exposed to LSi and LSn the complexes [Ir(IMes)(LSi)3(H)2]+ and 
[Ir(IMes)(LSn)3(H)2]+ were formed with hydrides present in their 1H NMR 
spectra at -22.44 and -22.06 ppm respectively. 29Si SABRE was observed 
making use of LSi and demonstrated a 200-fold increase in signal-to-noise 
compared with thermal conditions. 
119Sn SABRE was observed making use of LSn and optimised when a 
substrate loading of 17:1 substrate:[Ir(IMes)(COD)Cl] was utilised. This 
optimised system was responsible for a 772-fold enhancement which equates 
to a time saving of over 400 hours when compared to obtaining the same 
signal intensity under Boltzmann conditions. 
EXSY was utilised to give insight into the speed of hydride loss for these 
complexes with a hydride exchange rate at 295 K of 1.44 and 0.57 s-1 reported 
for [Ir(IMes)(LSi)3(H)2]+ and [Ir(IMes)(LSn)3(H)2]+ respectively. Notably, this is 
far slower than the equivalent exchange speed utilising pyridine as the 
substrate. The rate of hydride exchange may be increased through the usage 
of a carbene with a higher buried volume such as SIMes, which increases the 
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exchange rate at 295 K for hydride loss from 0.57 s-1 in [Ir(IMes)(LSn)3(H)2]+ to 
2.29 s-1 in [Ir(SIMes)(LSn)3(H)2]+. Increasing the exchange rate was, however, 
observed to be detrimental to observed polarisation levels which is postulated 
by Olaru et al. to suggest scalar coupling in this system between substrate and 
hydride is smaller in magnitude than in an analogous pyridine system. 
1.5.6. Fluorine 
Due to the high gyromagnetic ratio of 19F (94% compared to proton) and its 
100% natural abundance, this nucleus presents an attractive prospect for MR 
studies.66 19F is particularly attractive for in vivo imaging applications as there 
is minimal biological background signal and clinical MRI equipment may be 
easily adapted to detect 19F. This has led to the development of a range of 19F 
containing contrast agents, which are already detectable at millimolar levels 
when thermally polarised.67 The application of hyperpolarisation is hoped to 
potentially lower this detection limit by an order of magnitude. 
The application of SABRE to fluorinated molecules was first demonstrated by 
Duckett et al. in their 2009 initial report of SABRE.22 This report demonstrated 
a complicated antiphase signal which was polarised compared to thermal 
polarisation when 3-fluoropyridine was used as a substrate. It has been 
proposed that polarisation transfer occurs via a coupling system with JHF being 
similar to JHH. It is likely that a range of fluorine substrates could be polarised. 
However, Hovener et al. were unsuccessful in attempts to polarise 
pentafluoropyridine as a substrate when both [Ir(IMes)(COD)Cl] and 
Crabtree’s catalyst were used as the pre-catalyst.68 
Theis et al. have recently demonstrated 19F polarisation of ~0.3% (compared 
to ~50% demonstrated for 1H) for 3-fluoropyridine,46, 69 though Theis notes that 
only 50% parahydrogen was used, meaning that if 100% had been used this 
could lead to an effective polarisation of ~0.85%. While it is noted this 
polarisation is significantly lower than 1H and other heteronuclei, such as 15N,52 
it is hypothesised that this is due to the significantly lower T1 of 19F leading to 
signal loss during sample transfer prior to magnetisation read-out. 
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Theis et al. demonstrated that 19F SABRE results in an antiphase signal when 
conducted at earth’s magnetic field. Previous heteronuclei studies have 
demonstrated this due to intramolecular couplings;50 an antiphase signal 
would be less suitable for MR imaging as a smaller observation window may 
result in effective observed signal cancellation, negating some of the 
hyperpolarisation effect. However, SABRE-SHEATH has been applied to 
fluorine systems which, just like when SABRE-SHEATH is applied to 15N, 
results in an absorptive signal. In addition to 3-fluoropyridine, 
pentafluoropyridine and 2-fluoropyridine were also tested as substrates, 
however, both failed to demonstrate the SABRE effect. This is suggested to 
be due to steric effects. 
The application of 19F SABRE-SHEATH to MRI imaging has been successfully 
demonstrated as shown in  Figure 15. Finally, the application of hyperpolarised 
19F to pH detection was demonstrated. This is noted to be similar in capability 
to 15N while demonstrating a sensitivity >30 times larger than 1H NMR for 
changes in local pH. 
 
Figure 15. MRI imaging of 19F hyperpolarised 3-fluoropyridine compared to a 
thermally collected image under the same conditions at the same 
concentration.69 
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The combination of low background, high gyromagnetic ratio and relative ease 
of conversion for existing hardware to detect fluorine makes 19F an attractive 
prospect going forwards. In 2010 it was estimated that 20% of approved drugs 
contain fluorine and novel application of 19F SABRE to a drug currently on the 
market in addition to a new psychoactive substance (NPS) is presented in 
section 6.3.70 The relatively short T1 of these species currently presents a 
barrier to in vivo applications, however, methods for lengthening the relaxation 
time of SABRE substrates have been previously reported in literature.31  
1.5.7. Relaxation Rates 
Approaches have been reported which may enable the lengthening of 
relaxation time – in particular, it is important to note that the polarisation 
transfer catalyst (typically [Ir(IMes)(L)3(H)2]+) increases the speed of 
relaxation, known as T1.29 T1 or longitudinal relaxation describes the process 
by which magnetisation returns to thermal polarisation within an external 
magnetic field. Within the context of SABRE this process therefore describes 
how long the hyperpolarised state survives after polarisation transfer. 
Figure 16. T1 relaxation may be modeled as an exponential growth back to 
thermal equilibrium within an external magnetic field following the application 
of a 90º pulse. 
As shown in Figure 16 T1 may be described by the magnetisation (M) 
compared to the initial or thermal magnetisation (Mo) after a period of time t. 
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This means that after T1 63% of the hyperpolarised signal has relaxed back to 
thermal polarisation therefore a short T1 requires rapid interrogation of the 
hyperpolarised state. 
As the polarisation transfer catalyst facilitates T1 relaxation through spin lattice 
interactions the addition of a chelating agent, such as bipyridine (bpy) led to 
the formation of the species [Ir(IMes)(bpy)(H)2(L)]+, with nicotinamide being 
the ligand (L) in this report.31 This species was formed in ~1.2 s for a 97% 
conversion from [Ir(IMes)(L)3(H)2]+ meaning this method would be viable for 
rapid ‘quenching’ of SABRE after generating a hyperpolarised bolus. In this 
report 2,2’-bipyridine is bound bidentate trans to the hydride ligands and the 
remaining nicotinamide is bound trans to the carbene. Comparison of 
nicotinamide T1 values when the catalyst is not present, before catalyst 
deactivation and following catalyst deactivation demonstrated that 
deactivating the catalyst results in relaxation times comparable to that of 
nicotinamide without catalyst present as shown in Table 2. It is worth noting, 
however, that 4,4’-bipyridine has been SABRE hyperpolarised without any 
reported deactivation, meaning the binding mode of the ligand is important for 
deactivation.71 
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Table 2. Nicotinamide relaxation rates without catalyst present, before and 
after catalyst deactivation (at 9.4 T). 
 
Figure 17. Nicotinamide with proton environments labelled, T1 values for each 
environment are shown in Table 2. 
In addition to 2,2’-bipyridine, deactivation has been demonstrated making use 
of 1,10-phananthroline,31 bathophenanthrolinedisulphonic acid disodium salt 
(BPS),72 and with silica-based scavengers.73, 74 The deactivation and removal 
of the catalyst making use of silica scavengers is further discussed in 1.7.6. 
1.6. SABRE Reproducibility 
The SABRE process has a high degree of irreproducibility, in particular the 
‘shake and drop’ approach utilised within this work involves manual shaking of 
a Young’s capped NMR tube after the head space has been charged with 
parahydrogen. However, though this approach does not require specialised 
equipment, slight variations in height, angle and speed of shaking, in addition 
to the variable time of transfer before acquisition, may lead to a high degree 
of inconsistency. A variation of ±20% has been reported for the ‘shake and 
 T1 (s) 
Proton No catalyst [Ir(IMes)(L)3(H)2]+ [Ir(IMes)(bpy)(H)2(L)]+ 
H-2 43.1 7.0 38.0 
H-4 11.3 6.1 11.5 
H-5 13.5 3.7 14.0 
H-6 6.6 4.3 6.8 
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drop’ approach.61 This may be alleviated through bubbling of parahydrogen 
through the solution which may yield a significant increase in reproducibility at 
the cost of polarisation level due to the reduced vigour of interactions and the 
potential for line broadening if flow continues during the acquisition time.61, 75, 
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The traditional approach of utilising the stray field of a high-field NMR magnet 
in order to conduct polarisation transfer in a heightened magnetic field e.g. 65 
G has led to issues with being unable to regulate the polarisation transfer field 
closely. Recently this has been alleviated through the use of handheld 
permanent magnet arrays,77 or, as utilised herein, a tuneable electromagnetic 
coil where the polarisation transfer field may be set and controlled accurately. 
1.7. Towards in vivo application 
There are currently multiple challenges to be overcome before SABRE may 
be applied to in vivo imaging, amongst these are the need for polarisation to 
occur in a biologically compatible solvent and the expense/potential toxicity of 
catalyst injection. Parahydrogen hyperpolarisation techniques have recently 
been applied in vivo with PHIP being applied to 1-13C-phospholactate in vivo 
to successfully obtain hyperpolarised MR images of a mouse brain.78 
1.7.1. Progress towards aqueous SABRE 
Though SABRE has been optimised and found to be most efficient in d4-
methanol, this solvent is unsuitable for use in in vivo imaging.27, 33, 72, 79 
Solvents, such as D2O or ideally H2O, are better suited for biological 
applications. Progress has been made in making use of methanol/water 
mixtures to demonstrate SABRE; this has shown some activity for a limited 
range of analytes in mixtures of up to 90% water.80 This has been improved 
though the pre-activation of the pre-catalyst [Ir(IMes)(COD)Cl] in the presence 
of pyridine or nicotinamide and H2 in methanol or ethanol.81 Once activated in 
the presence of a suitable substrate and H2, the active species 
[Ir(IMes)(substrate)3(H)2] could be isolated and reconstituted in H2O – this 
yielded SABRE enhancements of roughly half of what could be achieved in d6-
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ethanol for nicotinamide, although this did demonstrate that SABRE in pure 
water solvent system was feasible. 
1.7.2. Water soluble catalysts 
In order to better study aqueous systems making use of SABRE, the synthesis 
of aqueous pre-catalysts has been a priority for several research groups. 
Fekete et al. successfully synthesised the pre-catalyst shown in Figure 18,82 
which facilitated a 750-fold enhancement of the proton environments in 
pyridine in d4-methanol after polarisation transfer at 60 G. In a partially 
aqueous media (67% D2O, 3% DMSO and 30% ethanol) an enhancement of 
9.4-fold was observed under the same conditions. DMSO was included to 
increase the solubility of H2. Enhancements for 4-hydroxypridine (22-fold) and 
oxazole (2.7-fold) were observed when making use of this catalyst in 70% D2O 
and 30% ethanol. 
 
Figure 18. Water soluble pre-catalyst synthesised by Fekete et al.82 
Other groups have also opted to modify the NHC of the pre-catalyst in order 
to include water-solubilising groups. In particular Spannring et al. have 
attempted to synthesise a water soluble pre-catalyst, [Ir(Itome)(COD)Cl], 
(Itome = 1,3‐bis(3,4,5‐trimethoxybenzyl)imidazole‐2‐ylidene) with the addition 
of methoxy groups to the NHC, demonstrated in Figure 19, however, this 
catalyst proved to be insoluble in D2O.83 The addition of the more sterically 
bulky 3,4,5-tri(diethyleneglycol)benzyl groups instead of the mesityl groups to 
give the pre-catalyst [Ir(IDEG)(COD)Cl], (IDEG = 1,3‐bis(3,4,5‐
tris(diethyleneglycol) benzyl)imidazole‐2‐ylidene), resulted in a 64-fold 
enhancement of pyridine in D2O with polarisation transfer in an 80 G field and 
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measurement in a 300 MHz field. This demonstrated that, despite the low 
solubility of H2 in water, SABRE may occur. 
No SABRE is observed for [Ir(IMes)(COD)Cl] in D2O, unless the catalyst is 
activated in an organic solvent and then isolated prior to reconstituting in 
water. Despite this, it has been demonstrated that replacing COD with a 
suitable diol such as CODDA (CODDA=1,2-dihydroxy-3,7-cyclooctadiene) 
allows catalyst activation and SABRE in an aqueous environment, forming the 
same catalytic [Ir(IMes)(substrate)3(H)2]+ species.84 
 
Figure 19. Structures of the pre-catalysts [Ir(Itome)(COD)Cl] and 
[Ir(IDEG)(COD)Cl].83 
1.7.3. SABRE-RELAY 
SABRE-RELAY was first reported in 2018 by Duckett et al. and demonstrated 
a route for the hyperpolarisation of previously inaccessible substrates, such as 
alcohols, carboxylic acids and amines.85 Figure 20 shows the SABRE-RELAY 
mechanism compared to the traditional SABRE approach, in SABRE-RELAY 
a carrier substrate such as ammonia is polarised, which then transfers 
polarisation to a secondary substrate via proton exchange or binding to a 
secondary metal complex.86 Notably, the relay approach provides access to 
many of the common substrates typically examined via DNP (e.g. pyruvate, 
glucose, urea), therefore Duckett et al. suggest that this may provide a cost 
effective route to polarise these substrates.87 The desired hyperpolarised 
substrate does not bind to the polarisation transfer catalyst; this has previously 
been achieved via molecular cleavage following polarisation transfer, 
rendering this approach irreversible compared to the relay method.88 SABRE-
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RELAY has been employed for the hyperpolarisation of 19F and 31P, through a 
proton exchange mechanism, of 2,2-difluoroethanol and 
diethyl(hydroxymethyl) phosphonate respectively.89 
 
Figure 20. Mechanisms of SABRE (top) and SABRE-RELAY (bottom).85 
Despite theoretically allowing access to a wider range of biologically relevant 
molecules such as amino acids, Duckett et al. note that a small level of 
contaminant H2O may drastically reduce the hyperpolarisation levels attained 
as proton exchange may then occur with the solvent. A sample of 1-propanol 
in dichloromethane-d2 (1 μL), [Ir(IMes)(COD)Cl] and a polarisation relay 
substrate, d7-BnNH2, initially demonstrated an enhancement of 537-fold for 
OCH2. Addition of 1 and 5 μL of dichloromethane-d2 reduced the polarisation 
level attained to 48- and 11-fold respectively due to spin dilution and reduced 
polarisation transfer efficiency between amine and alcohol, suggesting this 
technique is highly sensitive to small changes in solvent. The author postulates 
this may potentially be alleviated through the utilisation of a mixed solvent 
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system such as that employed in catalyst separated hyperpolarisation through 
SABRE (CASH-SABRE), discussed further in 1.7.5. 
1.7.4. Catalyst toxicity 
Unfortunately, Duckett et al. have demonstrated the toxicity of the most 
common SABRE reaction mixture (utilising the pre-catalyst [Ir(IMes)(COD)Cl]) 
through cell line studies such as that summarised in Figure 21.72 This toxicity 
may be primarily attributed to the iridium complex itself as an evaluation of the 
solvent system demonstrated that over a 24 hour period no cell viability was 
lost when a 30:70 mixture of deuterated ethanol and deuterated water 
respectively was utilised to make up 10% of the solvent within the cell medium. 
Evaluation of d2-methyl nicotinate demonstrated slight toxicity within a 6 hour 
timeframe, however, both cell lines remained in excess of 80% viable within 
this time period, even at 20 mM concentrations. The dramatic loss in viability 
for the full SABRE reaction mixture may, therefore, be attributed to the iridium 
species.  
 
Figure 21. Cell viability of cell lines A549 (A) and MCF7 (B) following exposure 
to 0, 1.25, 2.5, 5 and 10% bolus volumes of a SABRE reaction mixture 
containing [Ir(IMes)(COD)Cl] (5 mM), d2-methyl nicotinate (20 mM) in d6-
ethanol:D2O (30:70) after 1, 6 and 24 hours.72 
Changing the carbene identity associated with the pre-catalyst or utilisation of 
a significantly different species such as 
[Ir(H)2(Nam)(solv)(mPTA)(tmx)](I)(CF3SO3)], (Nam = 4,6‐nicotinamide, mPTA 
= methylated 1,3,5‐triaza‐7‐phosphaadamantane, tmx = tetramethylxanthine) 
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still demonstrated a significant loss of cell viability, suggesting the iridium itself 
is responsible for the cytotoxicity observed.79 
Due to the toxicity of the most effective reported polarisation transfer catalyst, 
[Ir(IMes)(COD)Cl], there has been a recent focus in literature to remove the 
catalyst from a bolus, be that through phase separation such as CASH-
SABRE, heterogeneous SABRE (HET-SABRE) or through catalyst 
sequestration through heterogeneous scavenging. 
1.7.5. CASH-SABRE 
CASH-SABRE, reported by Duckett et al. in 2017, utilises a mixed solvent 
system such as CDCl3/D2O where SABRE occurs within the organic CDCl3 
phase and the substrate, for instance pyrazine, resides primarily within the 
aqueous phase (~77% in aqueous phase under thermal conditions).90 This 
approach is similar to a phase separation approach, which has been reported 
for the preparation of an in vivo suitable aqueous bolus for PHIP.91-93 
Duckett et al. note that though chloroform is partially soluble in water, an 
assessment 10 seconds after phase mixing resulted in 0.08% CDCl3 within the 
water phase and doping of D2O with 0.16% w/v NaCl reduces the CDCl3 
present to 0.06%. The inclusion of sodium chloride within the aqueous phase 
also increases the speed of phase separation as previously an emulsion had 
been formed which did not provide phase separation within the timeframe of 
the hyperpolarised state. However, utilising the aqueous salt mixture phase 
separation was achieved in circa 10 seconds at which point an enhancement 
of 790-fold per proton was reported. Cell line studies making use of the 
aqueous phase did not demonstrate a decrease in cell viability within the 24 
hour period measured within the report.72  
1.7.6. Catalyst sequestration 
Expanding upon the work done with phase separation to remove the iridium 
complex from solution, Barskiy et al. have demonstrated that a silica or 
polymer particle may sequester the SABRE catalyst from solution.73 Barskiy 
et al. demonstrated that CASH-SABRE and sequestration may be combined, 
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with a bolus containing 81.67 ppm Ir, representative of the iridium content 
remaining after phase separation, demonstrating that iridium concentrations 
as low as 4.08 ppb may be attained after 12 hours exposure to 10 mg of a 
suitable metal scavenger. 
Addition of a scavenging agent such as 3-mercaptopropyl and 2-
mercaptoethyl ethyl sulfide following bubbling of parahydrogen through a 
metronidazole containing SABRE mixture utilising the pre-catalyst 
[Ir(IMes)(COD)Cl] has demonstrated that catalyst sequestration may occur on 
a timescale within the lifetime of the hyperpolarised state.74 In this instance 
there was no detectable iridium remaining in solution on this timescale, and 
attempts to re-hyperpolarise the sample following scavenger addition resulted 
in no SABRE enhancements being observed. ICP-MS (inductively coupled 
plasma-mass spectroscopy) of an analogous bolus suggested that ~98.381% 
iridium removal occurred on average after a scavenger exposure time of 
several minutes. The addition of unfunctionalised SiO2 was demonstrated to 
reduce the SABRE enhancements observed, however, hyperpolarisation 
continued to be observed in measurements following SiO2 addition.  
1.7.7. Heterogeneous catalysts 
The separation of catalytic species and a hyperpolarised bolus offers 
advantages both in the relaxation time of the hyperpolarised species and in 
advancement towards in vivo applications, as the separation of catalyst means 
toxicity concerns are reduced in addition to lowering costs if the catalyst can 
be recycled. To this end a number of heterogeneous SABRE catalysts have 
been synthesised, the structures of which are shown in Figure 22. These 
examples make use of a solid support framework bound trans to IMes which 
prevents exchange of the solid support during SABRE, whilst still enabling 
access to the equatorial plane for polarisation transfer and ligand exchange. 
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Figure 22. Pyridine activated HET-SABRE catalysts immoblised on 
polymermicrobeads (left),94 TiO2/poly(methacrylic acid) (PMAA) nanoparticles 
(middle)37 and bound to a silica supported amine linker (right).95 
The polymer microbead example has demonstrated SABRE activity polarising 
pyridine to yield an enhancement ~15 times lower than when the homogenous 
pre-catalyst [Ir(IMes)(COD)Cl] was utilised under the same conditions. No 
bound signals were observed in the hyperpolarised spectra due to the solid 
supported catalyst rapidly dropping to the bottom of the NMR tube after 
shaking. The binding of the catalyst to the solid support was confirmed making 
use of IR (infrared spectroscopy), MS (mass spectroscopy) and AAS (atomic 
absorption spectroscopy), with AAS showing that 4% of the total homogenous 
bulk was the iridium complex. Removal of the supernatant following 
heterogeneous hyperpolarisation and subsequent testing separated from the 
solid bulk revealed no SABRE activity, demonstrating that the heterogeneous 
catalyst was responsible for the polarisation. 1H NMR, AAS and MS were also 
used to interrogate this sample and failed to detect any catalyst leaching into 
solution. 
A further study by Shi et al. demonstrated the synthesis of a heterogeneous 
catalyst on both a TiO2/PMAA nanoparticle and PVP (polyvinylpyridine) 
polymer. These species were characterised by NMR, AAS and DLS (dynamic 
light scattering). AAS determined that 25% of the total nanoparticle catalyst by 
weight was iridium complex; the final filtrate wash following production of the 
heterogeneous species did not show the presence of iridium when analysed 
with AAS, indicating a robust heterogeneous catalyst. The enhancements 
52 
obtained from the nanoparticle catalyst were ca. 2.5 times higher than those 
obtained from the polymer based catalyst reported by Shi et al. making use of 
a ‘shake and drop’ method with pyridine as the substrate. When parahydrogen 
was bubbled through the solutions instead for 300 s the nanoparticle based 
catalyst’s enhancements increased from 18-, 17- and 7-fold for each pyridine 
site respectively to give enhancements of 26-, 39- and 11-fold respectively. 
This equates to an overall polarisation of ca. 0.13%. This study also 
demonstrated that the heterogeneous catalyst may be recycled for use in 
further SABRE experiments, though enhancements were slightly reduced 
following the recovery process. 
Kovtunov et al. demonstrated the use of a commercially available silica 
supported amine linker.95 Though this report demonstrates lower polarisations 
for pyridine (~2.6 fold) compared to the work of Shi et al.,37, 94 the aim of the 
publication was to demonstrate HET-SABRE of heteroatoms, specifically 15N. 
Therefore, the 1H polarisation was not optimised. Kovtunov et al. successfully 
demonstrated a 15N polarisation of ~100 fold under HET-SABRE-SHEATH 
conditions.50, 52 The lower gyromagnetic ratio of 15N compared to 1H suggests 
that far greater 1H polarisation would be feasible using this HET-SABRE 
system if 1H polarisation was optimised.5 The signal has been attributed to 
solid-supported catalyst through the lack of 15N bound peaks typically 
observed for axially and equatorially bound pyridine to [Ir(IMes)(COD)Cl] (4). 
The supernatant was further tested with x-ray photoelectron spectroscopy 
(XPS) and ICP-MS suggesting no iridium is lost from the surface during the 
HET-SABRE process and there is minimal leaching into the supernatant. 
1.7.8. Progress towards applying SABRE to biologically 
relevant substrates 
SABRE has been utilised to hyperpolarise a range of biologically relevant 
molecules including world health organisation (WHO) essential medicines 
such as metronidazole,30, 68, 74 and pyrazinamide,49, 96 in addition to 
voriconazole,97 the polarisation of which is reported in 6.2. 
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Furthermore, the application of SABRE to hyperpolarise pyridine in the 
presence of blood, has been examined.68, 98 Hövener et al. added 2 mL fresh 
human blood to an ethanol solution containing 4 equivalents of pyridine 
relative to 4.98 Continuous SABRE polarisation was attempted making use of 
parahydrogen bubbling through the solution and hyperpolarisation continued 
to be observed following the addition of blood. However, Hövener et al. note 
that, after a short time, the liquid coagulated and the observed hyperpolarised 
signal had decreased to approximately a tenth of its initial value. 
In a further report, Hövener et al. demonstrated that pyridine SABRE may be 
observed in a D2O solution containing HL-60 cells and a separate solution 
containing DPBS, both simulating parts of the blood environment.68 However, 
Hövener et al. were unable to observe SABRE within a mixture including whole 
blood, cells and serum when nicotinamide was the substrate. Hövener et al. 
note, however, that in a previous report where pyridine was utilised as the 
substrate, hyperpolarisation within a blood mixture was observed and attribute 
this to a higher initial signal enhancement.98 
Expanding the scope of biologically relevant substrates to which SABRE may 
be applied remains a key focus of current literature and it is envisaged that 
these substrates in combination with catalyst removal techniques such as 
CASH-SABRE and catalyst scavenging may provide a route towards SABRE 
in vivo imaging. 
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2. Aims 
The work contained herein aims to develop SABRE towards future biological 
applications. Several key areas have been identified as gaps within the current 
literature or areas that require expansion and further development. These are: 
• Testing alternative metals, such as rhodium, which may be capable of 
replacing iridium within the polarisation transfer catalyst required for 
SABRE. 
• Applications of SABRE to a range of biologically relevant substrates 
such as new psychoactive substances (NPS) and applying 19F SABRE 
to a WHO essential medicine to expand the biological applications of 
the SABRE technique. 
• Extending the scope of 19F SABRE as this may be utilised in vivo 
without the water background signal typically associated with 1H 
imaging. Developing HET-SABRE catalysts or catalyst scavengers 
capable of rapidly producing a metal free bolus so that the toxicity of 
the catalyst may be circumvented.  
• Applications of SABRE to a range of biologically relevant substrates 
such as new psychoactive substances (NPS) and applying 19F SABRE 
to a WHO essential medicine to expand the biological applications of 
the SABRE technique
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3. SABRE active complexes 
3.1. Introduction 
Despite there being numerous reports relating to the SABRE technique since 
it was first evidenced in 2009, nearly all reports utilise an iridium-based 
polarisation transfer catalyst similar to that utilised in the first reports.98, 99 
There have been some developments in catalyst design, in that the initially 
utilised Crabtree’s catalyst is now rarely employed to facilitate polarisation 
transfer. Instead, the current literature standard complex of [Ir(IMes)(COD)Cl], 
is almost exclusively used.26, 28, 32 
This chapter aims to investigate the use rhodium complexes for facilitating 
polarisation transfer in SABRE. These complexes will be compared to 
analogous, or similar, iridium complexes, to better understand their catalytic 
potential. 
3.1.1. Use of non-iridium metals for SABRE  
The majority of recent SABRE reports make use of the iridium complex 
[Ir(IMes)(COD)Cl], however, other metal complexes, such as platinum, cobalt 
and rhodium, have been used to facilitate parahydrogenation-based 
polarisation transfer. The following sections will detail how these metal 
complexes have been employed in this regard.  
3.1.1.1. Platinum 
A platinum complex, [Pt(OTf)(sub)(bis-diphenylphosphinopropane)]OTf 
(where OTf is trifluoromethanesulfonate), has been reported by Duckett et al. 
within SABRE-RELAY to transfer polarisation from a pre-polarised relay 
substrate onto the substrate of interest.85 Though, in this instance, the 
traditional SABRE process does not occur within the platinum containing 
complex as the parahydrogen derived hydrides are still bound to a polarisation 
transfer catalyst derived from [Ir(IMes)(COD)Cl]. The initially polarised 
substrate, such as ammonia or nicotinamide,37 then binds to platinum and 
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transfers polarisation to a secondary species which would not typically be 
accessible by SABRE, as shown in Figure 23.  
 
Figure 23. Schematic representation of the application of SABRE-RELAY 
where R is indirectly polarised. 
Though polarisation transfer takes place around the platinum complex, this is 
not a full SABRE process as a second iridium species is required for initial 
polarisation transfer from parahydrogen derived hydrides in order to facilitate 
the relaying of polarisation by a substrate, S1. Duckett et al. have utilised a 
range of N-heterocyclic substrates to fulfil this relay role including nicotinic 
acid, nicotinamide and pyrazine. Polarisation transfer from S1 to R was then 
reported via a scalar coupling network formed around the platinum complex in 
order to polarise the bis-diphenylphosphinopropane ligand of the platinum 
complex, resulting in 31P hyperpolarisation being observed. 
3.1.1.2. Cobalt 
As discussed in 1.4, cobalt has been used to facilitate simultaneous SABRE 
and PHIP polarisation using a [(MesCCC)Co(N2)(PPh3)] (MesCCC = (bis(mesityl-
benzimidazol-2-ylidene)phenyl)) pre-catalyst, shown in Figure 24.39, 100, 101 The 
bulky strongly electron donating tridentate ligand means the SABRE active 
form of this species has been proposed as [(MesCCC)Co(H2)(substrate)]. 
Polarisation transfer efficiency, though not reported within the literature, is 
likely to be significantly less efficient as only a single ligand may bind 
simultaneously, resulting in a far slower build-up of hyperpolarised species in 
solution. 
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Figure 24. Structure of [(MesCCC)Co(N2)(PPh3)] pre-catalyst utilised for cobalt 
SABRE.100 
3.1.1.3. Rhodium 
Despite its common use in PHIP,102 there is only a single literature source for 
the use of rhodium in SABRE. This report by Koptyug et al. comes from a 
mixed [Rh(DPPB)(COD)]BF4 (DPPB = 1,4-bis(diphenylphosphino)butane) 
and [Ir(PCy3)(COD)(Py)]PF6 (Crabtree’s catalyst) pre-catalyst system used to 
achieve 31P polarisation.40 However, the authors note that due to a complex 
equilibrium of multiple species within the sample, they were unable to assign 
polarisation transfer to a particular species. Crabtree’s catalyst has, however, 
been previously reported as an effective SABRE polarisation transfer species, 
in that this catalyst was utilised within the first report of SABRE.98 
Rhodium complexes such as Wilkinson’s catalyst, Rh(PPh3)3Cl, have been 
extensively utilised for PHIP for the hydrogenative integration of parahydrogen 
into the target substrate.102, 103 The substrates polarised included 
phenylacetylene, styrene, halide containing alkenes and branched alkenes. 
Given the reported potential for cobalt to be utilised as an unusual SABRE 
catalyst, and the report by Koptyug et al., further investigations into the 
potential of rhodium to facilitate SABRE were undertaken within this work. 
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3.1.2. Rhodium Hydride Species 
A key component of forming a SABRE active species from current literature 
appears to be the necessity to form a dihydride metal species capable of 
reversible exchange of both hydrides and the desired substrate.  
Unfortunately, while there is experimental evidence for rhodium dihydride 
species, they are known to typically be highly transient at room temperature 
and, whilst detection is possible, the process is challenging.103 In the majority 
of reported cases dihydride species have been observed at lower 
temperatures, with species stability differences primarily attributed to changes 
in electron donating properties of the associated ligands.104 Wilkinson’s 
catalyst has been reported to form a stable dihydride at room temperature,105 
however, other species such as dirhodium tetrahydride degrade above 273 
K,106 with some solvate dihydride species requiring study at temperatures in 
the range of 183 K – 213 K in order to remain stable during analysis.107 
An approximation with [Ir(IMes)(COD)Cl] may be found in [Rh(P,SR)(COD)Cl], 
where R = Ph, Et, tBu, Bz, which has been evaluated for PHIP by Manoury et 
al.108 This complex utilised a ferrocenyl phosphine thioether ligand, shown in 
Figure 25, which is bound trans to COD in the initial pre-catalyst.  
 
Figure 25. Structure of (P,SR) bidentante ligand utilised by Manoury et al.108  
Addition of H2 over the temperature regime 233 – 298 K did not result in an 
observable hydride species, however, there was a new set of peaks 
observed in the 1H NMR spectrum associated with partial hydrogenation of 
the COD ligand, suggestive of a slow reaction to form a Rh hydride species 
followed by rapid reaction with COD. Manoury et al. note that this is not 
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unexpected due to Rh(III) hydride complexes being known to be less stable 
than the Ir(III) analogues. Manoury et al. note that some free cyclooctene is 
observed in solution at temperatures as low as 253 K, demonstrating that H2 
addition occurs at this temperature. The presence of HD scrambling became 
evident at 273 K, suggestive of exchanging hydrides and solvent adducts. 
However, whilst direct observation of the hydrides is not reported, Manoury 
et al. note that these sites may exist primarily as deuterium and thus not be 
observed in the 1H NMR spectrum. While hydrides were not visible for 
reactions conducted within d4-methanol, utilisation of deuterated 
dichloromethane demonstrated weak hydride species at -9.7 and -23 ppm 
within a 1H spectrum that promptly disappeared upon addition of a low 
quantity of MeOH. 
 
Figure 26. Structural isomers of [Rh(P,SR)(Py)2(H)2]+ formed upon addition of 
H2 and pyridine.108 Structure of ligand is shown in Figure 25. 
Manoury et al. note, however, that when an excess of pyridine (initially 75 
equivalents relative to the polarisation pre-catalyst) is added alongside 
parahydrogen gas at a low temperature (233 K – 283 K), four hydride peaks 
are observed at -13.1, -14.3, -17.2 and -17.6 ppm. These are representative 
of two dihydride species, RhS1 and RhS2 as shown in Figure 26. These 
parahydrogen derived hydride peaks disappear when the sample is warmed 
to 298 K or above. When non-para enriched H2 was utilised at room 
temperature only the thermodynamically favoured complex RhS2 was 
observed. 
EXSY analysis of hydride exchange at 273 K within this complex yielded 
rates of 0.29 s-1 when 8 equivalents of pyridine were utilised, increasing to 
0.39 s-1 when 173-fold excess of pyridine was utilised. Manoury et al. note 
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that these transitions were only observed between RhS1 and RhS2, which 
exist at this temperature however, and no evidence was observed for hydride 
exchange with free H2, which would be a crucial requirement for SABRE 
activity. 
Despite this, the direct analogue of [Ir(IMes)(COD)Cl], [Rh(IMes)(COD)Cl] 
has been reported to conduct PHIP when partnered with an additional 
phosphine,109 and [Rh(IMes)2(CO)(H)] has been reported,110 demonstrating 
that rhodium NHC complexes are capable of forming hydrides. Therefore, 
the decision was made to evaluate the potential utility of [Rh(IMes)(COD)Cl] 
as a polarisation transfer pre-catalyst in order to directly compare with 
[Ir(IMes)(COD)Cl] utilised extensively within extant SABRE reports. 
3.2. Complex Characterisation 
3.2.1. [Ir(IMes)(COD)Cl] 
Initially both [Ir(IMes)(COD)Cl] and [Rh(IMes)(COD)Cl were synthesised 
utilising established literature methods for the reaction of the dimer 
[M(COD)Cl]2 with an NHC.28  
 
Figure 27. Reaction scheme for the synthesis of N,N'-bis(2,4,6-
trimethylphenyl)ethanediimine (1). 
N,N'-bis(2,4,6-trimethylphenyl)ethanediimine (1) was yielded from the reaction 
of 2,4,6-trimethyl aniline and glyoxal in a 39% yield, as shown in Figure 27. 
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Figure 28. Reaction scheme for the synthesis of 1,3-bis(2,4,6-
trimethylphenyl)-imidazolium hydrochloride (2). 
This was then reacted with paraformaldehyde in the presence of trimethylsilyl 
chloride to form 1,3-bis(2,4,6-trimethylphenyl)-imidazolium hydrochloride (2) 
in a 79% yield, as shown in Figure 28. [Ir(COD)Cl]2 (3) was formed by the 
reaction of IrCl3.xH2O with cyclooctadiene (COD) in an 18% yield based on 
anhydrous IrCl3. 
 
Figure 29. Reaction scheme for the synthesis of [Ir(IMes)(COD)Cl]. 
As shown in Figure 29, 2 was free based utilising potassium tert-butoxide 
before reaction 3 at room temperature. The reaction mixture was then 
separated via silica gel chromatography and the desired complex isolated in a 
71% yield for the iridium complex [Ir(IMes)(COD)Cl] (4). These complexes 
were then characterised, with the 1H NMR data for each complex shown 
below.
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Figure 30. 1H NMR spectrum of 4 in d4-methanol and species in solution responsible for proton environments. 
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Table 3. 1H NMR assignments of 4 from Figure 30. 
1H environment ppm Multiplicity 
1 2.36 s 
2 7.03 d, J= 6.46 Hz 
3 2.18 s 
4 2.29 s 
5 7.23 s 
6 4.02 - 3.97 m 
7 3.11 - 3.05 m 
8 1.67 + 1.33 m 
The 1H NMR spectrum of the complex 4 in solution is shown in Figure 30. The 
splitting of environments 3 and 4 suggests that the imidazole N-C bonds may 
not rotate freely, leading to the methyl environments being in different 
rotational environments. This rotational difference is represented to a lesser 
extent by the splitting of environment 2, resulting in a peak that appears as a 
doublet due to two very similar, but distinct, rotational environments. The 
cyclooctadiene ligand contributes four peaks in total in the 1H spectrum, two 
downfield peaks at 4.00 and 3.08 ppm respectively closest to the iridium η4 
COD bonds and two up-field aliphatic environments with complex splitting 
around the cyclooctadiene ring which are present at 1.67 and 1.33 ppm. 
3.2.2. Rh(IMes)(COD)Cl] 
The rhodium analogue, [Rh(IMes)(COD)Cl] (6) was then synthesised following 
the same scheme as shown within Figure 29, however, replacing [Ir(COD)Cl]2 
with [Rh(COD)Cl]2 (5, 50% yield based on anhydrous mass of RhCl3) to 
produce [Rh(IMes)(COD)Cl]. This reaction yielded 88% product, which is 
comparable to the 71% recorded for the iridium analogue and the difference 
is likely due to losses during purification, making use of silica gel 
chromatography. 
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Figure 31. 1H NMR spectrum of 6 and species in solution responsible for proton environments. 
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Table 4. 1H NMR assignments of 6 from Figure 31. 
1H environment ppm Multiplicity 
1 2.39 s 
2 7.08 s 
3 2.32 s 
4 2.16 s 
5 7.23 s 
6 4.41 - 4.35 m 
7 3.45 – 3.40 m  
8 1.86 + 1.58 m 
The 1H NMR spectra of 4, shown in Figure 30, and of 6, shown in Figure 31, 
as expected both structures demonstrate similar environments for the carbene 
backbone. While the spectrum of 6 shown in Figure 31 has the same peaks 
present as the analogous iridium system shown in Figure 30, the peak 
locations are generally shifted downfield by between 0.03 and 0.38 ppm, with 
the greatest shifts being present for the COD environments closest to the 
metal. The only exception to this trend is environment 4 that has slightly shifted 
up field, suggesting this methyl is furthest from the rhodium. The general trend 
of downfield shifting when iridium is replaced with rhodium is due to the latter 
possessing a higher electronegativity, leading to reduced electron density in 
the surrounding environments.111 In general, however, the two complexes are 
highly comparable, facilitating the testing of 6 as a potential SABRE 
polarisation transfer pre-catalyst with comparison to the well reported iridium 
system. 
3.3. Catalyst Activation 
In order to function as a polarisation transfer catalyst for SABRE, the metal 
complexes must be capable of reversibly binding a substrate of interest. To 
facilitate this, the substrate must be capable of displacing chlorine within the 
66 
complex and have an observable exchange on the NMR timescale. The 
assessment of these parameters for 4 and 6 is reported within this section. 
3.3.1. Chlorine displacement 
Following the addition of 5 equivalents of pyridine to 6, displacement of the 
chloride ion may be observed as bound peaks for pyridine are visible. The 
integration of these peaks demonstrates they are in a ratio of 4:1 free to bound, 
which is suggestive of a singular pyridine bound to the rhodium. The 
displacement of the chlorine is expected as this is the most labile of the 
previously bound ligands. However, this is further confirmed by minimal 
changes within the COD and IMes environments which were already present 
within 6. The main change is the appearance of a new set of peaks that, upon 
interrogation by correlation spectroscopy (COSY), are shown to cross 
correlate. These peaks are due to COD now being in a different environment 
within the rhodium pyridine complex with Rh η4 COD bound peaks now 
appearing at 3.71 and 3.87 ppm. Interestingly, COD environments for 6 are 
still present in a ratio of 35:65 suggesting that pyridine has only displaced 
chlorine in roughly two thirds of potential complexes.
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Figure 32. 1H NMR spectrum of 6 following addition of 5 equivalents of pyridine and proposed species in solution responsible 
for proton environments. 
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Table 5. 1H NMR assignments of 6 and pyridine from Figure 32. 
1H environment ppm Multiplicity 
1 2.45 s 
2 7.08 s 
3 2.32 s 
4 2.39 s 
5 7.31 s 
6 3.71 + 3.87 m 
7 2.15 + 1.82 m 
8 7.94 d, J=4.95 Hz 
9 7.23 t, J=3.37 Hz 
10 7.78 tt, J=7.73, 1.55 Hz 
11 8.53 d, J=4.32 Hz 
12 7.44 t, J=5.88 Hz 
13 7.86 tt, J=7.71, 1.71 Hz 
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Figure 33. 1H NMR spectrum of 4 following addition of 4 equivalents of pyridine and proposed species in solution 
responsible for proton environments.
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Table 6. 1H NMR assignments of 4 and pyridine from Figure 33. 
1H environment ppm Multiplicity 
1 2.43 s 
2 7.07 s 
3 2.29 s 
4 2.36 s 
5 7.35 s 
6 3.69 + 3.26 m 
7 1.64 m 
8 7.88 m 
9 7.28 
ddt, J=1.57, 4.95, 6.58 
Hz 
10 7.79 tt, J=1.56, 7.69 Hz 
11 8.53 dd, J=1.87, 4.34 Hz 
12 7.44 
ddt, J=1.54, 4.57, 5.95 
Hz 
13 7.86 tt, J=1.83, 3.51 Hz 
Addition of an excess of pyridine (4 equivalents) to 4 results in displacement 
of the chloride ion by pyridine similar to that within the analogous rhodium 
system with 3 equivalents remaining free in solution. The iridium complex 
demonstrates significantly higher degrees of spectral overlap within the 
aromatic region that makes accurate peak integration more challenging. 
However, both free and bound pyridine environments may be assigned both 
due to chemical shift and splitting patterns. The iridium system appears to 
possess a weaker metal-chloride bond that results in a higher ratio of iridium 
possessing a bound pyridine, determined by the COD environment associated 
with this species. Under the same conditions the pyridine bound proportion 
has increased from 65% within the rhodium system to 86% within the iridium 
analogue. This trend of stronger chloride binding is in general agreement with 
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lower yields obtained when insertion of SnCl2 occurs across a Rh-Cl bond 
compared to an Ir-Cl bond.112  
With both the Rh and Ir species demonstrating the ability for a substrate such 
as pyridine to displace the chloride and form the general species 
[M(IMes)(COD)Py]+, the first steps towards a SABRE active species have 
been demonstrated. However, crucially, both complexes need to form 
hydrides and demonstrate reversible exchange of the substrate and hydrides 
in order to be viable SABRE polarisation transfer catalysts. 
3.3.2. Pyridine Exchange 
The ability of the complexes [M(IMes)(COD)Py]+ to exchange pyridine at room 
temperature was investigated as this would be the temperature regime where 
most practical applications of SABRE would be desirable. EXSY was utilised 
to interrogate the bound pyridine peaks and observe any transitions from the 
bound complex to free within solution for a range of mixing times up to 5 
seconds. 
 
Figure 34. Relative integrals of excited bound (blue) and free (orange) pyridine 
within [Rh(IMes)(COD)Py]+  over a 5 second period at 295 K, interrogated by 
EXSY. 
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Interestingly, no pyridine dissociation was observed for [Ir(IMes)(COD)Py]+ at 
295 K, suggesting this complex is more stable than the rhodium analogue 
which did demonstrate pyridine exchange. Figure 34 demonstrates the 
conversion of excited bound (blue) and free (orange) pyridine within 
[Rh(IMes)(COD)Py]+ following selective excitation of the bound ortho peak at 
7.94 ppm. This determined the rate of pyridine dissociation at 295 K to be 
0.2415 ± 0.0056 s-1. This demonstrates that pyridine exchange occurs, 
however, this rate is still exceptionally slow when compared to literature 
reports of SABRE active species. For comparison, at 295 K, Duckett et al. 
have reported the exchange rate of pyridine within the commonly utilised 
iridium complex [Ir(IMes)(Py)3(H)2]+ to be 23 s-1.28 
3.4. Hydride formation 
As SABRE requires both substrate and hydride exchange for polarisation 
transfer from the singlet state of parahydrogen, the ability for the complex to 
form parahydrogen derived hydrides is essential. Now [Rh(IMes)(COD)Py]+ 
has demonstrated the ability to exchange the pyridine substrate, albeit slowly, 
the ability of this complex to form hydrides was then probed. 
3.4.1. Hydrogen Addition 
As previously discussed in 3.3.1, for SABRE to occur exchangeable metal 
hydride species must form which are capable of breaking the symmetry of 
parahydrogen and, thus, enabling SABRE hyperpolarisation. To that end, 
hydrogen was added to the samples characterised within Figure 32 and Figure 
33 and the resulting hydride region is shown in Figure 35. 
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Figure 35. 1H NMR spectra of the hydride regions following the addition of H2 
to [Ir(IMes)(COD)(Py)], [Rh(PPh3)3Py] (Wilkinson’s catalyst) and 
[Rh(IMes)(COD)Py] respectively. 
For [Ir(IMes)(COD)Py]+,  addition of H2 resulted in the formation of 
[Ir(IMes)(Py)3(H)2]+ for which hydrides are visible at -22.82 ppm in addition to 
a hydride due to the complex [Ir(IMes)(Py)3(H)(D)]+ being observed at -22.76 
ppm. These are very similar to the values reported by Duckett et al. for this 
complex.28 Unfortunately, under the same conditions, no hydrides were 
observed for the rhodium analogue. In addition, while the hydrogenation of 
COD is visible in the form of transient peaks briefly observed at ~-12 to -17 
ppm within the 1H NMR spectrum following H2 addition to the iridium system, 
this is not observed within rhodium. Even varying the ligand identity to 3-
fluoropyridine does not yield visible hydrides or evidence of the complex 
changing upon addition of H2. 19F NMR spectra of a sample containing 
[Rh(IMes)(COD)3-fluoropyridine]+ do not show variation within the free/bound 
peaks of 3-fluoropyridine following addition of parahydrogen. Additionally, after 
several days, no evidence of HD scrambling was observed with the rhodium 
[Ir(IMes)(COD)Py]+ 
[Rh(PPh3)3Py]+ 
[Rh(IMes)(COD)Py]+ 
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complex. This is typically observed when both a hydride and solvent adduct 
are present within the complex and deuterium transfer may occur. This was 
observed for [Ir(IMes)(Py)3(H)2]+ as the complex [Ir(IMes)(Py)2(d4-
methanol)(H)2]+ is formed as a minor component which may facilitate HD 
scrambling. 
The formation of rhodium hydrides was not observed following the addition of 
a reducing agent such as NaBH4, despite HD being observed in solution 
directly following the addition of sodium borohydride. Subsequent, degassing 
and refilling the Young’s NMR tube with fresh H2 eliminated the presence of 
HD and it was not regenerated over several days. The initial HD was, 
therefore, attributed to a reaction of NaBH4 with the deuterated methanol 
solvent, resulting in the formation of HD and MeONa, rather than activity 
around the rhodium, particularly in the absence of visible rhodium hydrides. 
The formation of hydrides when pyridine (4 equivalents) and H2 were added 
to Wilkinson’s catalyst, [Rh(PPh3)3Cl] was also investigated as this was one of 
the few rhodium species which has been reported to form a dihydride species 
at room temperature and, therefore, has been utilised for PHIP.105 This formed 
a species that demonstrates a hydride at -17.39 ppm with evidence of at least 
one PPh3 ligand still being within the coordination sphere of rhodium as 
deduced from the 31P coupling of 14.76 Hz within the hydride signal.  
3.4.2. Temperature study 
As no hydride ligands were formed when H2 was added to 
[Rh(IMes)(COD)Py]+ at room temperature, the potential of this complex being 
suitable to facilitate polarisation transfer for SABRE is low. Despite low 
temperatures typically being utilised to form stable rhodium dihydride species, 
the necessary exchangeable nature of the hydrides for SABRE meant that a 
transient species potentially obtained at a higher temperature regime may 
suffice for the lifetime required for polarisation transfer. Further to this, the low 
substrate exchange speeds measured within 3.3.2 suggested that cooling of 
the system, even if a hydride was generated, would exclude SABRE activity 
as substrate exchange would proceed too slowly, if at all. Therefore, 
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[Rh(IMes)(COD)Py]+ under H2 was heated and the hydride region observed 
as shown in Figure 36. 
 
Figure 36. 1H NMR spectra of the hydride region of [Rh(IMes)(COD)Py]+ after 
addition of H2 at the temperatures noted. Spectra are 32 scan collections with 
a relaxation delay of 5 seconds. 
At higher temperatures a minor hydride species was observed, however, a 
concurrent bound peak in the 19F NMR spectrum was not observed when 
[Rh(IMes)(COD)(3-fluoropyridine)]+ was investigated. This is suggests that a 
transient hydride containing species was present within solution or that the 
hydride containing complex did not contain the substrate. For instance, this 
hydride may be due to an exchangeable methanol adduct rather than a 
substrate containing species. Unfortunately, due to the low concentrations 
observed it is not practical to fully characterise this hydride species and the 
associated complex. Examination of [Rh(IMes)(COD)Py]+ was repeated in 
deuterated toluene, similar to the examination of hydrides within 
dichloromethane discussed within 3.1.2, in order to access a wider 
295 K 
300 K 
305 K 
310 K 
315 K 
320 K 
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temperature range. However, no hydride formation was observed in this 
aprotic solvent, supporting the supposition hydrides may be due to a methanol 
adduct containing species. 
3.5. SABRE using rhodium-based catalysts 
Rhodium-based catalysts, namely Wilkinson’s catalyst and 6, were 
investigated as potential SABRE pre-catalysts. These were compared to 4, an 
established pre-catalyst for use with SABRE.  
When Wilkinson’s catalyst was utilised with 4 equivalents of pyridine under 
parahydrogen no SABRE was observed, even when the polarisation transfer 
field was changed to 65 G from earth’s field. Given that Wilkinson’s 
demonstrates room temperature hydrides when in the presence of pyridine 
this lack of activity suggests that the hydride species or pyridine species do 
not exchange. Unfortunately, due to the high number of aromatic 
environments present within 1H NMR due to the presence of PPh3, 
examination of the pyridine binding and exchange is challenging. Therefore, 
3-fluoropyridine was utilised so that 19F observation may allow insight into 
substrate binding and exchange. Utilising 3-fluoropyridine as a 19F containing 
probe, chlorine displacement is observed (shown in Figure 37) through the 
presence of a new bound signal at -122.73 ppm compared to free at -126.48 
ppm. This bound signal demonstrates chlorine displacement and subsequent 
substrate binding has occurred for ~33% of the Wilkinson’s complexes within 
the sample (4 equivalents of 3-fluoropyridine are utilised). 
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Figure 37. 19F NMR spectrum of bound (-122.7 ppm) and free (-126.5 ppm) 
peaks for Wilkinson’s catalyst when 4 equivalents of 3-fluoropyridine were 
utilised. 
When 6 was utilised as a pre-catalyst in combination with parahydrogen and 
pyridine or 3-fluoropyridine this system did not display SABRE activity at room 
temperature. However, this is unsurprising given the lack of observed hydrides 
within this temperature regime. Given the low-level (~8% relative to the 
concentration of [Rh(IMes)(COD)Py]+) hydrides observed at higher 
temperatures and that the pyridine exchange rate is likely to be increased at 
higher temperatures, this system was investigated further at higher 
temperatures. A Young’s capped NMR tube containing 4 equivalents of 
pyridine relative to 6 under 3 bar of parahydrogen was heated to 50°C and 
SABRE attempted. Unfortunately, even at 50°C, no SABRE was observed 
making use of 6 and pyridine. 
Attempts to perform SABRE utilising rhodium complexes with a varied carbene 
were also attempted to see if a small change in ligand identity may facilitate 
SABRE through attenuation of the substrate and hydride exchange rates. 
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Figure 38. Carbenes utilised in further testing of rhodium complexes. 
Exchange rates noted are for [Ir(Carbene)(Pyridine)3(H)2] at the temperatures 
noted.28, 113 *Hydride data is for ImMe2NPri2. Compound numbers are reflective 
of [Rh(Carbene)(COD)Cl]. 
It was desired that changing the identity of the carbene may aid stabilisation 
of the complex as the carbenes utilised have all been reported to result in 
slower hydride and substrate exchange compared to IMes, as shown in Figure 
38, when utilised within an iridium system with pyridine as the substrate. 
Unfortunately, testing of complexes [Rh(ImNPri2)(COD)Cl] (7), 
[Rh(ItBu)(COD)Cl] (8) and [Rh(ICy)(COD)Cl] (9) demonstrated the same result 
with pyridine being capable of displacing chlorine, however, no visible hydrides 
were observed at room temperature and no SABRE observed when pyridine 
was utilised as the substrate. 
3.6. Conclusion 
A range of rhodium complexes have been synthesised and 6 has been 
characterised for direct comparison with the literature standard SABRE 
catalyst 4.  
For SABRE to occur reversible exchange of both substrate and hydrides must 
occur. It has been demonstrated that in both IMes-containing complexes 
chlorine may be displaced by the most commonly utilised SABRE substrate, 
pyridine, and the exchange rate of pyridine has been measured to be 0.2415 
± 0.0056 s-1 for the rhodium complex [Rh(IMes)(COD)Py]+. This exchange rate 
could feasibly be increased by increasing the pyridine equivalents present as 
observed by Manoury et al. and discussed in 3.1.1.3.108 However, COD 
hydrogenation is not observed and hydrides do not readily form for 6, with 
variable temperature interrogation demonstrating only trace hydride presence 
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at elevated temperatures. Attempting to conduct SABRE utilising 6 as the pre-
catalyst did not demonstrate SABRE activity at room temperature or 50°C 
where minor hydrides appear to be present. The disappearance of these 
transient hydrides and lack of associated polarisation suggests a methanol 
adduct containing species may be responsible for these hydrides. It was hoped 
that tuning the system to facilitate slower ligand/hydride exchange through the 
variation of the carbene present, such as 7, 8 and 9, would facilitate SABRE, 
however no SABRE or hydrides were observed at room temperature for these 
pre-catalysts.
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4. Applications of SABRE to 19F 
4.1. Introduction 
Signal amplification by reversible exchange (SABRE) has previously been 
applied to heteroneclei such as 15N and 31P but the high gyromagnetic ratio of 
19F (94% compared to proton) and its 100% natural abundance means that 
this nucleus presents an attractive prospect for MR studies.65 This will be 
explored in this chapter. 
4.1.1. Biological relevance of 19F from an applications 
prespective 
19F is particularly attractive for in vivo imaging applications as there is minimal 
biological background signal as mobile physiological 19F concentrations are 
typically below the detection limits (typically under 10-3 μmol/g wet tissue 
weight).115 Higher concentrations of 19F are present in bones and teeth, 
however these immobilized phases exhibit very short spin-spin (T2) relaxation 
times which mean they are not typically visible in clinical MRI. Conveniently, 
the similar gyromagnetic ratio of 19F compared to 1H means 19F can be 
measured with most existing MRI instruments after appropriate tuning of the 
RF coils.116 The potential advantages of 19F MRI has led to an increase in 
publications within this field in the last decade,117 within this literature there 
have been efforts to overcome the inherent insensitivity of magnetic 
resonance techniques through the incorporation of multiple 19F atoms in the 
same environment, particularly in perfluorocabons.118-123  
In 2010 it was calculated that 20% of approved drugs contain fluorine, with 
several structures already suitable for SABRE without modification, such as 
ripasudil and voriconazole.124 The advantages of 19F for clinical applications 
has led to the development of a range of 19F containing contrast agents, which 
are already detectable at millimolar levels when thermally polarised.66 It is 
hoped that hyperpolarisation techniques such as SABRE could potentially 
lower this detection limit by an order of magnitude. Indeed, developing the 
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applications of 19F SABRE to biologically relevant molecules has been 
highlighted in recent reviews of the field as a suggested focus for the field.5 
4.1.2. Literature applications of SABRE to 19F 
The application of SABRE to fluorinated molecules was first demonstrated by 
Duckett et al. in their 2009 initial report of SABRE.21 This paper demonstrated 
19F hyperpolarisation of 3-fluoropyridine, with the reported spectrum being 
characterised by a complicated antiphase multiplet, shown in Figure 39, that 
is enhanced relative to a thermal spectrum. 
 
Figure 39. 19F NMR spectra of 3-fluoropyridine collected under thermal (top) 
and SABRE hyperpolarised (bottom) conditions.21 
This antiphase multiplet was most likely due to 19F-31P coupling between the 
substrate and the spin transfer pre-catalyst, in this case 
[Ir(COD)(PCy3)(MeCN)][BF4]. It has been proposed that polarisation transfer 
occurs via a coupling system with JHF being commensurate to JHH. If this is the 
case then it is likely that a range of fluorine containing substrates could be 
hyperpolarised.  
Eshuis et al. included 3-fluoropyridine within a mixture of potentially SABRE 
active substrate species in a 2015 report, however, the SABRE hyperpolarised 
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spectrum was not sufficiently resolved to observe 1H hyperpolarisation of this 
substrate in this report, and no 19F spectra are included within this paper.125 
During the course of this work Theis and co-workers have demonstrated 19F 
polarisation of 3-fluoropyridine to give a polarisation level of ~0.3% (compared 
to ~50% demonstrated for proton).45, 68 Though Theis notes that only 50% 
parahydrogen was used, if 100% had been used this could lead to an effective 
polarisation of ~0.85%. Recent work, aiming to quantify the effect of 
parahydrogen enrichment on substrate polarisation, supports this estimate as 
for a range of substrates, catalysts and fields there was a ~3 times increase in 
signal when 99% enriched parahydrogen was used compared to 50%.37 
However, it is worth noting that this report only makes use of 1H SABRE to 
quantify the polarisation changes with parahydrogen enrichment. 
While it is noted this polarisation is significantly lower than 1H and other 
heteronuclei, such as 15N,51 it is hypothesised that this is due to the 
significantly lower T1 of 19F leading to signal loss during sample transfer prior 
to magnetisation read-out.  
The large chemical shift range of 19F was noted as a further advantage of 
heteroneuclei SABRE as Theis et al. demonstrate the application of 
hyperpolarised 19F to pH detection. This is noted to be similar in capability to 
15N while demonstrating a sensitivity >30 times larger than 1H NMR for 
changes in local pH and represents another potentially useful application for 
SABRE hyperpolarised 19F containing ligands.68 
In addition to 3-fluoropyridine, pentafluoropyridine and 2-fluoropyridine were 
also tested as substrates, however, both failed to demonstrated the SABRE 
effect. Theis et al. suggest the lack of activity and observed hydrides indicative 
of the formation of the spin transfer species [Ir(IMes)(L)3(H)2]+ is likely due to 
the steric effects of a fluorine in the neighbouring position to the nitrogen 
binding site. Pentafluoropyridine has been previously reported to be SABRE 
inactive by Rovedo et al. who made use of both [Ir(IMes)(COD)Cl] (4) and 
Crabtrees catalyst in testing this substrate.67 
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The lack of activity for substrates with 19F neighbouring the SABRE binding 
site is consistent with previous literature reports in which picolines and 
lutidines demonstrated that the inclusion of a methyl substituent in the ortho 
position of a pyridine ring leads to no SABRE activity.126 Though 19F is less 
bulky than a methyl group it has a larger steric effect than 1H typically present 
next to the substrate binding site.47, 95, 125, 127, 128  
Despite the examples of picolines and lutidines showing no SABRE activity, a 
methyl substituent next to the binding site in a substrate has been 
demonstrated in metronidazole.29, 73 However, this is a 5-membered ring 
system, and therefore, the higher internal angle will mean the functionality 
neighbouring the binding site has a lower steric effect on binding.  
Buckenmaier et al. additionally reported detecting 3-fluoropyridine, 3,5-
bis(trifuoromethyl)pyridine and ethyl-5-fluoronicotinic acid making use of a 
superconducting quantum interference device (SQUID) based detector.129 In 
this paper a 19F enhancement in excess of 2000 times the thermal signal is 
reported, when the absolute integral of the hyperpolarised signal is used as 
both emissive and absorptive signals are present. They note that the 
polarisation of 19F appears to be substrate dependent, with 3-fluoropyridine 
showing the highest enhancement followed by ethyl-5-fluoronicotinic acid and 
3,5-bis(trifuoromethyl)pyridine respectively. The polarisation of these 
substrates at a range of mixing fields is demonstrated in Figure 40 for both 1H 
and 19F in each substrate. 
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Figure 40. Area under peaks compared to polarisation field for SQUID 
measurements of ethyl-5-fluoronicotinic acid, 3-fluoropyridine and 3,5-
bis(trifluoromethyl)pyridine.129 
The polarisation transfer field is also noted to have an effect on the level of 
polarisation achieved, with polarisation transfer appearing to favour low fields. 
Buckenmaier, however, notes that the field dependence effect appears to be 
far less pronounced for 19F than 1H. In particular, the polarisation of 3,5-
bis(trifuoromethyl)pyridine appears to be independent of the polarisation 
transfer field – although there is an increase, shown in Figure 40, the authors 
attribute this to an increase in noise due to the low signal to noise ratio (SNR). 
Buckenmaier et al. also note that the polarisation transfer field yielding the 
maximum enhancement was different for 1H and 19F within the same substrate 
and field dependent for the monofluorinated substrates even when within a 
very low polarisation transfer field.130  
4.1.3. SABRE-SHEATH 
Theis et al. demonstrated that 19F SABRE of 3-fluoropyridine results in an 
antiphase signal when conducted at earth’s magnetic field. Previous 
heteronuclei studies have demonstrated this due to intramolecular couplings.49 
An antiphase signal would be less suitable for MR imaging, as a smaller 
observation window may result in effective observed signal cancellation, 
partially negating the polarisation gain from SABRE.  
Signal amplification by reversible exchange in shield enables alignment 
transfer to heteronuclei (SABRE-SHEATH) has previously been reported to 
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optimise polarisation transfer to 15N, though making use of a very low (μT) 
polarisation transfer field.49, 51 This is achieved by introducing parahydrogen 
into the sample within a magnetic shield – Truong et al. have presented a 
theoretical model demonstrating why a near-zero field is effective for 
polarisation transfer.51 They note that in a system where JHH dominates the J 
coupling terms, several resonance conditions are fulfilled simultaneously for a 
heteronuclear SABRE-SHEATH system and estimate that for a 15N system the 
optimal transfer field will be ~ 0.26 µT (assuming a value of ~9 Hz for JHH). 
Rayner et al. agree with this figure, suggesting an approximate transfer field 
of 0.2 - 0.4 µT is the optimum transfer field when a 2JHX scalar coupling is used 
to optimise polarisation transfer to a hetronucleus bound directly to the spin 
transfer catalyst.86 However, Truong et al. note that although PHIP requires 
the spin optimisation conditions to be met precisely, this is not the case for 
SABRE.51 They note the exchanging of parahydrogen derived hydrides, 
typically several times a second, means that the optimal transfer field has a 
reduced effect due to the low residence time of the hydride within the J-
coupling network responsible for polarisation transfer around the SABRE 
catalyst. Truong et al. conclude that, so long as the actual transfer field is 
commensurate in order with that of the optimal field, an effective polarisation 
transfer will take place.51 
4.2. Results 
4.2.1. Context of work 
When this project was conceived the only literature report at the start of this 
study was a single spectrum published in 2009 for 3-fluoropyridine,21 though, 
during the course of this work, two reports expanded upon this first report 
before the publication of the work presented in this results section.68, 129 The 
work presented in this chapter contributed to the publication ‘Extending the 
scope of 19F hyperpolarization through Signal Amplification by Reversible 
Exchange in MRI and NMR Spectroscopy’.96 
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4.2.2. Initial Testing 
Pyridine (L1) has been used as a benchmark ligand for SABRE testing in 
previous publications, therefore, several fluorinated pyridine derivatives were 
chosen as substrates for the initial testing of 19F SABRE; these are shown 
alongside their pKa in Figure 41 (with pyridine included for reference). 
L1 L2 L3 
  
 
5.17131 -0.44131 
0.49*132 
2.97131 
2.84*133 
L4 L5 L6 
 
 
 
3.83*134 0.66*135 -1.00*136 
Figure 41. Initial substrate scope for the application of SABRE to 19F with pKa 
data where available. As pKa data was not available for all substrates, the 
chloropyridine analogue pKa values are shown, denoted by an *. 
The substrates were tested in a range of concentrations relative to the pre-
catalyst 4 used for all measurements. These concentrations were 4, 10 and 
20 equivalents relative to the catalyst in order to provide between a 1 and 17 
fold excess due to the formation of [Ir(IMes)(L)3(H)2]+.  
In the case of L4 the freebase could not be isolated under conditions suitable 
for SABRE testing. This is likely due to self reaction to give N-(4’-pyridyl)-4-
fluoropyridinium fluoride which may hydrolyze to N-(4’-pyridyl)-4-pyridone, as 
shown in Figure 42.137  
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Figure 42. Self reaction of L4 to form N-(4’-pyridyl)-4-fluoropyridinium fluoride. 
N-(4’-pyridyl)-4-fluoropyridinium fluoride was found not to be suitable for 
SABRE due to its formation as a salt inhibiting binding to 4 in order to form the 
SABRE active species. Addition of L4 to 4 under H2 resulted in no bound 
signals in the 19F NMR spectrum which were observed for other ligands. 
Therefore, the testing for L4 was not carried out. All other ligands were tested 
with an excess of between 1 and 17 times relative to [Ir(IMes)(L)3(H)2]+. 
In the case of 1H NMR SABRE for substrates L2 and L3, the distinction between 
ortho and para environments signal enhancement is difficult to separate due 
to the collection of NMR spectra on a 1.4 T instrument, therefore this is labelled 
as ‘downfield’.  
Enhancements have been calculated as detailed in section 8.3.1. Due to the 
antiphase nature of some of the resulting spectra, magnitude mode has been 
used to prevent internal cancellation of the enhancement integral due to mixed 
phasing. A comparison between unprocessed and magnitude is shown in 
Figure 43. 
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Figure 43. Comparison of 19F NMR spectra of L3 (4 equivalents relative to 4) 
with (red) and without (blue) magnitude correction. The bound peak of 
[Ir(IMes)(L3)3(H)2] is shown downfield of the signal for free L3. 
The anti-phase signal appears to be characteristic to the majority of ligands; 
this is likely due to interactions between the 1H and 19F spins resulting in a 
coupled 1H-19F two spin order which is commensurate with antiphase signals 
observed from the homonuclear 1H-1H couplings generated when undertaking 
ALTADENA through substrate hydrogenation with parahydrogen. 
The results of the SABRE hyperpolarisation of the ligands, shown in Figure 
41, is detailed in Table 7 and Table 8 below. Enhancements are quoted both 
without magnitude processing and with magnitude processing (shown in 
parentheses).
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Table 7. 1H NMR SABRE substrate enhancements for L2, L3 and L5. The value given in parentheses are when the enhancement data 
has been magnitude corrected. *combination of ortho and para 1H NMR sites, indistinct as separate as spectra are collected at 1.4 T. 
Substrate L2 L3 L5 
Environment Downfield* Meta Downfield* Meta Ortho Para 
20 Equivalents 0.38 
(0.36) 
0.87 
(0.67) 
67 
(56) 
72 
(45) 
237 
(131) 
66 
(69) 
10 Equivalents 5.53 
(0.64) 
19.85 
(0.79) 
133 
(100) 
85 
(117) 
81 
(52) 
146 
(32) 
4 Equivalents 1.17 
(1.4) 
0.59 
(1.6) 
325 
(193) 
208 
(153) 
20 
(4.65) 
9 
(1.44) 
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Table 8. 19F NMR SABRE substrate enhancements for L2, L3 and L5. The value given in parentheses are when the enhancement 
data has been magnitude corrected. 
Substrate L2 L3 L5 
Mixing Field Earths Earths SABRE-SHEATH Earths SABRE-SHEATH 
20 Equivalents 1.91 
(1.38) 
8.75 
(37) 
 
43 
(34) 
8 
(3.27) 
10 Equivalents 0.71 
(0.66) 
9.24 
(80) 
 
71 
(35) 
4.48 
(6.62) 
4 Equivalents 0.11 
(0.57) 
67.61 
(166) 
808 
(243) 
14 
(3.43) 
14 
(3.53) 
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L6 is not included as no SABRE was observed for this substrate at any 
concentration. Following attempts to activate this species through the 
introduction of hydrogen, no hydride peak was observed in the 1H NMR 
spectrum. When L6 was introduced into the Young’s tube with L1 to ensure 
catalyst activation, the 19F NMR spectrum still possessed three ‘free’ peaks 
with no ‘bound’ peak being apparent to suggest L6 was binding to the iridium 
catalyst.  
The lack of L6 binding to 4 is likely due to two main factors: the steric bulk of 
the ortho fluorine and the pKa of the substrate. The steric bulk of 19F at ~1.47 
Å is smaller than that of a methyl group in the same position (radius =~2.00 
Å)138, 139 which would not be expected to form a SABRE active complex due 
to literature reports of picolines and lutidines with a methyl group in the ortho 
position failing to demonstrate SABRE.126 The radius of fluorine is, however, 
far closer to the ~1.20 Å of 1H than that of a methyl group so steric effects 
would not be expected to be as severe. It is worth noting that the pKa of L6 
shows it is the most acidic of the ligands tested within this study, therefore, 
may not be as effective a ligand as alternatives also investigated. Though no 
data could be found in literature for a precise pKa value for L6, a value of -1.00 
is reported for pentachloropyridine (all pKa values are shown in Figure 41).136 
This lack of SABRE activity is in agreement with previous literature which has 
reported no hyperpolarisation observed for pentafluoropyridine.67 
L2 demonstrated activity, however this was typically below unity and a hydride 
signal was not observed for [Ir(L2)(IMes)(H)]+. The lack of hydride signal did 
not enable exchange rates for this complex to be interrogated and therefore a 
detailed mechanistic explanation for the low activity level is not possible. This 
ligand does suffer from many of the same drawbacks as L6 discussed above 
with a fluorine substituent similarly in the ortho position and a low pKa (-
0.44).131  
Both L2 and L6 have been previously reported to be poor ligands for SABRE 
hyperpolarisation, with steric effects being cited as one of the limiting factors. 
The reported use of [Ir(IMe)(COD)Cl] as the polarisation transfer pre-catalyst 
(as opposed to 4 used here) does not demonstrate an increase in activity for 
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these two ligands, however.96 It was hoped the reduced buried volume of this 
carbene may better facilitate the binding of bulky ligands. The use of 
asymmetric carbenes within the pre-catalyst has recently been reported to be 
advantageous for bulky ligands, while reducing the enhancements of simpler 
substrates such as pyridine due to longer residence times bound to the iridium 
centre, these may present a potential route to increase the activity of L2 and 
L6.34 
L5 appears to show a reduction in enhancements with reducing excess of 
substrate, however this trend is partially reversed when SABRE-SHEATH is 
used. The 19F NMR spectra for this substrate are typically either emissive or 
absorptive with negligible antiphase characteristic. It is thought that this is due 
to the symmetrical nature of the coupling network around this ligand compared 
to the other ligands which demonstrate SABRE enhancements. The 
enhancement values obtained for this ligand system were surprisingly low 
when compared to L3, this is discussed, in section 4.2.5 when considering 
exchange rate data. Though it is worth noting that the pKa of L5 is still low (with 
the chloropyridine value available in literature being 0.66),135 meaning that this 
substrate is likely to be a worse ligand than L3 with its higher pKa value.  
L3 demonstrates the highest enhancements of the substrates tested, with 
NMR enhancements increasing, when the ratio of substrate : catalyst is 
decreased to 4:1 respectively, in agreement with prior reports for 1H SABRE. 
The 19F NMR spectra for this substrate, however, demonstrate a strong 
antiphase signal, leading to significantly reduced polarisation values when no 
phase processing is applied as the majority of the polarisation is cancelled 
within the integral calculation. The cause for this antiphasing is likely to be due 
to F-H coupling which doesn’t lead to an antiphase signal in L5 due to the 
symmetric nature of the substrate. 
In addition to being the least sterically bulky of the substrates tested, L3 has 
the additional advantage of a higher pKa (2.97) than the other fluoropyridines 
tested and is the most similar to the reported pKa of pyridine (5.17).131 In 
combination with the exchange rates collected for the SABRE active ligands 
discussed in 4.2.5 this explains the increased enhancements of L3  compared 
93 
to the other ligands tested. However, the antiphase characteristic of the 
spectra obtained means this signal would have limited in vivo use without a 
method of avoiding internal signal cancellation. 
4.2.3. SABRE-SHEATH testing 
In an attempt to counteract the antiphase nature of the L3 the magnetisation 
transfer field (MTF) was varied based on previous 15N work by Theis et al.51 
 
Figure 44. Comparison of 19F NMR spectra of L3 when SABRE-SHEATH is 
utilised (top) and when polarisation transfer takes place at earth’s field 
(bottom). 
The unprocessed signal of L3 when SABRE-SHEATH was employed is in 
excess of 95% in phase (as shown in Figure 44) leading to a 12-fold apparent 
increase in integration (for an overall enhancement of 808) when compared to 
the unprocessed signal without making use of a μ-magnetic shield due to the 
reduction in internal signal cancellation. This has important implications when 
moving towards in vivo applications as the smaller collection window of MRI 
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would lead to significant signal cancellation if the signal contained a large anti-
phase characteristic. 
This has been reported during the course of this study with L3 as the only 
substrate examined and Theis et al. demonstrated a 100% in phase signal.68 
The method used for this measurement was the bubbling of parahydrogen 
through the sample, leading to more controlled polarisation transfer while at a 
reduced magnetic field, whereas the results presented in this thesis involved 
manually shaking the sample within the μ-shield. This ‘shake and drop’ method 
potentially allows polarisation transfer to continue during the non-adiabatic 
transfer to the measurement field - resulting in an element of polarisation 
transfer occurring at earth’s field during transfer, likely leading to the less than 
fully emissive spectra collected in this work. 
The work presented here, however, demonstrates a 1.6% total polarisation of 
L3 at 4 equivalents relative to 4 based on a 808-fold signal increase in a 
measurement field of 1.4 T, a significant improvement on the 0.3% polarisation 
reported. 
4.2.4. SABRE active species 
Both L3 and L5 demonstrated good enhancements due to the SABRE 
process. The complex responsible for polarisation transfer was characterised 
to inform EXSY investigation of the exchange thermodynamics, discussed in 
section 4.2.5, and to gain insight into the differences, if any, between the two 
complex’s which may affect polarisation transfer efficiency.  
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Figure 45. 1H NMR spectrum of [Ir(IMes)(L3)3(H)2]+. Hydride region is shown 
in expansion. 
L3 forms [Ir(IMes)(L3)3(H)2]+ when reacted with 4 in the presence of H2. This 
is supported by the relative integrals of peaks associated with the ortho 
protons of 3-fluoropyridine at 8.39, 8.31 and 8.28 ppm giving the relative 
integrals of 1.56:1.53:0.90 respectively when four equivalents of L3 was 
added relative to 4. These three environments demonstrate that with four 
equivalents of L3 present three bind, with two trans to the hydrides and one 
substrate trans to the carbene which has been shown not to participate in 
polarisation transfer.140 The hydride region shows a major hydride at -23.11 
ppm; there were also two minor broad hydrides at -23.87 and -25.19 ppm 
which are diagnostic of a second complex in solution, likely to be 
[Ir(IMes)(L3)2(H)2(MeOH)] with the methanol adduct cis and trans to the 
hydrides respectively. Methanol adducts have been previously reported.35, 128 
Enhancement of the solvent OH protons was observed during this study and, 
again, this has been previously reported.141 The methanol attributed hydride 
peaks were too broad for rigorous investigation making use of EXSY, and 
previous literature has assumed a component two exchange system 
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(hydrides and the primary substrate trans to the hydrides exchanging only). 
Therefore, for comparisons sake only the major hydride attributed to 
[Ir(IMes)(L3)3(H)2] will be used for EXSY. 
L5 forms [Ir(IMes)(L5)3(H)2]+ with peaks for the ortho protons being present at 
8.48 and 8.32 ppm for free and bound substrate respectively. These peaks 
are present in a 2.08:1.92 ratio when 4 equivalents of L5 are present. A 
similar ratio of free and bound substrate is observed within the para proton 
environments at 7.57 (free) and 7.42 (bound) ppm – though in this instance 
the ratio is 1.94:2.06 suggesting that not all of the complex in solution exists 
in the form [Ir(IMes)(L5)3(H)2]+ as a ratio of 1:3 would be expected in this 
instance. This is supported by the presence of a main hydride at -24.02 ppm 
accompanied by hydrides representative of methanol adducts present at -
24.16 and -24.77 ppm. 
4.2.5. Exchange Rates 
The initial SABRE testing revealed that L3 produced the largest enhancement 
of the substrates tested; though this may partially be explained through the 
pKa difference between the two substrates, L5 would still be expected to have 
a greater enhancement due to two polarisable 19F sites. Burns et al. report that 
this is demonstrated for 31P polarisation when pyridine is meta substituted with 
diethylphosphonate (31P enhancement of 860) compared to the singly meta 
substituted substrate with a 31P enhancement of 336.63 However, Burns et al. 
do note that the steric bulk of the substituents results in a chlorine adduct being 
present in the polarisation transfer complex for this substrate. 
The exchange rates of the hydride and substrate ligands in these complexes, 
was examined by exchange rate spectroscopy (EXSY). The exchange rate of 
pyridine with the pre-catalyst 4 was initially investigated both as method 
validation, given these values are reported, and as a benchmark for the 
comparison of the unreported substrates. Eyring-Polanyi plots making use of 
the exchange data have been used to provide an insight into the 
thermodynamics of the ligand exchange process. Initially [Ir(IMes)(L1)3(H)2]+, 
shown in Figure 46, was interrogated for literature comparison. 
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Figure 46. [Ir(IMes)(L1)3(H)2]+ complex to be interrogated by EXSY. 
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Table 9. Hydride exchange rates in the [Ir(IMes)(L1)3(H)2]+ complex. 
Temperature (K) Exchange Rate (s-1) 
268 0.2181 ± 0.001 
275 0.6668 ± 0.010 
280 0.9692 ± 0.021 
285 1.6962 ± 0.041 
290 2.6507 ± 0.091 
300 6.1498 ± 0.213 
 
Figure 47. Eyring-Polanyi plot for the hydride exchange rate in the complex 
[Ir(IMes)(L1)3(H)2]+. 
Table 10. Hydride energy values for the exchange rate in [Ir(IMes)(L1)3(H)2]+.  
ΔH (kJ mol-1) ΔS (J K-1 mol-1) ΔG300 ( kJ mol-1) 
Literature26 79 ± 1 41 ± 3 66.4 ± 0.3 
Experimental 71.3 ± 6.2 14.83 ± 21.79 66.8 ± 0.3 
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Table 11. Pyridine exchange rates in the [Ir(IMes)(L1)3(H)2]+ complex. 
Temperature (K) Exchange Rate (s-1) 
268 0.3019 ± 0.014 
275 0.7788 ± 0.046 
280 1.4240 ± 0.040 
285 2.0792 ± 0.057 
290 3.8554 ± 0.046 
300 11.9357 ± 0.215 
 
Figure 48. Eyring-Polanyi plot for the pyridine exchange rate in the complex 
[Ir(IMes)(L1)3(H)2]+. 
Table 12. Pyridine energy values for the exchange rate in [Ir(IMes)(L1)3(H)2]+. 
 
ΔH (kJ mol-1) ΔS (J K-1 mol-1) ΔG300 ( kJ mol-1) 
Literature26 93 ± 3 97 ± 9 64 ± 2 
Experimental 71.5 ± 1.3 19.12 ± 4.65 65.7 ± 0.1 
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The energy values generated from this data validated the method for 
application on novel systems. There is a large difference between the 
experimental and tabulated entropy values, particularly for pyridine exchange, 
however the contribution of this value to the overall Gibb’s energy is minimal 
and the overall Gibb’s free energy for the system shows reasonable literature 
agreement. Therefore, the system [Ir(IMes)(L3)3(H)2]+, shown in Figure 49, 
was interrogated. 
 
Figure 49. [Ir(IMes)(L3)3(H)2]+ complex to be interrogated by EXSY.  
101 
Table 13. Hydride exchange rates in the [Ir(IMes)(L3)3(H)2]+ complex. 
Temperature (K) Exchange Rate (s-1) 
275 0.5577 ± 0.051 
280 1.2001 ± 0.072 
285 2.2009 ± 0.073 
290 3.9706 ± 0.147 
300 11.5417 ± 1.015 
 
Figure 50. Eyring-Polanyi plot for the hydride exchange rate in the complex 
[Ir(IMes)(L3)3(H)2]+. 
Table 14. Hydride energy values for the exchange rate in [Ir(IMes)(L3)3(H)2]+. 
 ΔH (kJ mol-1) ΔS (J K-1 mol-1) ΔG300 ( kJ mol-1) 
Literature 
(for Pyridine) 
79 ± 1 41 ± 3 66.4 ± 0.3 
Experimental 80.0 ± 2.6 48.05 ± 9.05 65.6 ± 0.1 
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Table 15. Substrate exchange rates in the [Ir(IMes)(L3)3(H)2]+ complex. 
 
 
 
 
 
 
 
 
Figure 51. Eyring-Polanyi plot for the 3-fluoropyridine exchange rate in the 
complex [Ir(IMes)(L3)3(H)2]+. 
Table 16. 3-Fluoropyridine energy values for the exchange rate in 
[Ir(IMes)(L3)3(H)2]+. 
 ΔH (kJ mol-1) ΔS (J K-1 mol-1) ΔG300 ( kJ mol-1) 
Literature 
(For Pyridine) 
93 ± 3 97 ± 9 64 ± 2 
Experimental 69.2 ± 3.2 15.96 ± 10.92 64.4 ± 0.1 
Temperature (K) Exchange Rate (s-1) 
268 0.5268 ± 0.008 
275 1.7190 ± 0.048 
280 2.7007 ± 0.030 
285 3.9581 ± 0.046 
290 7.3558 ± 0.037 
300 18.1232 ± 0.626 
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In the L3 system the experimentally observed exchange rates are ~50% faster 
than those in pyridine. The commensurate exchanges of hydride and substrate 
in the same order of magnitude as pyridine provide a theoretical basis for the 
polarisation transfer leading to high SABRE enhancements. When combined 
with the pKa of L3 (discussed in section 4.2.2) the observed exchange rates 
explain why 3-fluoropyridine demonstrates the highest enhancements of 
substrates tested here. The EXSY interrogation of [Ir(IMes)(L5)3(H)2]+, shown 
in Figure 52, was then attempted. 
 
Figure 52. [Ir(IMes)(L5)3(H)2]+ complex to be interrogated by EXSY. 
EXSY of [Ir(IMes)(L5)3(H)2]+ was attempted and values obtained at 268 and 
280 K, are shown in Table 17 and Table 18 for hydride ligands and L5 
respectively. 
Table 17. Hydride exchange rates in the [Ir(IMes)(L5)3(H)2]+ complex. 
Temperature (K) Exchange Rate (s-1) 
268 2.1616 ± 0.097 
280 11.1510 ± 0.513 
 
  
104 
Table 18. Substrate exchange rates in the [Ir(IMes)(L5)3(H)2]+ complex. 
Temperature (K) Exchange Rate (s-1) 
268 2.3428 ± 0.039 
280 16.9151 ± 1.301 
EXSY for temperatures above 280 K was attempted, however, exchange rates 
were too fast to accurately track on the NMR timescale. It is worth noting that 
one of the closest literature reports available (excluding the publication of this 
work) notes the hyperpolarisation build up time of 3,5-ditrifluoromethylpyridine 
is also too short to measure.129 Hydride exchange at 268 and 280 K was 10 
times faster than in a pyridine system at the same temperature, with substrate 
exchange being 20 times faster at the same temperatures. The speed of these 
exchanges explains the SABRE enhancement at room temperature being 
lower than expected for L5 as exchange is too fast for a J-coupling network to 
be formed which facilitates polarisation exchange. 
The high exchange speed suggested that, if SABRE were to be carried out on 
L5 at reduced temperature regime, there may be an increase in enhancement. 
Therefore, this was tested with the results of the study presented in Table 19. 
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Table 19. L5 enhancements at room temperature and after 90s in an ice bath 
without and (with) magnitude processing of data. 
 Room Temperature After 90 s in ice bath 
1H Ortho Para Ortho Para 
20 
equivalents 
237 
(131) 
66 
(69) 
12 
(12) 
7.57 
(10) 
10 
equivalents 
81 
(52) 
146 
(32) 
15 
(4.13) 
0.94 
(2.31) 
4 
equivalents 
20 
(4.65) 
9 
(1.44) 
7.18 
(0.76) 
0.04 
(0.42) 
19F Earths Shield Earths Shield 
20 
equivalents 
43 
(34) 
8 
(3.27) 
3.34 
(3.35) 
46 
(20.32) 
10 
equivalents 
71 
(35) 
4.48 
(6.62) 
2 
(4.5) 
31 
(59) 
4 
equivalents 
14 
(3.43) 
14 
(3.53) 
20 
(9) 
239 
(82) 
Polarisation transfer after 90 seconds in an ice bath at 0°C appears to reduce 
the 1H enhancement, particularly for the ortho site of the ring. This is likely due 
to a shortened T1 resulting from prolonged exposure to the polarisation 
transfer catalyst, particularly for the ortho protons. 
19F enhancements also show a reduction, again potentially due to relaxation 
effects. However, when sample shaking was undertaken in the magnetic 
shield directly after removal from the ice bath, enhancements were noticeably 
increased – this may be suggestive of an optimal temperature slightly above 
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0°C as these samples will have had maximum time to warm between removal 
from the ice bath and transfer to the collection field. This does, however, 
demonstrate that L5 may be optimised at a temperature lower than that of the 
initial measurements for 19F polarisation. 
4.2.6. Signal relaxation 
Quick relaxation rates can be a barrier to potential in vivo use, as even the 
collection of MR images following a short (~8 s) transfer time may result in a 
significant decrease in signal for substrate systems with a low relaxation time 
(T1).86, 142 This may be overcome through the bubbling of parahydrogen 
through the sample within the image collection instrument however this would 
not be viable for clinical applications.  
The short T1 values of some substrates is further complicated through the 
potential mixing of Zeeman values when the SABRE-SHEATH technique is 
employed.55 This can lead to drastically reduced T1 values, an order of 
magnitude smaller than those available at earth’s field or higher. This can 
significantly decrease the potential polarisation build up for SABRE-SHEATH.  
Now 19F SABRE has been demonstrated, the longevity of the signal was 
investigated as a high enhancement shortly lived signal may exclude biological 
applications; methods exist for lengthening of the relaxation time and these 
are discussed further in 5.2.4.30 
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Table 20. 1H T1 relaxation times for the substrates recorded at 9.4 T. 
Substrate L1 (s) L2 (s) L3 (s) L5 (s) 
 Ortho Meta Para Meta 3 Para 4 Meta 5 Ortho 6 Ortho 2 Para 4 Meta 5 Ortho 6 Ortho Para 
20 eq 15.58 26.22 19.58 24.56 26.18 27.91 7.20 16.04 26.13 24.05 16.61 21.90 29.24 
10 eq 9.12 15.44 12.95 20.78 24.02 24.88 19.36 8.21 15.13 11.99 10.06 17.74 28.44 
4 eq 4.18 7.78 6.46 27.93 18.43 20.22 18.48 10.44 16.39 14.12 12.90 4.87 1.08 
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Table 21. 19F T1 relaxation times for the substrates recorded at 1.4 T. 
Substrate L2 (s) L3 (s) L5 (s) L6 (s) 
    Ortho Para Meta 
20 eq 12.52 23.56 18.21 26.36 30.55 43.05 
10 eq 13.13 18.63 21.67 19.94 25.52 23.10 
4 eq 9.59 19.23 17.95 12.57 20.10 18.05 
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The 19F T1 values reported are reasonably short, with relaxation times of ~20 
s for four equivalents of L3 relative to 4 (the optimum for enhancements). It is 
notable that these relaxation times are lengthened by ~3 times when 19F 
measurements are taken at 1.4 T compared to 9.4 T; suggesting these signals 
may be useful for low field MRI.96 A theoretical basis for this is provided by 
Theis et al.49 
Relaxation times show a trend with shorted T1 durations for lower 
concentrations of ligand relative to 4, this is because of increased spin 
interactions when L is bound to the metal centre of the catalyst. The relaxing 
effect of the polarisation transfer catalyst means that optimisation of a SABRE 
system requires a balance between high enhancement levels associated with 
four equivalents of ligand relative to 4 and the shorter relaxation times this 
leads to. Methods for lengthening T1 have been previously reported,30 in 
particular through the deactivation of the SABRE active species following 
polarisation transfer – attempting to make this process heterogeneous is 
discussed further in section 5.2. 
4.2.7. Deuteration Studies 
The selective deuteration of a hyperpolarisation ligand of interest has been 
well established to increase the polarisation levels achieved through 
preventing ‘dilution’ of the hyperpolarisation to a range of receiver nuclei.26, 45, 
143, 144 This has been reported in biologically relevant ligands, such as the 
tuberculosis drug isoniazid and its derivatives,86, 95 where elongation of T1 
values are reported in addition to improved signal enhancements. The use of 
a fully deuterated carbene has also been reported to lead to higher levels of 
ligand polarisation, though this can be partially balanced by a reduced 
relaxation time.32, 145 
Though deuteration of the SABRE ligand and catalyst bound carbene have 
both been well established in literature the impact of a selective deuteration 
strategy SABRE of heteroatoms remains, to the best of the authors 
knowledge, unreported.  
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In most reported instances of a selective deuteration strategy reported for 1H 
SABRE a single proton in the ortho position of a pyridyl ring was left 
undeuterated to act as a polarisation receptor. However, as described in 
section 4.1.2, the polarisation of substrates with a 19F atom present in this 
position has failed to result in SABRE activity. A deuteration strategy for 
selective labelling of a 19F containing substrate for SABRE would therefore 
likely have to include the 19F to be polarised in the meta or para positions if the 
‘benchmark’ pyridine ring scaffold is to be used, as shown in Figure 53. 
 
Figure 53. Possible deuterated fluoropyridine structures suitable for SABRE. 
However traditional SABRE models suggest that polarisation is relayed to the 
meta and para positions via a J-coupling network formed with the proton in the 
ortho position.129 Therefore deuterating this site would mean that polarisation 
transfer didn’t take place to the hetroneuclei. However, in their recent report of 
3-fluoropyridine being hyperpolarised using SQUID detection Buckenmaier et 
al. note that if the protons are required to relay polarisation onto the 19F present 
then the field dependencies (shown in Figure 40) would be similar and 
correlated, which is not the case. They therefore propose that a direct transfer 
of polarisation from the catalyst-bound parahydrogen derived hydrides to the 
heteroatom may be feasible, as shown in Figure 54.  
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Figure 54. Possible polarisation transfer mechanisms to spin-1/2 heteronuclei 
(X, eg. 19F) of pyridine derivatives. (a) Indirect polarisation transfer: the 
polarisation of hydrogen is transferred to hydrogen of the pyridine derivative 
and subsequently to X. (b) Direct polarisation transfer: the polarisation is 
transferred directly to heteronucleus X. (c) Polarisation transfer after H/H 
exchange reaction. Hydrogens of a pyridine ligand in ortho-position can 
exchange during SABRE polarisation transfer could then relay polarisation to 
heteronucleus X.146 
If mechanism B from Figure 54 occurs then the deuteration of other positions, 
shown in Figure 53, may be an effective strategy to increase the 19F 
polarisation levels obtained and potentially increase the relaxation time, T1. If 
this is the case then this would represent a novel mechanism for SABRE 
polarisation transfer to heteronuclei. 
As initial substrate tests reported L3 to demonstrate the highest 19F SABRE 
enhancements, the deuterated analogue of L3 was synthesised (see section 
8.6). Utilising TMS as an internal standard collection of a 1H spectrum 
suggests a circa 52% deuteration. However, protonation of the ortho site was 
observed within this d4-methanol sample. Subsequent attempts to perform 
SABRE with d4-L3 did not result in an observed hyperpolarised signal for the 
substrate, suggesting that mechanism A described within Figure 54 may be in 
effect within this sample. Alternatively, mechanism B may occur, however, the 
long range J-coupling is not strong enough to effectively transfer polarisation 
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form the parahydrogen derived hydrides directly to the fluorine hetronuclei 
present in d4-L3. 
4.3. Conclusion 
The SABRE hyperpolarisation of a range of 19F containing substrates is 
presented. At the time of project commencement the only prior literature for 
19F SABRE was a single spectrum for 3-fluoropyridine without a quoted 
enhancement factor in the SI of the first report of SABRE.21 An additional 
report had found pentafluoropyridine to be SABRE inactive, however, no 
explanation for this had been presented.67 During the course of this project 
there were two additional publications for 19F SABRE.68, 129  
The work presented here demonstrates SABRE hyperpolarisation of 
previously unreported ligands. This work explains the lack of activity in 2-
fluoropyridine, 4-fluoropyridine and pentafluoropyridine while demonstrating 
high enhancement values for 3-fluoropyridine and 3,5-difluoropyridine. 
SABRE-SHEATH was applied to the SABRE active ligands demonstrating a 
route towards phase correction of the hyperpolarised signal for future in vivo 
application.  
The species responsible for polarisation transfer were characterised and the 
binding affinities of the ligands discussed. The characterisation of these 
species has enabled interrogation of the ligand and hydride exchange rates 
for the successfully polarised ligands. 
Exchange rates of ligand and hydride species provide a basis to explain the 
higher polarisation levels of 3-fluoropyridine compared to 3,5-difluoropyridine. 
The results suggest [Ir(IMes)(3,5-difluoropyridine)3(H)2] will better facilitate 
polarisation transfer at a low temperature regime. Conducting SABRE with 3,5-
difluoropyridine at low temperature has then been attempted resulting in 
increased 19F SABRE-SHEATH polarisations. However 1H polarisation has 
decreased – this was investigated through examination of the ligand relaxation 
time for the SABRE active species. 
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The relaxation times of all SABRE active species have been investigated, 
demonstrating the difficulty in optimising a polarisation transfer system as 
reduced ligand equivalents relative to the polarisation transfer catalyst result 
in a higher enhancement, due to a higher efficiency transfer process, but also 
results in a reduced relaxation time meaning the resulting hyperpolarised 
signal returns to unity faster. This work also demonstrates that low field 
applications such as benchtop NMR have an advantage over more traditional 
high field applications due to longer T1 values for the same sample.96 
Finally, a deuteration approach has been taken to gain insight into the 
mechanism of polarisation transfer to 19F and to increase the overall levels of 
polarisation. Testing of d4-L3 revealed that no hyperpolarised signals were 
present when this substrate was assessed for SABRE activity. This result 
suggests that polarisation transfer may require a proton within the ortho site 
for this ligand to facilitate indirect polarisation transfer from the iridium bound 
parahydrogen derived hydrides onto the 19F via this proton. It may also suggest 
that long range scalar couplings are simply not strong enough to facilitate 
direct polarisation transfer to the heteronuclei in this ligand. 
This thesis demonstrates the feasibility of using 19F SABRE to hyperpolarise 
a range of ligands, including those demonstrated here, and has been utilised 
as a basis for the polarisation of biologically relevant 19F containing ligands, 
including a world health organisation (WHO) essential medicine the results of 
which are presented in section 6.2.  
114 
5. Studies towards a metal-free 
SABRE bolus 
5.1. Introduction 
Recent studies have demonstrated that the typically employed SABRE pre-
catalyst, [Ir((IMes)(COD)Cl] (4), demonstrates cytotoxicity.71, 78 This chapter 
details the application of heterogeneous SABRE (HET-SABRE) catalysis to 
hyperpolarise molecules, and the use of heterogeneous supports as catalyst 
scavengers. Both of these approaches are viable methods to separate a 
SABRE catalyst, such as 4, from solution in order to prepare a bolus suitable 
for in vivo imaging. These methodologies have been explored in direct 
response to circumventing the cytotoxicity of the SABRE catalyst. 
5.1.1. Catalyst toxicity 
One of the key goals of SABRE hyperpolarisation is the eventual application 
to in vivo imaging, with that in mind any toxicity attributed to the SABRE 
catalyst, substrate or solvent should be minimised or avoided. Substrate 
toxicity will have to be tested on an individual basis, however, as the SABRE 
process doesn’t chemically change the substrate, previously approved drugs 
should be safe to use. Indeed, SABRE has already been demonstrated on 
several commercially available drugs.48, 95, 96  
Recent developments towards a biocompatible SABRE solvent system have 
also been reported through approaches including the use of water-soluble 
catalysts and pre-activating 4 to endow water solubility.80-83 However, the 
highest enhancement levels have been reported when polarisation transfer 
occurs in a deuterated alcoholic solvent,28, 45 therefore a simple method 
suggested to generate a biologically compatible bolus is polarisation transfer 
in d6-ethanol before dilution with D2O,71, 78 with lower ethanol concentrations 
significantly decreasing mortality in mice.147 Indeed, high ethanol 
concentrations have been utilised for the euthanasia of laboratory mice and 
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rats,148-150 so work to determine a suitable dilution has been conducted by 
Duckett et al.71, 78 
The remaining, potentially toxic, component of the SABRE process is the 
(typically) iridium containing polarisation transfer catalyst. Iridium toxicity has 
been previously reported, however, iridium compounds are, in general, 
defined as ‘practically non-toxic’ in a recent review.151 Iridium and rhodium 
chloride salts have been reported to inhibit rat fibroblast cell proliferation in 
vitro in addition to inducing DNA damage, though notably iridium(III) chloride 
hydrate had a reduced effect compared to rhodium(III) chloride hydrate.152 
Hypersensitivity to iridium salts has also been reported to be developed after 
long term exposure in a factory setting.153 
Recently, Duckett et al. have sought to evaluate the toxicity of the SABRE 
process, specifically to determine if additional work is required to overcome 
toxicity barriers before considering progressing SABRE towards clinical 
applications. This work first sought to establish if a d6-ethanol:D2O mixture led 
to loss of cell viability, as shown in Figure 55. 
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Figure 55. Evaluating the effect of a d6-ethanol:D2O mixture on cell viability 
against two different cell lines: A549 (dark blue) and MCF7 (light blue) after 6 
hours (A) and 24 hours (B).71 
This led to the conclusion that a 30% d6-ethanol mixture in D2O did not lead to 
a drop in cell viability so would be ideal for potential in vivo use. Although D2O 
has been reported to induce cell apoptosis, this is typically at higher 
concentrations or longer timescales than those utilised in by Duckett et al.154, 
155  
 
Figure 56. Methyl nicotinate and d2-methyl nicotinate utilised by Duckett et al.71 
Methyl nicotinate and d2-methyl nicotinate, as shown in Figure 56, were the 
substrates utilised for this study and also did not show a statistically significant 
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(P<0.05) loss of cell viability over a 6 hour period, even at relatively high (20 
mM) concentrations. After 24 hours cell mortality did occur at this 
concentration, with only the A549 cell line utilising undeuterated methyl 
nicotinate at a concentration of 5 mM reporting a cell viability in excess of 90% 
after 24 hours.  
The limiting factor for biological hyperpolarisation is likely to be signal 
relaxation with Roy et al. and Theis et al. currently reporting substrate T1 
values of under half an hour.50, 156 Given SABRE-focused pharmacokinetic 
nicotinamide studies have demonstrated a terminal elimination phase half-life 
of close to an hour in rat studies, even when the lowest dose tested was 
utilised (20 mg/kg), hyperpolarisation is likely to only be observed for a minor 
portion of the bolus’ in vivo residence time.157 
Duckett et al. then prepared a full SABRE reaction mixture consisting of 4 (5 
mM) and 20 mM deuterated methyl nicotinate in 30% d6-ethanol:70% D2O in 
order to test the cell viability of the full SABRE mixture with the activated 
catalyst, the results of this assay are shown in Figure 57. 
 
 
Figure 57. Cell viability of two cell lines A549 (A) and MCF7 (B) after 1, 6 and 
24 hours (A) and 24 hours (B) when exposed to several bolus volumes (0, 
1.25, 2.5, 5, and 10%) of SABRE reaction mixture.71 
Figure 57 shows there was no significant loss of cell viability after 1 hour with 
the lowest bolus volume of SABRE mixture used, 1.25%. However, any higher 
concentration or longer exposure time led to significant drops in cell viability. 
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This toxicity was attributed to 4 itself as the toxicity was not present when the 
solvent and substrates were tested individually. Duckett et al. demonstrated in 
a later extension of this study that changed the identity of 4 to an alternative 
water soluble iridium containing catalyst, that this improved both aqueous 
solubility and could potentially increase activity.35, 78 The water soluble catalyst 
utilised was [Ir(H)2(tmx)(mPTA)](I)(CF3SO3)], shown in Figure 58, where tmx 
is tetramethylxanthine and mPTA is the coligand ethylated 1,3,5-triaza-7-
phosphaadamantane. 
 
Figure 58. Structure of [Ir(H)2(tmx)(mPTA)](I)(CF3SO3)] water soluble catalyst 
utilised by Duckett et al.78 
Utilising [Ir(H)2(tmx)(mPTA)](I)(CF3SO3)] or deuterating (either the imidazole 
ring for d2-IMes, all positions but the imidazole ring for d22-IMes or fully 
deuterated for d24-IMes) IMes in 4, still demonstrated toxicity.78 Though it was 
noted that deactivating the catalyst after polarisation transfer may be an 
effective approach to negate some of the toxicity,71 in addition to significantly 
increasing the relaxation times of the substrate,30 this increase in signal 
longevity is due to limiting access to the iridium which acts as a relaxing agent. 
The associated toxicity of the iridium complex means that techniques such as 
heterogeneous SABRE (HET-SABRE) catalysis,36, 93, 94 the use of biphasic 
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mixtures to separate the catalyst and substrate,89 or making use of metal 
scavengers to remove the catalyst from solution are logical progressive steps 
towards clinical application.72 
5.1.2. HET-SABRE catalyst systems 
The separation of the catalytic species, to form a hyperpolarised bolus, offers 
advantages both in the relaxation time of the hyperpolarised signal and in 
advancement towards clinical applications, as the removal of the catalyst 
means toxicity concerns are reduced in addition to lowering costs if the catalyst 
can be recycled. To this end, four heterogeneous SABRE (HET-SABRE) 
systems have been reported to date: these have been attached to either 
polymer microbeads,93 TiO2/PMAA (poly(methacrylic acid)) nanoparticles,36 or 
silica labelled with amine linkers.94 The structures of these HET-SABRE 
catalysts are shown in Figure 59. 
 
Figure 59. Pyridine activated HET-SABRE catalysts immobilised on polymer 
microbeads (left),93 TiO2/PMAA nanoparticles (middle)36 and bound to a silica 
supported amine linker (right).94 
All these HET-SABRE catalysts make use of a solid support axially bound to 
the iridium; ligands in this position have been reported not to exchange due to 
its stronger metal bonding interaction.28 
The polymer microbead example has demonstrated SABRE activity polarising 
pyridine to yield an enhancement of between 5.2 (ortho protons) and 2.7 (para 
proton). No bound signals were observed in the hyperpolarised spectra due to 
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the solid supported catalyst rapidly settling to the bottom of the NMR tube after 
shaking, and was, therefore, not excited during the 90° pulse subsequently 
applied. The binding of the catalyst to the solid support was confirmed making 
use of IR, MS and AAS, with AAS showing that 4% of the total homogenous 
bulk was the iridium complex. Removal of the supernatant following 
heterogeneous hyperpolarisation and subsequent testing separated from the 
solid bulk revealed no SABRE activity, demonstrating that the heterogeneous 
catalyst was responsible for polarisation - 1H NMR, AAS and MS were also 
applied to this sample and failed to detect any catalyst leaching into solution, 
within the detection limits of the instrumentation employed.93 
A further study demonstrated the synthesis of a heterogeneous catalyst on 
both a TiO2/PMAA nanoparticle and PVP (polyvinylpyridine) polymer.36 These 
species were characterised by NMR, AAS and DLS (dynamic light scattering). 
AAS determined that 25% of the total nanoparticle catalyst by weight was 
iridium complex and that the final filtrate wash following production of the 
heterogeneous species did not show the presence of iridium, indicating a 
robust heterogeneous catalyst. The enhancements obtained from the 
nanoparticle catalyst were ca. 2.5 times higher than those obtained from the 
polymer based catalyst making use of a ‘shake and drop’ method with pyridine 
as the substrate. When parahydrogen was bubbled through the solutions 
instead for 300 s, the nanoparticle based catalyst’s enhancements increased 
from 18-, 17- and 7-fold for ortho, meta and para pyridine environments 
respectively to give enhancements of 26-, 39- and 11-fold respectively. This 
equates to an overall polarisation of ca. 0.13%. The improved enhancements 
when a bubbling approach was taken to the introduction of parahydrogen to 
the HET-SABRE solution suggests this may be a more efficient approach 
given the difficulty of facilitating an interaction between dissolved gas and the 
HET-SABRE catalysts in solution, particularly given the relatively low H2 
solubility in most of the deuterated solvents employed. This study also 
demonstrated that the heterogeneous catalyst may be recycled for use in 
further SABRE experiments, though enhancements were slightly reduced 
following the recovery process. 
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Kovtunov et al. demonstrated the use of a commercially available silica 
supported amine linker to form a HET-SABRE catalyst.94 Though this report 
demonstrates lower polarisations for pyridine (~2.6 fold) compared to the work 
of Shi et al.,36, 93 the aim of the publication was to demonstrate HET-SABRE 
of heteroatoms, specifically 15N. Therefore, the proton polarisation was not 
optimised. Kovtunov et al. successfully demonstrated a 15N polarisation of 
~100 fold under HET-SABRE-SHEATH conditions.49, 51 The lower 
gyromagnetic ratio of 15N compared to 1H suggests that far greater 1H 
polarisation would be feasible using this HET-SABRE system if 1H polarisation 
was optimised.5 The signal has been attributed to solid-supported catalyst 
through the lack of 15N bound peaks typically observed for axially and 
equatorially pyridine to 4. The supernatant was further tested with XPS and 
ICP-MS suggesting no iridium is lost from the surface during the HET-SABRE 
process and there is minimal leaching into the supernatant. 
5.1.3. Catalyst deactivation 
Another alternative approach towards biological SABRE applications would be 
the employment of scavengers to remove the toxic iridium species following 
polarisation, but before injection of the hyperpolarised bolus. For this 
application, catalyst removal would have to proceed within the relaxation time 
of the substrate in order to produce a non-toxic bolus that still contains 
hyperpolarised substrate. Recent work has demonstrated T1 values of 9.71 
min for specifically 15N enriched metronidazole substrates at 1.4 T. However, 
the authors noted that the method could be expanded to the FDA approved 
anti-infective nimorazole,158 so a catalyst removal time in the order of ~5 mins 
would be ideal. 
The first catalyst deactivation report by Mewis et al. polarised nicotinamide 
making use of pre-catalyst 4 before employing 2,2’-bipyridine (bpy) or 1,10-
phenanthroline to homogenously rapidly deactivate the catalyst when the 
Young’s capped NMR tube was opened to air and the deactivating agent 
added.30 
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Table 22. T1 of nicotinamide (5 equivalents relative to 4) under H2 for the proton 
spins shown in Figure 60 when nicotinamide is without SABRE catalyst, with 
4 and with 4 and deactivating agent bpy.30 
 T1 (free)/s T1 (with 4)/s T1 (with 4 and bpy)/s 
a 43.1 7.0 38.0 
b 11.3 6.1 11.5 
c 13.5 3.7 14.0 
d 6.6 4.3 6.8 
 
Figure 60. Nicotinamide with proton environments labelled; nomenclature 
utilised in Table 22. 
As shown in Table 22, the deactivation of 4 led to the near total regeneration 
of the T1 measured when the relaxing agent 4 is not present in solution. The 
authors had hoped to produce a re-activatable system making use of UV light 
to dissociate the deactivating agent from the metal, however, this was proven 
not to be possible. When discussing the potential for heterogeneous 
scavenging of the metal catalyst, this effect may be helpful in prolonging the 
hyperpolarisation, through limiting interactions with the iridium catalyst which 
acts as a relaxing agent of the catalyst-free bolus, in addition to removing the 
toxic component. 159 
A similar approach has been reported making use of 
bathophenanthrolinedisulfonic acid disodium salt (BPS).71 This is structurally 
similar to 1,10-phenanthroline which had been reported by Mewis et al., with 
additional steric bulk incorporated away from the iridium binding sites. Once 
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deactivated the catalyst was then removed to produce a biocompatible bolus, 
making use of ion exchange chromatography to remove ~98% of the iridium 
present.  
During the course of this work, a range of silica supported scavengers have 
been assessed as catalyst scavengers by Barskiy et al.72 Barskiy et al. began 
by making use of a biphasic mixture approach, using a mixed aqueous/organic 
phase to remove >99% of the activated iridium catalyst as the substrate 
favours the aqueous phase. There was, however, still a measurable quantity 
of iridium present in the aqueous phase, likely due to the reported water 
solubility of the catalyst once activated,80 which may prevent this approach 
being used in isolation to produce a biocompatible bolus.160
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Figure 61. Solids tested by Barskiy et al. for scavenging efficacy,72 SA-SF are silica mounted except SE which is polystyrene mounted.
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Barskiy et al. then assessed the metal scavenging efficacy of a range of 
nitrogen and sulphur containing commercially available scavengers, shown in 
Figure 61, which widely ranged in size from ~20 – 750 μm and loadings 
between 0.5 and ~2 mmol/g. This work demonstrated that solid supported 
scavengers could be effective at removing low concentrations of iridium over 
a 12 hour period with 10 mg of the most effective scavenger removing ~95% 
of ~82 ppb iridium. The most effective scavenger, SC, was then assessed for 
the quantity of iridium that varying quantities of the scavenger could remove 
and syringes packed with SC were assessed as a practical method for the 
removal of SABRE catalyst and preparation of a bolus. Capture efficiencies 
>99% were reported when >75 mg of SC was used.  
In a further report, SC and SF are added, along with unfunctionalised silica, to 
a mixed solvent system.73 This resulted in catalyst capture within the lifetime 
of the substrate, in this case metronidazole, resulting in an average of >98% 
catalyst removal (with SC removing a higher percentage than SF) compared to 
the theoretical maximum iridium concentration value. Attempts to conduct 
SABRE following the addition of the scavengers were unsuccessful with the 
authors noting the previously iridium containing supernatant had become clear 
and the scavengers taking on a pale yellow colour similar to the catalyst. 
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5.2. Solid Supported HET-SABRE catalyst results 
The following section reports the attempts to utilise silica particles for the 
support of SABRE catalysts and their potential application for the deactivation 
of homogenous SABRE catalysts. 
5.2.1. Synthesis of potential HET-SABRE catalysts 
The initial aim of this work was to expand upon the initial report in which a 
silica support functionalised with a primary amine had been utilised (support 
S1).94 Substrates for testing were therefore chosen (see Figure 62) to examine 
if this approach was feasible for application in instances where secondary 
amine binding site(s) were available (supports S2 and S3), heterocyclic rings 
were present (supports S4 and S5) and the identity of the solid support was 
varied from silica to a polymer (supports S6 and S7).  
Commercially available supports were employed in order to be able to 
compare and contrast based on a quality controlled particle size and labelling 
quantity information. The smallest possible range of particle sizes and loadings 
was desirable as though this limits the validity of direct comparisons with the 
work of Barskiy et al., particularly when comparing the otherwise structurally 
analogous pairs SB/S4 and SD/S3. The approach presented here has the 
advantage of improved internal comparisons. In the instances where an 
alternative support is utilised, the binding mode of the functional labelling was 
as close as feasible to silica supports also being tested – in particular supports 
S1 and S2 being comparable with supports S6 and S7. HET-SABRE catalyst 
synthesis was attempted making use of supports S1-S7 using a synthetic 
approach based on the work of Kovtunov et al.94 (see section 8.6.13). 
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Figure 62. Solid supports tested as HET-SABRE catalyst candidates. Supports S1-S5 are silica supported, S6 and S7 are polystyrene 
bound.
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5.2.2. EDX testing of solid supports 
Following the exposure of the supports to the SABRE pre-catalyst the species 
produced were evaluated for iridium content to assess the efficacy of this 
technique for a wider range of substrates. EDX was utilised to examine the 
iridium atomic weight percentage on the surface of the silica as the quantities 
utilised meant that analysis techniques such as XRF were not viable.  
EDX is typically utilised to analyse samples with higher (circa. >10%) 
elemental weight loadings and iridium sensitivity, particularly for scavengers 
S1-S5, is hampered by the close proximity of K emission bands for Si and Ir. 
The iridium loading appeared to be relatively inconsistent across particles with 
the data shown in Table 23 representing an average from a minimum of 8 
replicates. There is still, however, likely to be a large error in the data due to 
the lack of uniformity between particles – the relatively high deviations shown 
in Table 23 reflect this.  
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Table 23. Iridium percentage weight on the surface of the potential HET-
SABRE catalysts synthesised with the standard deviation of measurements 
shown. 
 
Table 23 highlights that at such low elemental concentrations there are large 
errors associated with some samples analysed by EDX. However, this was the 
most suitable quantitative technique available for the produced sample 
volumes. 
Supports S1-S3 show that, with increased chain length and potential binding 
sites, more iridium appears to be bound to the silica surface. Though a higher 
catalyst loading would likely be advantageous for HET-SABRE activity, it is 
possible that the binding of the iridium to supports S2 and S3 is enhanced 
through a chelate effect that may not be advantageous for catalyst turnover; 
this is further discussed in section 5.2.4. 
Interestingly the relatively high iridium quantities detected for supports S1 and 
S2 aren’t reflected in the results for the polymer bound analogues of similar 
functionality in supports S6 and S7. This may be due to changes in surface 
area as the polymer particles appeared to demonstrate significantly more 
uniform shapes compared to the silica which demonstrate a wider range of 
Sample Average iridium weight % 
S1 0.459% ± 0.194% 
S2 0.796% ± 0.267% 
S3 0.891% ± 0.284% 
S4 0.693% ± 0.268% 
S5 0.194% ± 0.102% 
S6 0.386% ± 0.158% 
S7 0.422% ± 0.319% 
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particle shapes, potentially increasing surface area, as demonstrated in Figure 
63. 
 
Figure 63. SEM image of S5 prior to iridium loading. 
The quantity of iridium bound to the surface of support S4 is commensurate 
with that of support S1 with a similar binding mode. Support S4 does show a 
slight increase in iridium quantity compared to S1 that may be due to the 
increased distance between the binding site and the steric bulk of the support. 
The additional iridium bound to S4 may also be explained by the higher pKa of 
the imidazole (pKa of imidazole ~18.6)161 leading to more favourable metal 
binding compared to the amine binding site of S1 (pKa of ethylamine ~10.9).162 
Support S5 demonstrates the lowest iridium quantity on the surface which is 
unsurprising given previous attempts to bind a 2-substituted pyridine ring to 
the SABRE catalyst utilised have been unsucessful for 2-picoline,126 for which 
the steric bulk of the methyl substituent had been blamed. Attemps to 
hyperpolarise 2-fluoropyridine have also resulted in negligible catalyst binding, 
as discussed in section 4.2.2, with only hyperpolarisation near unity being 
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observed, in addition to no hydrides attributable to an activated catalyst 
species being found, even when an alternative SABRE catalyst with a less 
bulky carbene was utilised.96 Notably the less sterically encumbered 2-
methylthiophene has reported SABRE hyperpolarisation utilising 
[Ir(IMes)(COD)Cl].163 
5.2.3. HET-SABRE testing 
Following initial analysis, all potential HET-SABRE catalysts were tested for 
activity making use of a sample containing 15 μL pyridine and 10 mg 
synthesised potential HET-SABRE catalyst in d4-methanol (see 8.6.13).  
Making use of the standard SABRE procedure utilised throughout this work, 
with a 10 s mixing time, no hyperpolarisation was observed. However, 
increasing the mixing time led to observable HET-SABRE in the catalyst 
derived from S1, with hyperpolarised signals first observed following a 20 s 
shake time and 30 s shake yielding the highest signal enhancements, 
suggesting a slow build-up of polarised species in solution. The proposed 
structure of this HET-SABRE active species is shown in Figure 22. It is 
proposed that the increased shake time is required due to the low frequency 
of triphasic interactions of parahydrogen with the catalytic surface within the 
solvent, likely limiting the availability of replacement parahydrogen derived 
hydrides to enable consistent polarisation transfer. The molecular tumbling 
effects of the solid support may have additional T1 shortening effects upon the 
substrate that may compound an already slow polarisation build up. The 
consistent bubbling of parahydrogen through a HET-SABRE solution would 
likely, therefore, increase the enhancements observed. However, making use 
of the available equipment, this was not feasible and no HET-SABRE was 
observed for species derived from the other heterogeneous supports. 
132 
 
Figure 64. Observed HET-SABRE (top, red) of pyridine utilising catalyst 
synthesised from S1. The associated thermal spectrum is shown below in blue. 
Though HET-SABRE making use of S1 and [Ir(IMes)(COD)Cl] has been 
previously reported,94 and the enhancements demonstrated in Figure 64 are 
below unity, the presence of antiphase signals, particularly for the ortho 
environment, demonstrates that a SABRE active species has formed on the 
support surface. The low enhancements are expected for a HET-SABRE 
system due to the scarcity of triphasic interactions between the catalytic sites 
on the support surface, the substrate and parahydrogen. The previous report 
of S1 forming a HET-SABRE catalyst sought to overcome this barrier to 
application through the use of continuous parahydrogen bubbling through 
solution.94 However, the formation of an active species and subsequent 
observable SABRE polarisation is the aim of this study. 
5.2.4. SABRE catalyst deactivation 
As no HET-SABRE was observed for the prepared species, with the exception 
of support S1, it was noted that supports S2/S7 and S3 could potentially facilitate 
bidentate or tridentate binding modes respectively. This could therefore 
deactivate the SABRE catalyst in a similar manner to that previously reported 
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for bipyridine.30 This could, therefore, explain the relatively high iridium 
loadings observed via EDX resulting in no observed HET-SABRE. 
The characterisation of the support-bound species would be challenging, 
therefore analogues were sought. The ligands ethylenediamine and 
diethylenetriamine were utilised to simulate the heterogeneous supports in 
combination with 4. 
Following the addition of ethylenediamine or diethylenetriamine to a SABRE 
sample containing four equivalents of pyridine, relative to 4, a significant 
reduction in polarisation on average across all environments was observed – 
99.04% in the case of ethylenediamine and 99.55% in the case of 
diethylenetriamine. This result demonstrates that the homogenous equivalent 
to supports S2, S3 and S7 are effective at catalyst deactivation, which may 
prevent the formation of a HET-SABRE catalyst though the prevention of 
substrate binding. 
The displacement of pyridine from the activated species 
[Ir(IMes)(Pyridine)3(H)2] may be observed through monitoring the T1 values 
associated with pyridine before and after the addition of ethylenediamine or 
diethylenetriamine. 
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Table 24. Pyridine T1 values demonstrating the effect of changing environment with and without 4, ethylenediamine and 
diethylenetriamine present. 
4 present Condition 
Additional Ligand 
Added 
Pyridine 
Environment 
Pyridine Proton Environment T1 (seconds) 
ortho meta para 
No Vacuum No Free 31.165 26.892 35.221 
No H2 No Free 30.384 26.232 35.166 
Yes H2 No Free 4.176 6.452 7.848 
Yes H2 No 
Equatorially 
bound 
4.044 5.897 9.494 
Yes H2 No Axially bound 1.802 3.433 5.103 
Yes H2 
Ethylenediamine 
(1.5 eq relative to 4) 
Free 15.094 25.316 18.871 
Yes H2 
Diethylenetriamine 
(1.5 eq relative to 4) 
Free 30.030 25.422 33.079 
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Table 24 demonstrates that the relatively long T1 of pyridine is significantly 
reduced when in the presence of [Ir(IMes)(Pyridine)3(H)2] due to interactions 
with the extended spin system surrounding the iridium.159 Notably exchanges 
are brisk enough, with recorded pyridine exchange speeds of 11.7 s-1 at 300 
K,26 that the T1 of the pyridine free in solution and not currently bound to the 
catalyst is still drastically shortened compared to when the catalyst is not 
present. 
The addition of ethylenediamine reverses much of the decrease in T1 caused 
by interaction with the iridium species. This is due to a majority complex 
forming (~90%), as shown in Figure 65, in which ethylenediamine binds trans 
to the parahydrogen-derived hydrides. This is analogous with reported 
orientations for bipyridine deactivation,30 and prevents pyridine (substrate) 
exchange. Notably, in this spatial orientation with ethylenediamine bound trans 
to hydride ligands, pyridine would still be bound trans to IMes. Ligands bound 
to this site have been reported not to exchange, so this is unlikely to impact 
the relaxation time of free pyridine.30 
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Figure 65. Major species in solution following addition of three equivalents 
ethylenediamine to [Ir(IMes)(pyridine)3(H)2]. 
Table 25. 1H NMR characterisation data for complex shown in Figure 65. 
Site number 1H chemical shift/ppm 
1 7.10 
2 2.20 
3 7.13 
4 2.39 
5 8.49 
6 7.16 
7 7.73 
8 2.05 
9 -21.84 
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Figure 66. Hydride region demonstrating the major and minor species in 
solution following addition of three equivalents ethylenediamine to 
[Ir(IMes)(pyridine)3(H)2]. 
However, even with 1.5 equivalents of ethylenediamine added relative to the 
polarisation transfer pre-catalyst [Ir(IMes)(COD)Cl], the deactivation process 
appears incomplete as demonstrated by the incomplete restoration of 
relaxation times to levels commensurate with isolated free pyridine and the 
continued presence of some SABRE signals. Addition of 3 equivalents of 
ethylenediamine results in near complete catalyst deactivation, however, there 
are still minor hydride signals present, as shown in Figure 66, at -22.54 and -
23.78 ppm at a ratio of ~5% each compared to the major species in solution. 
These chemical shift values are likely due to pyridine and methanol 
respectively bound trans to the parahydrogen derived hydrides. These peaks, 
however, are present at such concentration that full characterisation of the 
complexes was not possible. 
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Addition of diethylenetriamine appears to deactivate the SABRE active 
species more effectively with an average relaxation time (Table 24) of 96.6% 
that of isolated pyridine; this is commensurate with the 99.55% decrease in 
hyperpolarisation observed following diethylenetramine addition. This 
increase in deactivation efficacy may be due to a chelate effect with the 
tridentate diethylenetriamine forming a predominantly fac-isomer in solution, 
displacing pyridine from sites both trans to hydrides and the IMes ligand as 
shown in Figure 67. The formation of this isomer is supported though the lack 
of visible bound signals for pyridine in the 1H NMR spectrum, even trans to 
IMes as shown in Figure 68. 
 
Figure 67. Majority species in solution following addition of 1.5 equivalents 
diethylenetriamine to [Ir(IMes)(pyridine)3(H)2]. 
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Table 26. NMR characterisation data for complex shown in Figure 67. 
Site number 1H chemical shift/ppm 
1 7.03 
2 2.11 
3 7.07 
4 2.36 
5 
2.16 
6 
7 -22.68 
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Figure 68. Aromatic region demonstrating the lack of bound pyridine peaks 
following addition of 3 equivalents diethylenetriamine to 
[Ir(IMes)(pyridine)3(H)2]. 
The main hydride occurring at -22.68, as shown in Table 26, is also similar to 
the reported signal attributed to [Ir(IMes)(ammonia)3(H)2] in which the hydride 
resonance is present at -23.61.84 
With the homogenous model demonstrating that supports S2, S3 and S7 
specifically may deactivate the SABRE active species, an assessment was 
undertaken to consider if these supports may be useful in attempting to 
progress SABRE towards in vivo application through removing the cytotoxic 
iridium species and aiding in the preparation of a biocompatible bolus.71 
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5.3. Solid Supports as catalyst scavengers 
The majority of the proposed solid supports S1-S7 did not show HET-SABRE 
activity, however, all supports did show that iridium, specifically in the form of 
4, may bind to their surface.  
The value of these proposed supports was, therefore, evaluated as a catalyst 
scavenger in order to remove the toxic iridium component from a homogenous 
SABRE hyperpolarised bolus that would be required for future in vivo 
application.71, 78 
5.3.1. ICP-OES optimisation 
ICP has previously been used for the determination of iridium removal from 
solution,72, 73 therefore a method was designed for use with ICP-OES. This 
method made use of the most sensitive detection line at 224.268 nm with 
manual inspection of sample data ensuring there were no interferences.164 
SABRE samples will contain a significant quantity of organic residue due to 
the catalyst bound carbene, methanol and pyridine used in this work. Though 
it is not possible to matrix match the iridium-bound organics, it was possible to 
account for the methanol solvent and pyridine substrate used to activate the 
polarisation pre-catalyst 4. To do this, a stock solution containing the quantities 
of pyridine and methanol representative of a SABRE sample with 4 equivalents 
of pyridine used relative to 4 was prepared. This organic containing stock was 
then used to spike a range of iridium standards from 10 ppb to 10 ppm with 0-
1% organic spiking. These standards were then analysed in both axial and 
radial viewing modes to assess which would be most suitable for this work 
(Figure 69 and Figure 70, respectively).
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Figure 69. A calibration plot of 0 to 10 ppm iridium making use of the axial viewing mode. The stock solutions had been spiked with 
between 0 and 1% of an organic stock representative of the organics present in a SABRE sample.  
● 0% Organic 
● 0.2% Organic 
● 0.4% Organic 
● 1% Organic 
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Figure 70. A calibration plot of 0 to 10 ppm iridium making use of the radial viewing mode. The stock solutions had been spiked with 
between 0 and 1% of an organic stock representative of the organics present in a SABRE sample. 
● 0% Organic 
● 0.2% Organic 
● 0.4% Organic 
● 1% Organic 
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These tests demonstrated that the presence of organics had a minor effect on 
the signal intensity observed. Changing the radiofrequency (RF) power from 
which the plasma is induced within the working range between 1050 and 1150 
W demonstrated little effect, therefore, the instrument optimised value of 1175 
W was used. The axial viewing mode was also utilised for further work as this 
provided the highest intensity and thus minimised the effect of the organic 
sample spiking. The standards spiked with 1% organic stock were utilised as 
standards for the quantitative determination of iridium concentration for the 
rest of this chapter as this was most representative of the analyte. 
5.3.2. Effectiveness of heterogeneous catalyst 
scavengers 
With an ICP-OES method established for accurately determining iridium 
content, the supports shown in Figure 62 were tested for efficacy as catalyst 
scavengers. 10 mg of each scavenger was vortexed into an iridium stock 
solution of known concentration in order to determine which support was the 
most effective scavenger and how much iridium was removed over a temporal 
range. Scavenger particles could potentially interfere with measurement via 
blockages in the sample injection system. Therefore, it was experimentally 
challenging to measure the iridium remaining after very short time periods as 
samples required centrifuging before analysis. The time point labelled t = 0 is 
therefore the fastest experimentally feasible testing time, with other time points 
labelled for the total ‘wait’ time without necessary centrifuge time considered. 
Further details of this method are included in section 8.8.3, with a flow chart 
demonstrating the preparation of samples t = 0 and t = 2 shown in Figure 71 
and the actual exposure times of each sample summarised in Table 27. 
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Table 27. Actual exposure times due to experimental limitations of ICP-OES 
samples. An example of the preperation steps utilised for samples t = 0 and t 
= 2 is detailed in Figure 71. 
Label Actual exposure time 
t = 0 ~ 2 mins 
t = 2 ~ 6 mins 
t = 5 ~ 11 mins 
t = 10 ~ 18 mins 
t = 15 ~ 25 mins 
t = 20 ~ 32 mins 
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Figure 71. Flow chart demonstrating the preperation steps for ICP-OES 
samples t = 0 and t = 2. Additional time samples were gathered through the 
repetition of the vortex, wait, centrifuge, sample steps. This resulted in the 
actual exposure times shown in Table 27. 
.
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Figure 72. Iridium present in samples following the addition of 10 mg of scavengers S1-S7 and with no scavenger added (4). Aliquots 
were taken over a range of time points with t = 0 being the fastest experimentally feasible sampling time (see section 8.8.3). Errors 
are one standard deviation between repeat samples. For ease of comparison, the ordinate has been focused towards the top end of 
the scale.  
S1 S2 S3 S4 S5 S6 S7 4 
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Figure 73. Iridium present in samples following the addition of 10 mg of scavengers S1-S7 and with no scavenger added (4) after 12 
days normalised to iridium content of the blank sample with no scavenger added. 
S1 S2 S3 S4 S5 S6 S7 4 
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Figure 72 and Figure 73 show the results for the testing of the potential catalyst 
scavengers (shown in Figure 62), thus enabling trends to be examined based 
on the labelling of the solid support.  
Scavengers S1, S2 and S3 share a common structure with increasing potential 
binding sites: surprisingly S1 was shown to be the most effective scavenging 
agent of these silica based materials. Chelate effects would imply that S2 and 
S3 may form more stable complexes with the iridium SABRE catalyst. This is 
supported by a previous report by Mewis et al. wherein 2,2’-bipyridine and 1, 
10-phenanthroline,30 which share a binding motif with scavenger S2, strongly 
binding to the SABRE active iridium species homogenously to effectively 
deactivate the catalyst; this has been further discussed in section 5.2.4.30 
However, it is possible that the steric bulk of the silica support prevents 
multiple binding sites from being favoured. Scavenger S3 (reported as SD by 
Barskiy et al.) has been shown to be capable of scavenging the iridium catalyst 
from solution, however, it was shown to be largely ineffective.72 This appears 
to be in good agreement with the data presented in Figure 72 and Figure 73, 
however, a direct comparison cannot be made due to the decision to make 
use of a more uniform range of scavenger particle sizes and loadings than 
Barskiy et al., this decision is discussed in section 5.2.1. Notably S2 appears 
to be a more effective scavenger than S3 despite diethylenetriamine 
demonstrating more effective catalyst deactivation in a homogenous model. 
The reduced efficacy demonstrated here to sequester the catalyst may be due 
to the local steric bulk of the support preventing the formation of the fac-isomer 
characterised in section 5.2.4. Scavenger S1 is demonstrated to be the most 
effective sequestering agent of S1-S3; the ability of this support to bind iridium 
has been previously reported in the context of synthesising an HET-SABRE 
catalyst during which catalyst leaching into solution was not observed.94 
Scavenger S4 was also reported as SB by Barskiy et al. in their 2018 report, 
however, it was shown to be significantly more effective than that of scavenger 
S3 – removing ~81% of the iridium present in solution within 12 hours.72 
Although Figure 73 shows that only ~42% of the iridium was removed in this 
work, it is worth noting that while the scavenger quantities are the same (10 
150 
mg of each), the initial iridium concentrations varied by orders of magnitude 
with this report’s initial concentration being ~3.25 ppm compared to the ~82 
ppb in the solution tested by Barskiy et al. It is, therefore, likely that this 
discrepancy is due to a saturation of the available binding sites on the surface 
of scavenger S4 in this report.  
Scavenger S5 is novel and the most effective scavenger included in this test, 
continuing the theme of nitrogen containing heterocyclic binding motifs that 
began with S4. This result represents a novel and potentially highly effective 
new scavenger that may be used in the preparation of an iridium-depleted 
bolus. Despite this, previous attempts to hyperpolarise 2-substituted picoline 
substrates has been unsuccessful.126 This has been attributed to steric effects, 
however, 2-substituted pyridine compounds have been shown to bind to 4 
through the binding of 2,2’-bipyridine and 1,10-phenanthroline by Mewis et al. 
demonstrating that a sterically hindered pyridine may bind apparently 
irreversibly.30 In a separate report, Pravdivtsev notes that SABRE 
hyperpolarised signals for sites on bound 2,2’-bipyridine may be detected but 
evidence of this ligand exchanging is not presented.165 
Attempts to hyperpolarise 2-picoline as a homogenous analogue of scavenger 
5 were unsuccessful as reported in literature.126 However, when a co-ligand is 
utilised which may activate 4, such as acetonitrile, then hyperpolarised signals 
corresponding to the ring of 2-picoline were evident, as shown in Figure 74. 
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Figure 74. Spectra of 2-picoline (4 equivalents), acetonitrile (10 equivalents) 
relative to a single equivalent 4. Hydride region shown as expansion. Thermal 
spectrum is scaled by 2-fold relative to the other spectra. 
Table 28. 2-Picoline SABRE enhancements at earth’s field and 65 G when 
acetonitrile is utilised as a co-ligand. 
Magnetic Field in 
which 
hyperpolarisation 
conducted 
Proton Environment Enhancement  
Ortho Meta Para 
Earth’s Field 9.28 28.14 39.35 
65 G 19.46 32.53 54.62 
Utilising acetonitrile as a co-ligand in order to hyperpolarise 2-picoline resulted 
in SABRE being observed. This novel result shows relatively good 
enhancements and a pair of hydrides occurring at -21.69 and -23.14 ppm. The 
first resonance is broadly in agreement with a resonance of -20.56 which has 
been reported for a hydride trans to acetonitrile in the complex 
x2 
x2 
Thermal 
Earth’s Field SABRE 
65 G Field SABRE 
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[Ir(IMes)(Acetonitrile)(Pyridine)2(H)2] suggesting this is the acetonitrile adduct 
within the 2-picoline containing complex.166 The hydride trans to pyridine in the 
report by Mewis et al. is reported at -22.12 ppm and hydrides trans to ammonia 
have been reported at -23.61 ppm,84 therefore it seems likely the hydride 
herein present at -23.14 ppm can be attributed to the hydride trans to 2-
picoline. The polarisation reported here demonstrates that when a co-ligand is 
present which can pre-activate the metal complex then the functionality 
present in S5 is capable of binding to the iridium catalyst. In this instance 
pyridine pre-activated the complex as this was utilised in the preparation of the 
ICP-OES bolus due to the need for water solubility.80 
Interestingly scavengers S6 and S7 demonstrated essentially no scavenging 
effect, with Figure 73 showing <5% iridium removal for both agents after a 
period of 12 days. As scavengers S1 and S2 are directly comparable with 
scavengers S6 and S7 in terms of binding modes, this significant difference in 
efficacy is likely due to the difference in support identity, polystyrene for 
scavengers S6 and S7 compared to silica for scavengers S1-S5. This 
observation is in line with the single polystyrene scavenger reported which was 
the worst of the scavengers so far assessed in literature with steric effects of 
the support cited as the likely cause.72, 93 
From the data presented in Figure 72 and Figure 73, the most effective 
scavengers appear to be agents S1, S4 and S5, having all shown that 10 mg 
scavenger may remove >1 ppm iridium over a long time period (12 days) and 
>60 ppb by t = 0 (method in 8.8.3). By t = 5 these three scavengers had 
removed >115 ppb Ir from solution, notably more than the initial concentration 
tested by Barskiy et al. in their 12 hour assessments of scavenger efficacy.72  
5.3.3. Effect of changing scavenger quantity utilised  
Given the performance of scavengers S1, S4 and S5 examined in 5.3.2, it was 
decided to increase the concentrations of these scavengers above the 10 mg 
of each scavenger utilised in 5.3.2. This increase in quantity used was to 
examine the effect of this on their iridium scavenging efficiency.
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Figure 75. Amount of iridium present in samples following the addition of a variable amount of each scavenger (S1 blue, S4 orange, 
S5 grey) after t = 0, 2 and 5 as defined in section 8.8.3. Error bars omitted for clarity.  
t = 0 t = 2 t = 5 
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Figure 76. Amount of iridium present in samples following the addition of a variable amount of scavenger S1 after t = 0, 2 and 5 as 
defined in section 8.8.3. Error bars show the standard deviation between repeats of the same sample.  
■ t = 0 
■ t = 2 
■ t = 5 
155 
 
Figure 77. Amount of iridium present in samples following the addition of a variable amount of scavenger S4 after t = 0, 2 and 5 as 
defined in section 8.8.3. Error bars show the standard deviation between repeats of the same sample.  
■ t = 0 
■ t = 2 
■ t = 5 
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Figure 78. Amount of iridium present in samples following the addition of a variable amount of scavenger S5 after t = 0, 2 and 5 as 
defined in section 8.8.3. Error bars show the standard deviation between repeats of the same sample.  
■ t = 0 
■ t = 2 
■ t = 5 
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Figure 79. Amount of iridium present in samples following the addition of a variable amount of each scavenger (S1 blue, S4 orange, 
S5 grey) after one day. Error bars show the standard deviation between repeats of the same sample.
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Figure 75 - Figure 79 present an overview of data for varying the scavenger 
quantities of S1, S4 and S5. As expected, increasing the quantity of scavenger 
and exposure time both resulted in a marked decrease in iridium concentration 
remaining in solution for all scavengers. 
Figure 77 demonstrated that scavenger S4 resulted in the least iridium being 
removed from solution of this study, supporting the data shown in Figure 72, 
that over short time periods both scavengers S1 and S5 perform better. 
Scavenger S1 performs well, with Figure 76 demonstrating that 100 mg is able 
to sequester ~692 ppb of iridium in t = 0 (actual exposure time ~2 min), 
however, the previously unreported scavenger S5, is able to remove ~939 ppb 
Ir in the same time period, shown in Figure 78. This represents a total removal 
of ~55% of the iridium present. This may be compared with the results of 
Barskiy et al. whose best scavenger removes ~99.6% of the iridium present 
under the same conditions.72 Although a higher percentage removal, the initial 
concentration reported by Barskiy was 63.7 ppb, meaning the absolute iridium 
removed was 63.4 ppb, an order of magnitude below that demonstrated herein 
by scavenger S5. It is not possible to directly compare the individual scavenger 
efficacy beyond overall percentage removal due to the considerations 
discussed in 5.2.1, however S4, the least effective of these three scavengers 
was employed by Barskiy et al. as SB (significantly higher particle size, similar 
loadings) and found to be one of the most effective scavengers previously 
reported.72 Comparing the efficacy of SB and S4, the latter is likely to have a 
higher surface area due to it’s smaller particle size which may increase its 
scavenging efficacy but it is still outperformed by S1 and S5 reported here. 
With a longer retention time, as shown in Figure 78, of t = 2 (actual exposure 
time ~6 mins) a far higher quantity of iridium may be removed by scavenger 
S5, with ~1.4 ppm (~83%) removal. After t = 5 (actual exposure time ~11 mins) 
this increases to 1.6 ppm (~94%) of the iridium present. 
159 
 
Figure 80. Amount of iridium present in samples following the addition of a variable amount of scavenger S5 after t = 0, 2 and 5 as 
defined in section 8.8.3. Quantity of scavenger is extrapolated to demonstrate how much scavenger would be required for near 
complete iridium removal. 
● t = 2 
 
● t = 5 
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The quantity of scavenger S5 required to achieve a level of iridium equal to the 
average value of the deionized water blanks (0.2126 ppb) run at the same time 
as these samples may be calculated through extrapolation of the data, 
presented in Figure 80, making use of the calculation detailed in 8.8.4. 
Table 29. Calculated quantities of scavenger S5 required to achieve iridium 
level equal to the measured blanks. 
 
Calculated (equation shown in 8.8.4, data shown graphically in Figure 80), 
quantities of scavenger S5 required to achieve iridium level equal to the 
average of deionized water blanks are shown in Table 29. This assumes the 
trends observed over the measured quantities continue. 
Table 29 demonstrates that for t = 0 (actual exposure time ~2 mins, see section 
8.8.3) about 1 g of scavenger S5 would be required to remove ~1.7 ppm of 
iridium from solution under the conditions employed in this report. Recent 
reports have demonstrated that longer residence times are not necessarily a 
barrier to application towards an in vivo usage as biologically relevant drugs, 
such as the antibiotic metronidazole,55 may be hyperpolarised with a T1 of ~10 
mins allowing time for iridium removal.158, 167 This solid scavenging technique 
could be further integrated with complimentary purification techniques such as 
catalyst separated SABRE (CASH-SABRE) in order to formulate an efficient 
approach towards a clinical setting.89 
It is notable that the experimental method reported here is unlikely to be the 
most effective approach towards catalyst sequestering as limits on available 
SABRE pre-catalyst stock meant that samples for different time points were 
repeatedly vortexed and centrifuged. This centrifugation likely reduced the 
Time 
Quantity of S5 Required 
(mg) 
T = 0 999.1 
T = 2 528.9 
T = 5 345.8 
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scavenging efficiency of the solids due to a reduction in sample homogeneity. 
It is envisioned that moving towards an automated flow system approach the 
scavengers may therefore be slightly more effective. The logical approach for 
preparing a metal free bolus for injection would be packing a column and 
injecting the iridium rich solution through a plug of the scavenger – this has 
been reported to have similar efficiency to ‘passive’ scavenger exposure over 
a short retention time.72 
5.4. Conclusion 
The attempted synthesis of a range of HET-SABRE catalysts is presented and 
HET-SABRE is demonstrated for S1. Though the enhancement attained was 
reduced compared to a previous report this could likely be improved through 
the utilisation of parahydrogen bubbling through solution, and demonstrated 
the synthetic approach employed could result in HET-SABRE activity.94 
Though the majority of supports tested did not show HET-SABRE activity, this 
was explained utilising a homogenous model for supports S2, S3 and S7, which 
demonstrated they may be effective agents for catalyst deactivation.30 
Removal of [Ir(IMes)(COD)Cl] from solution by a support may be a timely 
solution as despite its utilisation as the SABRE catalyst resulting in highest 
enhancement levels attained, in the majority of cases, recent work has 
demonstrated this iridium species is cytotoxic.32, 71, 78, 113 Therefore, the 
potential for the supports to be utilised removing this cytotoxic species from a 
bolus was examined. 
The metal scavenging efficacy of the supports was examined and scavengers 
S1, S4 and S5 were shown to be particularly effective. During this work a report 
was published which meant literature comparisons could be made with 
scavengers S3 and S4. Though the work reported here represents a lower 
percentage removal of iridium from a SABRE bolus, the quantity removed was 
significantly higher making use of an initial iridium concentration closer to that 
which may be required in a clinical setting.  
Extrapolation of the scavenger data suggests that ~1 g of the most effective 
scavenger, S5 (which is novel), would render iridium below the level detected 
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in blanks for the ICP-OES instrument utilised in this study with an initial 
concentration of ~1.7ppm and an exposure time of ~2 mins. With the quantity 
required dropping significantly with longer exposure times, the relaxation time 
of the proposed substrate would have to be considered when designing 
applications of this approach. It is envisaged that this novel scavenger could, 
in combination with other approaches, such as CASH-SABRE,89 enable the 
rapid preparation of a biocompatible SABRE hyperpolarised bolus. Barskiy et 
al. demonstrated that a biphasic approach could remove 99-99.9% of iridium 
from a sample.72 This means utilisation of this approach, combined with ~1g 
of S5 should be capable of reducing a sample commensurate with a typical 
SABRE sample (2 mg of 4 in 0.6 ml, ~1005 ppm) to background levels of 
iridium present within the hyperpolarised T1 of a suitable substrate.158, 167 
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6. Studies towards the application 
of SABRE to biologically relevant 
substrates 
6.1. Introduction 
Despite progress towards an in vivo application of SABRE through the 
utilisation of 19F to alleviate background signal interference,68, 96 extending the 
longevity of the hyperpolarised state,30, 168 and progress towards a non-toxic 
bolus,71, 72, 78 the scope of biologically relevant molecules to which SABRE has 
been applied remains relatively limited.  
This chapter aims to demonstrate the application of SABRE to the study of 
new psychoactive substances (NPS), specifically fentanyls, in which sensitivity 
is an issue due to their potency and to a world health organisation (WHO) 
medicine, voriconazole, which is approved for clinical use.169 
6.1.1. Previous SABRE of biomolecules 
SABRE has been applied to a range of biologically relevant molecules within 
literature. These molecules broadly fall within two categories: those which are 
clinically relevant and do not require chemical modification to be suitable for 
SABRE (may reversibly bind to the polarisation transfer catalyst), and those 
biomolecules, such as peptides, which require chemical modification and 
labelling, typically with pyridine, in order to be SABRE active. 
6.1.1.1. Drugs 
Early work by Olaru et al. to apply SABRE towards biomolecules focused on 
applications to vitamin B3 and nicotinic acid.128 Olaru et al. demonstrated that 
5 equivalents of nicotinic acid relative to 4 yielded the greatest enhancements 
(though 4 equivalents was not examined) when measured at a magnetic field 
of 65 G.  
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Figure 81. Hyperpolarised nicotinic acid at pH 3.6 (a), 4.6 (b), 5.1 (c), 5.7 (d), 
5.9 (e) and 6.9 (f).128 
This work sought to demonstrate that nicotinic acid may be utilised as a pH 
probe when combined with SABRE and achieved this, with the pH of the 
solution directly effecting the observed polarisation due to interconversion 
between the conjugate acid, uncharged, zwitterion and conjugate base 
species in solution. The changes in pH may be observed in 1H MR images of 
SABRE hyperpolarised nicotinic acid taken at a range of pH values, as shown 
in Figure 81. 
Following this work a further two simple biomolecules suitable for SABRE were 
identified in the form of the active tuberculosis drugs pyrazinamide and 
isoniazid – both of these drugs share N-heterocycles which are suitable for 
reversibly binding to 4; their structures are shown in Figure 82.48 
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Figure 82. Structures of pyrazinamide (left) and isoniazid (right). 
The tuberculosis drugs pyrazinamide and isoniazid have been polarised by 
SABRE in a range of solvents (methanol, d4-methanol, ethanol and DMSO).48 
With optimal enhancements of up to 1400-fold being observed in d4-methanol, 
for pyrazinamide at 65 G; this corresponds to a polarisation of ~8%. In the 
case of isoniazid, polarisation transfer was again optimised in a magnetic field 
of 65 G, where the ortho proton nuclei were enhanced by ca. 60-fold. 
Pyrazinamide and isoniazid have been further examined in an attempt to 
increase their polarisation levels and lifetimes through a deuteration 
approach.95 This report by Duckett et al. demonstrated that deuterating IMes 
in 4 results in significant increases in both ligand T1 and attainable polarisation 
levels for the substrate as polarisation is not ‘diluted’. This deuteration 
approach is also effective when applied to the substrate itself, though this does 
mean chemically changing the drug slightly from the currently clinically 
approved version. In particular, Duckett et al. evaluated a series of substrates 
related to methyl pyrazine‐2‐carboxylate, which has been shown to be active 
against tuberculosis.170-172 The structure of methyl pyrazine‐2‐carboxylate and 
a partially deuterated methyl pyrazine‐2‐carboxylate derivative are shown in 
Figure 83. 
 
Figure 83. Structures of methyl pyrazine‐2‐carboxylate (left) and a partially 
deuterated methyl pyrazine‐2‐carboxylate (right) derivative. 
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Utilising the partially deuterated structure shown in Figure 83, polarisation of 
11.9 and 9.2% for the 3- and 5- proton environments of the aromatic ring were 
attained with T1 values of 99.7 and 144.5 seconds respectively. 
 
Figure 84. Structure of metronidazole. Available site to bind with 4 is labelled 
A. 
In addition to literature reports on currently available tuberculosis medication, 
several reports have focused on metronidazole (shown in Figure 84), an 
antibiotic included in the WHO essential medicine’s list.173 
15N SABRE-SHEATH of metronidazole has resulted in polarisation levels in 
excess of 20% for the imidazole nitrogen binding site (labelled A in Figure 84) 
when 80% parahydrogen was utilised with nitrogen in all sites at natural 
abundance.29 Barskiy et al. speculate that utilisation of 100% enriched 
parahydrogen would result in 15N polarisation levels of circa 32% which would 
be equivalent to a polarisation level of ~100,000 fold within a measurement 
field of 9.4 T. Though impressive, polarisation build up within this system may 
be limited by the short T1 relaxation times observed for A within the microtesla 
regime required for SABRE-SHEATH polarisation transfer. Spin lattice 
relaxation of A is highly dependent on external magnetic field with a T1 of 4.5 
seconds recorded at microtesla fields compared to 191 seconds within a 0.3 
T field. The short relaxation time at low field may limit the polarisation build up, 
however, once within a suitable measurement field the lengthened T1 may be 
advantageous to the application of metronidazole to clinical application. 
In addition to studies making use of currently available drugs, the application 
of SABRE to hyperpolarisation in the presence of blood has been examined 
making use of pyridine as a substrate.67, 97 In an earlier report, Hövener et al. 
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added 2 mL fresh human blood to an ethanol solution containing 4 equivalents 
of pyridine relative to 4.97 Continuous SABRE polarisation was attempted 
making use of parahydrogen bubbling through the solution and 
hyperpolarisation continued to be observed following the addition of blood. 
However, Hövener et al. note that after a short time the liquid coagulated and 
the observed hyperpolarised signal had decreased to approximately a tenth of 
its initial value. 
In a further report, Hövener et al. demonstrated that SABRE of pyridine may 
be observed in a D2O solution containing HL-60 cells and a separate solution 
containing DPBS, both simulating parts of the blood environment.67 Hövener 
et al. attempted the hyperpolarisation of a range of other substrates, including 
pentafluoropyridine, but pyridine was the only substrate that demonstrated 
SABRE in these mixtures, likely due to the high polarisation levels that may be 
obtained with this substrate. Hövener et al. report that in this instance, upon 
addition of blood, the hyperpolarised signal present for pyridine dropped below 
the limit of detection. They speculate that this may be due to the lower 
polarisation levels attained in D2O compared to an ethanol solvent system 
combined with an increased likelihood that blood components, e.g. salts and 
proteins, may precipitate from solution in an alcoholic solvent. In conclusion, 
Hövener et al. speculate that blood components may suppress 
substrate/hydride exchange and reduce substrate T1. 
6.1.1.2. Peptides and pyridine labelling 
In addition to applications of SABRE to drug molecules, peptides have also 
been an area of interest with the polarisation of amino acids and some 
representative small peptides using SABRE first being reported by Appelt et 
al.46 Appelt et al. utilised Crabtree’s catalyst (Figure 85) as a polarisation 
transfer catalyst and SABRE was observed for all of the proteinogenic amino 
acids. 
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Figure 85. Structure of Crabtree’s catalyst, utilised for polarisation transfer by 
Appelt et al.46 
In addition to singular amino acids, two peptides, GlyGly and ProHisLeu, were 
also polarised by Appelt et al., but highlighted the need for water-soluble 
catalysts as their solubility in d4-methanol was poor. Since this report, the 
water solubility of 4 following activation has been demonstrated so this 
limitation has now been resolved.80 
Building on this work, oligopeptides have also been successfully polarised by 
SABRE.47 The oligopeptides were effectively SABRE-labelled with 
nicotinamide or isonicotinamide. The investigated models are shown in Figure 
86. 
For all the investigated oligopeptides, no signal enhancement was observed 
for the peptide unit. However, the pyridyl motif did polarise with enhancements 
of 15- to 25- fold being recorded. These decreased to about 10% of their value 
from moving from d4-methanol to a 50:50 d4-methanol:D2O mix. 
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Figure 86. Oligopeptide models investigated by Ratajczyk et al.47 
In a further study, the hyperpolarisation of eNOS (endothelial Nitric Oxide 
Synthase) substrates were investigated to quantify the production of NO using 
1H NMR spectroscopy.127 This report continued to develop the utilisation of a 
pyridyl motif label to facilitate sensitive detection of a substrate that would likely 
demonstrate minimal SABRE hyperpolarisation. Two generations of eNOS 
substrates were synthesised; the first generation were focused on the use of 
a L-arginine carboxylic function to introduce a pyridyl binding group, whereas 
the second generation made use of Nω–hydroxy-L-arginine (L-NOHA) to 
incorporate the pyridyl ring.  
 
Figure 87. Chemical structure of the pyridyl labelled L-arginine substrate 
synthesised and polarised by Zanda and co-workers.127 
The best enhancement obtained was for the derivative shown in Figure 87, 
which gave an enhancement of 870-fold for the four pyridyl ring protons after 
polarisation transfer in earth’s magnetic field. However, for the dipeptide 
derivatives, no significant enhancement was observed, most likely due to 
steric hindrance around the binding site. All of the substrates led to 
comparable or higher NO production by eNOS than L-arginine. These 
substrates could, therefore, be potentially used to monitor NO production in 
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vivo. However, both the signal enhancement and the longevity of the 
hyperpolarised signal (T1 values of the pyridyl protons of the substrate in 
Figure 87 were only 3.2 – 3.3 s at physiological pH) would need to be 
improved.  
The work reported herein aims to extend the scope of SABRE application to 
higher molecular weight drugs currently available on the market through the 
application of 19F SABRE discussed in 4.3. Additionally this study investigates 
new psychoactive substances (NPS), specifically focusing on fentanyl, and 
how SABRE may be utilised for the detection of fentanyl derivatives. 
6.2. Voriconazole 
Voriconazole, shown in Figure 88, is a world health organisation (WHO) 
essential medicine for its activity as an anti-fungal and belongs to the triazole 
class of drugs.174 As a broad spectrum fungicidal treatment, voriconazole 
demonstrates good activity against a range of common and several less 
common fungi. Voriconazole concentrations in vivo have been assessed 
utilising MRI and metabolites have been identified utilising 19F NMR following 
stress testing.175, 176 The existing literature demonstrating voriconazole may 
be studied in vivo and NMR characterisation of both voriconazole and it’s 
degradation products made it an attractive prospect for SABRE 
hyperpolarisation. 
 
Figure 88. Structure of voriconazole. 
This work, reported herein, demonstrates the novel application of 19F SABRE 
to a currently utilised drug through the application of the techniques discussed 
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in section 4.1.3. This work has also been reported by the author in ‘Extending 
the Scope of 19F Hyperpolarization through Signal Amplification by Reversible 
Exchange in MRI and NMR Spectroscopy’.96 
6.2.1. Hyperpolarisation of voriconazole 
As discussed in 6.2, voriconazole was identified as an interesting target for the 
application of SABRE to a commercially available and clinically approved drug. 
Utilising 4 equivalents of voriconazole relative to 4, both 1H and 19F polarisation 
was attempted. 
 
Figure 89. Structure of voriconazole with 1H and 19F environments labelled.176 
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Figure 90. 1H spectra of voriconazole under thermal (bottom) and SABRE (top) 
conditions. Hydride region (-21 to -25 ppm) is shown as an expansion. 
1H SABRE was observed, as shown in Figure 90, with a pair of major hydride 
resonances forming at -22.72 and -22.91 ppm following the observed 
hydrogenation of cyclooctadiene. The 1H environment at 8.75 ppm 
demonstrated the highest level of 1H SABRE with an enhancement of ~4-fold. 
Unfortunately, due to the multiple hydrides present at low intensities, EXSY 
interrogation of the hydride exchange rate was not feasible. Interestingly, 
polarisation levels for the environment at 9 ppm demonstrated an 
enhancement of only ~1.5-fold times under the same conditions, suggesting 
preferential transfer towards the 19F environment at -137.3 ppm.  
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Figure 91. 19F spectra of voriconazole, SABRE hyperpolarised trace in red, 
thermal spectra under the same conditions shown in blue. 
19F SABRE was conducted (Figure 91) making use of the same sample and 
demonstrated selective hyperpolarisation of the 19F environment at -137.3 
ppm; this is likely due to the other fluorine environments being too far removed 
from the parahydrogen derived hydrides present in the polarisation transfer 
catalyst for polarisation to be propagated through very long range coupling.  
A combination of the 19F polarisation only being observed for this environment 
and the highest 1H hyperpolarisation being present in the neighbouring 
environment, suggests that voriconazole primarily binds to the catalyst making 
use of nitrogen A in Figure 89. A spectrum of the hydride region at 400 MHz 
revealed a high number of hydride resonances, in particular the presence of a 
peak at -23.67 ppm suggests that there is a mixture of species in solution, at 
least some of which are likely to contain MeOH bound trans to parahydrogen 
derived hydrides.28 The aromatic region also demonstrated low level bound 
peaks with integrals ~12% that of the free voriconazole in solution. The 
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combination of the low levels of these bound and hydride peaks made 
characterisation of the complexes in solution infeasible. 
Table 30. Relaxation times for 19F environments of voriconazole at 1.4 T. 
19F environment (ppm) T1 (s) 
-109.4 3.08 
-112.9 7.73 
-137.4 5.15 
The measured relaxation times for the 19F environments of voriconazole at 1.4 
T are short enough that potential biological application would need to utilise 
strategies, such as those discussed within section 5.4, for lengthening of T1. 
The relaxation times within Table 30 also suggest that higher polarisation 
values than those reported herein are likely accessible as this work has utilised 
a ‘shake and drop’ method that necessitates a time delay before measurement 
for sample transfer to the measurement field. Utilisation of a parahydrogen 
bubbling method would enable SABRE to occur in situ within the magnet and 
partially negate polarisation loss due to relaxation on the sample transfer 
timescale. 
A 19F enhancement of 5 times is modest compared to the pyridine substrates, 
as detailed in section 4.1, however, this substrate contains significant steric 
bulk in proximity to the binding site which is likely to reduce turnover efficiency. 
Notably, the quantity used for this enhancement, 13.4 mg, is significantly 
below the lowest dosage of 50 mg noted in the WHO essential medicines 
list.177 This result represents a major step forwards in the SABRE of medicines 
as voriconazole is significantly more complex than those drugs discussed in 
section 6.1.1. 
6.3. Fentanyl 
Fentanyl (Figure 92, left), functions as a synthetic opiate, despite the chemical 
structure differing significantly from morphine, codeine and heroin (Figure 92, 
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right), which are natural opiates. Fentanyl exhibits a strong affinity towards the 
μ-opioid receptor, which is found across the central and peripheral nervous 
system and thus acts in a similar way to naturally occurring opiates. Activation 
of the μ-opioid receptor leads to analgesia and euphoria, but also physical 
dependence, constipation and respiratory depression,178 which can lead to 
death in the case of an overdose. 
 
Figure 92. Structure of fentanyl (left) and common natural opiates (right). In 
morphine R1=R2=H, in codeine R1=CH3, R2=H, in heroin R1=R2=(CO)CH3. 
Fentanyl has attained widespread medical use due to its very strong and fast 
action. In fact, fentanyl is included on the WHO essential medicines list as a 
painkiller for severe cases. Fentanyl has an estimated potency of 50 to 100 
times stronger than morphine.179 The euphoric effects of fentanyl, resembling 
those of heroin, have led to recreational use which poses a public health threat 
as quantities of circa 2 mg may induce overdose in the average adult.180  
Instances where sample purity increases may pose a particular health risk, is 
due to samples reportedly showing a wide variation within dose sizes (28 – 35 
mg) and purity (5.8 – 6.6%).181 This equates to an active pharmaceutical 
ingredient (API) of between 1.62 and 2.31 mg, meaning relatively minor 
increases in purity could push the API of street samples significantly above the 
estimated lethal dose. An additional issue leading to negative health outcomes 
is the contamination of heroin samples with fentanyl, often without the users 
knowledge.182  
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Figure 93. Office of National Statistics data by year in England and Wales for 
instances where fentanyl is mentioned on death certificate with and without 
heroin or morphine.183, 184 
Unfortunately in recent years opiate abuse, including fentanyl and its 
derivatives, have been responsible for an increasing number of deaths, 
including 42,249 opioid related deaths in America in 2016.185 Of these, circa 
19,400 were attributed to synthetic opioids, representing a 100% increase in 
synthetic opioid deaths between 2015 and 2016. In Europe, fentanyl has 
resulted in fewer deaths. However, trends appear to show fatalities increasing 
year by year, as demonstrated in Figure 93,183, 184, 186 though Morley et al. note 
that these figures may underestimate the actual numbers. This is because if a 
cause of death has been established, fentanyl screening is not typically 
undertaken and many laboratories may be unable to detect fentanyl in low, but 
potentially lethal, concentrations. This highlights the need for greater 
sensitivity in detection methods.186 
Unfortunately, fentanyl derivatives, or fentalogues, such as carfentanil 
(estimated potency 10,000 times that of morphine), may pose even larger 
threats to public health and drug detection.187, 188 Between 2009 and 2017, 18 
new fentalogues were detected by the European Monitoring Centre for Drugs 
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and Drug Addiction (EMCDDA), though 8 of these were reported for the first 
time in 2016.189 Fentalogues are already being identified as causes of death 
with fentanyl present in 56.3% of opioid deaths in the United States and 
fentalogues present in an additional 14% of cases in July to December 
2016.190 
Given the low-threshold for overdose, it was sought to employ SABRE 
methodology for detecting pyridyl-labelled fentanyl derivatives in addition to 
mirfentanyl, which has been assessed for biological activity in rats.187 
Furthermore, it was sought to demonstrate that a fentalogue can be readily 
detected despite being in a matrix consisting largely of heroin (97% w/w). 
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6.3.1. Hyperpolarisation of fentalogues 
F1, as discussed in section 6.3, is a drug that, though it can have significant 
positive impacts on health when utilised correctly, has recently been becoming 
a significant concern as a drug of abuse. Given the apparent pharmacological 
activity of modified fentanyl derivatives, as well as the number of derivatives 
which are on the market and with more being detected each year, fentanyl was 
chosen to be the subject of a systematic assessment for SABRE activity.  
 
Figure 94. Fentanyl and derivatives (F1- F4) synthesised by the group of Dr 
Oliver Sutcliffe for evaluation in this work. 
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In this study a series of fentanyl derivatives, F2 – F4, shown in Figure 94, were 
synthesised by the Sutcliffe research group. These derivatives aimed to label 
the fentanyl structure through an existing ring in derivatives F3 and F4 or 
through the addition of a new pyridyl motif in the case of F2. Labelling of a 
substrate for SABRE has been previously reported as an efficient way to 
enable hyperpolarisation and, in this instance, is commensurate with a feasible 
modification that may be done, in coming years, to create a new street 
derivative of fentanyl.46, 47, 127 
6.3.2. Complexes formed 
Utilising 4 as the polarisation transfer pre-catalyst, addition of 4 equivalents of 
F2 results in the formation of the complex [Ir(IMes)(F2)3(H)2]+ with a hydride 
signal being observed at -23.17 ppm for this species. A smaller pair of hydride 
resonances representative of hydrides trans to methanol are present at -23.52 
and -25.56 ppm respectively. The resonance of the hydride trans to methanol 
is in very good agreement with reported values for hydrides trans to methanol 
where pyridine is the substrate, as in this instance these hydrides have been 
reported at -23.44 and -25.49 ppm.28 
Relative integrals of the hydrides suggest that 
[Ir(IMes)(F2)3(H)2]:[Ir(IMes)(F2)2(MeOH)(H)2] are present in the ratio of 98:2 
respectively. The low relative size of these hydrides made characterisation of 
this complex impractical, and it has been ignored for the purposes of exchange 
rate spectroscopy conducted on this complex.  
The analogous complexes, [Ir(IMes)(F3)3(H)2] and [Ir(IMes)(F4)3(H)2], are 
formed when F3 and F4 are utilised with hydride resonances observed at -
22.70 and -22.83 ppm respectively. In both instances only a single hydride is 
formed, suggesting that F2 contains the most sterically hindered binding site 
as this is the only substrate for form methanol adducts. 
6.3.3. Exchange Rate determination of fentalogues 
Using exchange spectroscopy (EXSY), the exchange rates of substrates F2 - 
F4 and hydride in the complex [Ir(IMes)(F)3(H)2]+ where L is F2, F3 or F4 were 
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investigated. This data is tabulated within Table 31 and Table 32, as well as 
shown graphically within Figure 95 and Figure 96.
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Table 31. Exchange rate data for the loss of substrate and hydride from [Ir(IMes)(F)3(H)2]+. 
Complex [Ir(IMes)(F2)3(H)2]+ [Ir(IMes)(F3)3(H)2]+ [Ir(IMes)(F4)3(H)2]+ 
Gradient 
y = -9266x + 
27.571 
y = -8370.7x + 
24.655 
y = -9114.4x + 
26.31 
y = -8385.6x + 
24.69 
y = -10235x + 
31.042 
y = -9545.6x + 
28.156 
Data R2  0.9949 0.9971 0.9613 0.9973 0.9955 0.9946 
Temperature / K 
Loss of hydride / 
s-1 
Loss of F2 / s-1 
Loss of hydride 
/ s-1 
Loss of F3 / s-1 
Loss of hydride 
/ s-1 
Loss of F4 / s-1 
268 - 0.17 - - - - 
275 - 0.45 - - - - 
277 0.37 - - - - - 
280 - 0.77 0.32 0.72 0.09 0.07 
282 0.71 - 0.39 1.22 0.28 0.22 
285 1.14 1.29 0.74 2.23 0.68 0.39 
290 1.82 2.04 1.88 4.05 1.17 0.72 
295 2.92 3.88 2.99 5.52 1.94 1.28 
300 5.59 5.43 3.69 8.61 3.62 2.24 
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Figure 95. Example Eyring-Polanyi plot for the loss of hydride from the complex [Ir(IMes)(F2)3(H)2]+. 
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Figure 96. Example Eyring-Polanyi plot for the loss of F2 from the complex [Ir(IMes)(F2)3(H)2]+. 
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Table 32. Thermodynamic activation parameters and exchange rates at 300 K for complexes [Ir(IMes)(F)3(H)2]+ where L is F2, F3 or 
F4. 
 F2 F3 F4 Pyridine26 
Hydride 
loss 
∆G300 / kJ mol-1 67.6 ± 0.07 69.4 ± 0.16 66.9 ± 0.06 66.4 ± 0.3 
∆H / kJ mol-1 75.8 ± 1.4 75.7 ± 4.8 85.1 ± 1.5 79 ±1 
∆S / J mol-1 K-1 27.4 ± 5.0 21.0 ± 16.4 60.5 ± 5.0 41 ± 3 
Loss of 
ligand 
trans to 
hydride 
∆G300 / kJ mol-1 67.4 ± 0.07 67.4 ± 0.05 68.4 ± 0.11 64 ± 2 
∆H / kJ mol-1 69.6 ± 1.2 69.7 ± 0.6 79.4 ± 2.4 93 ± 3 
∆S / J mol-1 K-1 7.44 ± 4.3 7.73 ± 2.2 36.6 ± 8.2 97 ± 9 
Loss of hydride at 300 K / s-1 5.6 3.0 6.8 9 
Loss of ligand at 300 K / s-1 5.4 5.5 3.5 11.7 
185 
Using EXSY measurements, the loss of hydride and loss of fentanyl ligand 
trans to hydride from the complexes are shown in Table 32. The loss of hydride 
from [Ir(IMes)(F2)3(H)2]+ proved to be 5.6 s-1 at 300 K; this is significantly slower 
than the previously reported hydride loss in [Ir(IMes)(Py)3(H)2]+ which was 9 s-
1 when probed under the same conditions.26 An Eyring-Polanyi plot of hydride 
loss produced a value for ∆H of 75.8 ± 1.4 kJ mol-1; this value of ∆H suggests 
that that the Ir-H bond is relatively strong and is similar to the 79 ± 1 kJ mol-1 
reported when pyridine is utilised. 
The loss of F2 from [Ir(IMes)(F2)3(H)2]+ was found to be 5.4 s-1 at 300 K. Similar 
to the hydride loss rate, this process is much slower than pyridine in the 
analogous complex [Ir(IMes)(Py)3(H)2]+ which has a reported speed of 11.7 s-
1. The Ir-N bond in [Ir(IMes)(F2)3(H)2]+ is much weaker than in the analogous 
pyridine complex with ∆H values of 69.6 ± 1.2 kJ mol-1 and 93 ± 3 kJ mol-1 
respectively. This is the lowest ∆H value for any of the fentanyl derivatives 
tested within this study; this appears to support the supposition that this may 
be the most sterically hindered of the fentalogues and this may account for the 
presence of methanol adducts discussed in section 6.3.2.  
Ligands F2 and F3 result in very similar exchange rates for the loss of ligand, 
whilst hydride loss is quicker for F2 than F3 at 300 K. The thermodynamic 
activation parameters for both F2 and F3 show significant similarity, despite the 
pyridine ring location changing. When F4 is considered, the loss of F4 trans to 
hydride from [Ir(IMes)(F4)3(H)2]+ requires a considerable amount of energy. 
This is reflected in the ΔH value 85.1 ± 1.5 kJ mol-1 which is ~10 kJ mol-1 higher 
than the respective values for F2 and F3, implying that the Ir-N bond in 
[Ir(IMes)(F4)3(H)2]+ is relatively the strongest of the fentalogues investigated. 
This is likely representative of the relative steric isolation of the pyridyl 
functionality in ligand F4. The relatively strong Ir-N bond results in the slowest 
observed rate of ligand loss and this may have negative effects of the overall 
SABRE polarisation transfer efficiency of F4. 
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6.3.4. SABRE of fentalogues 
The polarisation of fentanyl and fentanyl hydrochloride was attempted making 
use of SABRE and the recently reported method SABRE-RELAY, which 
utilises a polarisation carrier, such as ammonia, for indirect polarisation of the 
ligand. Utilisation of polarised ammonia, followed by proton exchange in 
solution, has enabled the transfer of hyperpolarised protons into an alcohol.37, 
85, 86 SABRE of fentanyl proved ineffective due to the lack of suitable ligation 
groups for reversible binding to the polarisation transfer catalyst. The SABRE-
RELAY approach had to be combined with CASH-SABRE (catalyst separated 
hyperpolarisation-signal amplification by reversible exchange) as, due to the 
unavailability of facilities for the manipulation of ammonia gas, ammonia (35%) 
in solution with water was utilised. No SABRE-RELAY signals attributable to 
fentanyl or fentanyl hydrochloride were observed, however, proton exchange 
with water would likely have led to dilution of any polarisation successfully 
transferred to the target analyte. In addition, to the best of the author’s 
knowledge, SABRE- RELAY has only been exemplified for primary and 
secondary amines; polarisation of tertiary amines such as those present in 
fentanyl has not been reported. 
The fentalogues synthesised by the Sutcliffe group for this project all contain 
pyridyl moieties which makes them suitable for SABRE. Substrates F2 – F4 
have therefore been tested for SABRE activity making use of 4 equivalents of 
F2 – F4 relative to the polarisation transfer pre-catalyst 4. 
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Figure 97. 1H NMR spectra of F2 and 4 in the ratio of 4:1 in the presence of p-
H2 in d4-methanol. Spectrum 1 is the thermal spectrum whereas spectra 2 and 
3 are hyperpolarised following polarisation transfer in earth’s magnetic field or 
at 65 G respectively. Multiplication factors indicate scaling of the vertical axis.  
Polarisation is typically observed for just the pyridine ring when a labelling 
approach is taken. In the cases of ligands F2 and F3 this is the case, however 
ligand F4 shows a small enhancement in the ethylene chain that connects the 
pyridine ring to that of the piperidine ring in a small emissive peak at 2.65 ppm. 
In fentalogues F2 – F4 polarisation was observed, with SABRE of F2 being 
exemplified in Figure 97. Unfortunately, spectral overlap at a 1.4 T 
measurement field means that, even though polarisation of meta protons is 
observed, spectral overlap with phenyl protons from elsewhere within the 
fentalogue means that polarisation cannot be accurately calculated for this 
environment. The ortho and meta signals of the pyridyl ring are observed as 
emission and absorption signals respectively. However, the ortho protons are 
sufficiently resolved that polarisation levels may be calculated for this 
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environment for all fentalogues; a summary of the enhancements observed is 
shown in Table 33. 
Table 33. 1H NMR enhancements of the ortho proton observed for fentalogues 
F2 – F4 when polarisation transfer is conducted at both earth’s field and 65 G. 
 
Enhancement value obtained after transfer of 
polarisation in the field indicated 
Fentanyl derivative (F) Earth’s magnetic field 65 G 
F2 −168 −79 
F3 −38 −2 
F4 −50 −14 
When polarisation transfer was conducted at 65 G the enhancements 
dramatically decrease; while this may be due to relaxation associated with 
increased field cycling time due to additional manual handling required for 65 
G measurements, this observation is similar to that made for NOS substrates 
bearing 4-substituted pyridyl-tethers.127 In addition, though 65 G has been 
reported to typically be highly effective for pyridine based substrates,30, 45, 60, 
64, 76, 82, 166 it is possible that this does not optimise the level anti-crossing (LAC) 
conditions which would optimise polarisation transfer for this system.130, 191-193 
The enhancements achieved for these substrates are reduced compared to 
model substrates such as pyridine, however it is worth noting that only 50% 
para-enriched hydrogen has been utilised. Theoretical models suggest that 
utilising 100% parahydrogen would result in ~3 times the polarisation levels 
observed here.54  
The highest enhancements at both earth’s and 65 G polarisation transfer fields 
correspond with fentalogue F2. This aligns well with the measured exchange 
rates at 300 K for hydride and ligand loss being 5.6 s-1 and 5.4 s-1 respectively, 
as this highly commensurate exchange is likely to result in the most efficient 
polarisation transfer of the fentalogues tested. 
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Comparing the polarisation levels obtained for F2 to those obtained for F3 and 
F4, demonstrates that F2 has a significantly more efficient polarisation build-
up. This is unsurprising as the exchanges for both F3 and F4 at 300 K reveal 
either loss of hydride or loss of ligand proceeds at approximately twice the 
speed of the other component. This will lead to ligands reversibly binding to 
the polarisation transfer catalyst without parahydrogen derived hydrides being 
present for SABRE to occur (as in the case of F3) or parahydrogen derived 
hydrides reversibly binding without an unpolarised ligand present due to a slow 
ligand turnover rate (as in the case of F4). Interestingly the polarisation levels 
for F4 are higher than F3, giving the order F2>F4>F3 – this is likely 
representative of the fact the rate limiting step of polarisation transfer in 
[Ir(IMes)(F4)3(H)2] is the ligand loss at 3.5 s-1 compared to hydride loss at 3 s-
1 in the complex [Ir(IMes)(F3)3(H)2]. 
6.3.5. Fentalogue relaxation 
The final element in overall polarisation efficiency is the T1 value for the 
protons, in order to examine if relaxation is occurring on the timescale of the 
SABRE experiment. 
  
190 
Table 34. T1 values for F2 – F4 in different environments at 298 K. 
 
T1 in the presence 
of [Ir(IMes)(F)3(H)2] 
and H2 (s) 
T1 in the presence 
of air (s) 
T1 in the presence 
of vacuum (s) 
Ligand 
Ortho 
proton 
Meta 
proton 
Ortho 
proton 
Meta 
proton 
Ortho 
proton 
Meta 
proton 
F2 3.1 3.5 2.6 1.5 2.9 2.0 
F3 2.9 3.2 2.0 2.1 4.3 2.9 
F4 3.3 2.1 2.3 2.0 3.2 2.5 
The relaxation times are largely commensurate between fentalogues with only 
minor deviations. This reinforces the conclusion in section 6.3.4 that the 
exchange rate is the primary factor determining the polarisation build up 
efficiency and thus the enhancements levels observed. Despite several meta 
protons, particularly for F3, being part of multiplets, the T1 noted in Table 34 is 
the overall value for these superimposed environments. 
The T1 values here are very short, with multiple T1’s occurring within the 
polarisation transfer timeframe as shaking was carried out for ~10 seconds 
before transfer to the 1.4 T measurement field. This means that techniques 
which may extend the signal relaxation time such as catalyst deactivation,30 or 
flow techniques in which there is a continuous build-up of a hyperpolarised 
bolus, may be effective in increasing the enhancements observed for these 
fentalogues.194 
6.3.6. Hyperpolarisation of a fentalogue in a heroin 
mixture 
The fentanyl work reported thus far within this chapter has utilised fentalogues 
that have been specifically synthesised with pyridine labelling in order to make 
them suitable for SABRE without modification. Though an increasing number 
of fentalogues are being detected within street samples, and it is not 
unreasonable to see the incorporation of a pyridine ring being a logical step 
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towards derivatising the fentanyl pharmacophore, these structures have no 
extant reports from street samples or medical testing. 
However, mirfentanil (F5), shown in Figure 98, has been demonstrated to 
possess analgesic effects alongside respiratory depression in animal 
models.195 Although, F5 appears to be highly selective for μ-opioid receptors, 
it does not interfere with the immune system through suppression of natural 
killer (NK) cells that is a known side-effect of morphine and fentanyl. To the 
best of the authors knowledge, F5 has not been identified as responsible for 
deaths. However, the structurally similar analogue furanyl fentanyl, frequently 
found in combination with heroin, has been found responsible for at least 8 
deaths.196 
 
Figure 98. Chemical structure of mirfentanil (F5). 
As F5 has known biological activity and is far more likely to be found in street 
samples and cause negative health outcomes compared to fentalogues F2 – 
F4, the SABRE hyperpolarisation of this fentanyl derivative was attempted. 
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Figure 99. 1H NMR spectra of F5 and 4 in the ratio of 4:1 (4.7 mg mirfentanil) 
in the presence of p-H2 in d4-methanol. Spectrum 1 is the thermal spectrum 
whereas spectra 2 and 3 are hyperpolarised following polarisation transfer in 
earth’s magnetic field or at 65 G respectively. Multiplication factors indicate 
scaling of the vertical axis. Expansion showcases hydride region. 
SABRE of F5 resulted in successful hyperpolarisation being observed. 
Enhancements for the peak at 8.59 ppm of 11- and 78-fold were attained at a 
polarisation transfer field of earths and 65 G respectively. Interestingly, though 
the binding site is now a pyrazine ring, this result demonstrates a higher 
polarisation transfer at 65 G, unlike the fentalogues discussed in section 6.3.4 
and previously reported NOS substrates bearing 4-substituted pyridyl-
tethers.127  
Hydrides are observed for the polarisation transfer species at -22.64 ppm and 
-24.41 ppm. Though there are two potential binding sites within the pyrazine 
ring for the polarisation pre-catalyst 4 to form a SABRE active species, it is 
highly unlikely that there is a species in solution with the iridium bound to 
nitrogen b in Figure 98. This is due to the reported inability of 2-picoline to form 
a SABRE active species,126 though in section 5.2.3 it was demonstrated that 
x10 
x10 
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2-picoline may form a SABRE active complex, albeit this did require the 
presence of a co-ligand which was not utilised here. Therefore, the hydrides 
are likely representative of F5 bound through nitrogen a in Figure 98 to form 
[Ir(IMes)(F5)3(H)2] leading to hydride signals for hydrides trans to F5 at -22.64 
ppm. The second hydride species at -24.41 ppm may be representative of F5 
bound trans to a methanol adduct. 
As SABRE of F5, a known biologically relevant fentalogue, has been 
demonstrated it was decided to examine a system where heroin was also 
present as literature reports suggest heroin containing street samples are 
often contaminated with fentanyl.182 
A mock, street-like sample was produced which contained between 0.63% and 
3.80% mirfentanil in heroin (w/w). This was then solvated in 3.6 ml of d4-
methanol and a 0.6 ml aliquot taken for SABRE. Therefore, between 0.183 mg 
and 1.15 mg of mirfentanil (81 – 509 μM) was present within the NMR tube 
utilised for SABRE. This value is far below the estimated lethal dose of ~2 mg. 
Conducting SABRE on these mirfentanil containing heroin mixtures resulted 
in enhancements for the pyrazine ring of between 2-fold and 4-fold for the 
lowest and highest concentrations respectively. However, conducting 
polarisation transfer within a 65 G field followed by rapid transfer to the 1.4 T 
measurement field resulted in a significant increase in hyperpolarisation, with 
enhancements of between 18- and 44-fold respectively recorded. The SABRE 
of these samples is shown in Figure 100 and Figure 101 respectively. 
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Figure 100. 1H NMR spectra of F5 and 4 in the ratio of 4:1 (0.183 mg 
mirfentanil) in the presence of heroin (43.7 mg) and p-H2 in d4-methanol. 
Orange spectrum is the thermal spectrum whereas the green and blue spectra 
are hyperpolarised following polarisation transfer in earth’s magnetic field or 
at 65 G respectively. 
 
Figure 101. 1H NMR spectra of F5 and 4 in the ratio of 4:1 (1.15 mg mirfentanil) 
in the presence of heroin (43.7 mg) and p-H2 in d4-methanol. Orange spectrum 
is the thermal spectrum whereas the green and blue spectra are 
hyperpolarised following polarisation transfer in earth’s magnetic field or at 65 
G respectively. 
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This result demonstrates for the first time that SABRE could be utilised for the 
selective hyperpolarisation of a fentalogue within a heroin mixture 
representative of a street sample within seconds. Despite the lower 
enhancements present at 81 μM, the presence of mirfentanil is still clearly 
distinguishable through the presence of an emissive peak within the NMR 
spectrum. Even for the highest dose tested here, the quantity of mirfentanil 
within the Young’s tube is below the lethal dose and could not be detected by 
casual inspection at thermal polarisation, making use of 128 scans (collection 
time ~15 mins) as shown in Figure 102. 
 
Figure 102. 1H NMR spectrum of F5 and 4 in the ratio of 4:1 (0.183 mg 
mirfentanil) in the presence of heroin (43.7 mg) and p-H2 in d4-methanol. 
Spectrum collected under thermal conditions for 128 scans at 1.4 T. 
6.4. Conclusion 
The 19F SABRE of a WHO medicine is presented for the first time with 
hyperpolarisation present even when a quantity of voriconazole significantly 
below the current dosing guidelines was utilised. This represents the first time 
a 19F containing molecule has been SABRE hyperpolarised which is currently 
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approved for clinical use. It is envisaged that, in combination with techniques 
for catalyst scavenging discussed in section 5.4, the foundation work for the in 
vivo application of 19F SABRE are presented here. 
The hyperpolarisation of a range of fentalogues has also been presented. This 
work started with investigating the activity of a range of fentalogues F2 – F4 
specifically synthesised for this work. These ligands all demonstrated SABRE 
activity that was investigated through the examination of exchange rates 
making use of EXSY interrogation and relaxation times. It was found the 
relaxation rates for these fentalogues were similar, so likely didn’t have a 
significant effect upon the variation within polarisation values reported. 
However, the short T1 values of 2.9 – 3.3 s did mean that multiple T1s will have 
occurred within the ~10 s shaking time. 
The thermodynamic activation parameters of ligand loss trans to hydride, 
where F= F2, F3 or F4, and hydride loss from [Ir(IMes)(F)3(H)2]+ were obtained. 
Polarisation levels demonstrated that enhancements followed the trend F2> 
F4>F3. The enhancements for F2 were highest and also possessed the most 
commensurate rates for loss of ligand and hydride. The slowest transfer 
process of ligand or hydride loss was ligand loss of 3.5 s-1 for F4 compared to 
hydride loss at 3 s-1 for F3. 
Enhancements were consistently lower at 65 G than earth’s magnetic field, 
which is in agreement with previously reported NOS substrates bearing 4-
substituted pyridyl-tethers.127 In addition, the time to field cycle the samples 
will have impacted negatively on the enhancements obtained given that the 
time taken to transfer is of the same magnitude as the T1 values measured 
(ca. 3 s).  
F5 demonstrated that a fentalogue of known biological activity may be 
hyperpolarised utilising SABRE. SABRE on a mixture containing 81 μM of F5, 
below the lethal dose, and an excess of heroin has been demonstrated to 
reveale the presence of the fentalogue within seconds. This represents the 
selective detection of mirfentanil in a street-like sample where an NMR 
spectrum of the same sample could not visibly detect its presence, even after 
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15 mins collection time. It is envisaged that if the SABRE approach may be 
expanded to a wider range of fentalogues (e.g. thiofentanyl), and remains 
resilient to mixture content, SABRE may be utilised as a forensic tool for the 
qualitative detection of fentalogue contaminated drug samples.
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7. Conclusions 
The use of iridium based pre-catalysts for SABRE has been well established 
within the literature,1-4 with several reports also demonstrating cobalt 
SABRE.5-7 However, there is only a single report of potential rhodium SABRE, 
which made use of a mixed iridium/rhodium system.8 Therefore it was prudent 
to assess if rhodium complexes may be effectively utilised for SABRE 
polarisation transfer. 
A range of rhodium complexes were synthesised and [Rh(IMes)(COD)Cl] was 
characterised for direct comparison with the literature standard SABRE 
catalyst [Ir(IMes)(COD)Cl].  
For SABRE to occur reversible exchange of both substrate and hydrides must 
occur. It has been demonstrated that in both IMes-containing complexes 
chlorine may be displaced by the most commonly utilised SABRE substrate, 
pyridine. This was further observed for the complexes [Rh(ImNPri2)(COD)Cl], 
[Rh(ItBu)(COD)Cl] and [Rh(ICy)(COD)Cl]. However, COD hydrogenation is not 
observed and hydrides do not readily form for the rhodium complexes, with 
variable temperature interrogation of [Rh(IMes)(COD)Cl] demonstrating only 
transient hydrides at elevated temperatures. However, the disappearance of 
these transient hydrides when a non-methanol solvent is utilised suggests that 
an adduct containing species may be responsible for these hydrides. 
Wilkinson’s catalyst was evaluated for SABRE due to the clear formation of 
hydrides upon addition of H2 and its previous utilisation within PHIP.9 When 3-
fluoropyridine was utilised, 19F NMR spectroscopy provided evidence for 
substrate binding to ~33% of the Wilkinson complexes in solution. 
Unfortunately, for both substrates, no SABRE was observed suggesting there 
was no reversible substrate binding despite the potential presence of 
parahydrogen derived hydrides. Therefore, [Ir(IMes)(COD)Cl] was utilised in 
this thesis as the SABRE pre-catalyst. 
At the start of this work the only report of 19F SABRE was the initial 2009 report 
of SABRE itself, which contained a single spectrum for 3-fluoropyridine (L3) 
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without a quoted enhancement factor.10 Though an additional report had found 
pentafluoropyridine (L6) to be SABRE inactive, no explanation for this was 
presented.11 Therefore, a desired goal was to expand the substrate scope to 
which 19F SABRE could be applied. As pyridine is the benchmark substrate for 
SABRE a range of fluorinated pyridine substrates were identified as initial 
ligands to be evaluated for SABRE activity. 
The work presented here demonstrates SABRE hyperpolarisation of novel 
ligands. While L2, L4 and L6 did not demonstrate SABRE explanations for this 
could be found in the lack of formation of a complex capable of polarisation 
transfer or self-reaction in the case of L4. However, 19F SABRE was 
demonstrated for L3 and L5, with L3 being the better SABRE ligand, with 19F 
enhancements of up to 166-fold being demonstrated under thermal conditions. 
SABRE-SHEATH was applied to L3 and L5. This approach demonstrated 
significantly increased polarisation levels of ~4-fold greater than polarisation 
transfer in earth’s field for L3. SABRE-RELAY also produced an in-phase 
spectrum, avoiding potential internal signal cancelation for MRI applications. 
The polarisation transfer species [Ir(IMes)(L)3(H)2] responsible for the SABRE 
of L3 and L5 was interrogated making use of EXSY. This provided a theoretical 
basis for the improved polarisation levels demonstrated by L3 over L5 as the 
complex formed by the later had a non-commensurate rapid exchange of 
ligand and hydride. However, this insight meant that subsequent cooling of L5 
demonstrated improved levels of 19F polarisation as the polarisation transfer 
process was optimised at lower temperatures due to more commensurate 
ligand and hydride exchange speeds. 
The relaxation times of L1 - L6 have been investigated, demonstrating the 
difficulty in optimising a polarisation transfer system as reduced ligand 
equivalents relative to the polarisation transfer catalyst result in a higher 
enhancement due to a higher efficiency transfer process but also results in a 
reduced relaxation time meaning the resulting hyperpolarised signal returns to 
unity faster. This work also demonstrated that low field applications such as 
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benchtop NMR have an advantage over more traditional high field applications 
due to longer T1 values for the same sample.12 
A deuteration approach was taken to gain insight into the mechanism of 
polarisation transfer to 19F and to increase the overall levels of polarisation. 
Testing of d4-L3 did not result in SABRE, suggesting that polarisation transfer 
may require a proton within the ortho site for this ligand to facilitate indirect 
polarisation transfer from the iridium-bound parahydrogen-derived hydrides to 
19F via this proton. It may also suggest that long-range scalar couplings are 
simply not strong enough to facilitate direct polarisation transfer to the 
heteronuclei in this ligand. 
An investigation was conducted to evaluate a range of functionalised solids for 
the potential formation of HET-SABRE catalysts as this would negate the 
toxicity concerns associated with [Ir(IMes)(COD)Cl] through simple phase 
separation of catalyst and hyperpolarised substrate. A HET-SABRE catalyst 
was produced which was capable of hyperpolarising pyridine, although this 
structure has been previously reported.13 
Though the majority of supports tested did not show HET-SABRE activity, this 
was explained utilising a homogenous model for supports S2, S3 and S7, which 
demonstrated they may be effective agents for catalyst deactivation.3 Removal 
of [Ir(IMes)(COD)Cl] from solution by a support may be a timely solution as 
despite its utilisation as the SABRE catalyst resulting in the highest 
enhancement levels attained, in the majority of cases, recent work has 
demonstrated this iridium species is cytotoxic.14-17 Therefore, the potential for 
the supports to be utilised removing this cytotoxic species from a bolus was 
examined. 
The metal scavenging efficacy of the supports was examined and scavengers 
S1, S4 and S5 were shown to be particularly effective. During this work a report 
was published which meant literature comparisons could be made with 
scavengers S3 and S4. Though the work reported here represents a lower 
percentage removal of iridium from a SABRE bolus, the quantity removed was 
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significantly higher making use of an initial iridium concentration closer to that 
which may be required in a clinical setting. 
Extrapolation of the scavenger data suggests that ~1 g of the most effective 
novel scavenger, S5, would render iridium below the level detected in blanks 
for the ICP-OES instrument utilised in this study with an initial concentration of 
~1.7ppm and an exposure time of ~2 mins, with the quantity required dropping 
significantly with longer exposure times. It is envisaged that this novel 
scavenger could, in combination with other approaches such as CASH-
SABRE,18 enable the rapid preparation of a biocompatible SABRE 
hyperpolarised bolus. Utilisation of this approach combined with ~1g of S5 
should be capable of reducing a sample commensurate with a typical SABRE 
sample (2 mg of 4 in 0.6 ml, ~1005 ppm) to background levels of iridium 
present within the hyperpolarised T1 of a suitable substrate.19, 20 
As a route to potential biological application has been identified a range of 
biologically relevant substrates were investigated. Initially the 
hyperpolarisation of a range of fentalogues was presented. This work started 
with investigating the activity of a range of fentalogues F2 – F4 specifically 
synthesised for this work by the Sutcliffe research group. These ligands all 
demonstrated SABRE activity that was investigated through the examination 
of exchange rates making use of EXSY interrogation and relaxation times. The 
thermodynamic activation parameters of ligand loss trans to hydride, where F 
= F2, F3 or F4, and hydride loss from [Ir(IMes)(F)3(H)2]+ were obtained. 
Polarisation levels demonstrated that enhancements followed the trend 
F2>F4>F3. The enhancements for F2 were highest and also possessed the 
most commensurate rates for loss of ligand and hydride. The slowest transfer 
process of ligand or hydride loss was ligand loss of 3.5 s-1 for F4 compared to 
hydride loss at 3 s-1 for F3. 
Enhancements were consistently lower at 65 G than earth’s magnetic field, 
which is in agreement with previously reported NOS substrates bearing 4-
substituted pyridyl-tethers.21 In addition, the time to field cycle the samples will 
have impacted negatively on the enhancements obtained given that the time 
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taken to transfer is of the same magnitude as the T1 values measured (ca. 3 
s).  
F5 demonstrated that a fentalogue of known biological activity may be 
hyperpolarised utilising SABRE. SABRE on a mixture containing 81 μM of F5, 
a concentration below the lethal dose, and an excess of heroin has been 
demonstrated, revealing the presence of the fentalogue within seconds. This 
represents the selective detection of mirfentanil in a street-like sample where 
a 1H NMR spectrum of the same sample could not visibly detect its presence, 
even after 15 mins collection time.  
The 19F SABRE of a WHO medicine, voriconazole, was presented and 
hyperpolarisation observed, even when a quantity of voriconazole ~4 times 
below the current dosing guidelines was utilised. This represents the first time 
a 19F containing molecule has been SABRE hyperpolarised that is currently 
approved for clinical use. As voriconazole has previously been studied using 
MRI to obtain brain images, it is envisaged that in combination with techniques 
for catalyst scavenging discussed in section 5.4, the foundation work for the in 
vivo application of 19F SABRE are presented herein. 
The work presented in this thesis has contributed to the publications: 
‘Perspective on the Hyperpolarisation Technique Signal Amplification By 
Reversible Exchange (SABRE) in NMR and MR Imaging’, T. B. R. Robertson, 
R. E. Mewis, Annu. Rep. NMR Spectrosc., 2018, 93, 145-212. 
‘Extending the Scope of 19F Hyperpolarization through Signal Amplification by 
Reversible Exchange in MRI and NMR Spectroscopy’, A. M. Olaru, T. B. R. 
Robertson, J. S. Lewis, A. Anthony, W. Iali, R. E. Mewis, S. B. Duckett, 
ChemistryOpen, 2018, 7, 97-105. 
‘Hyperpolarization of Pyridyl Fentalogues by Signal Amplification By 
Reversible Exchange (SABRE)’, T. B. R. Robertson, L. H. Antonides, N. 
Gilbert, S. L. Benjamin, S. K. Langley, L. J. Munro, O. B. Sutcliffe, R. E. Mewis, 
ChemistryOpen, 2019, 8, 1375-1382. 
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7.1. Future Work 
A range of rhodium complexes have been evaluated as part of this work for 
comparison with the commonly utilised iridium based polarisation transfer 
catalysts. While these have not demonstrated the capability to perform 
SABRE, it is possible that utilising a tridentate ligand system similar to that 
utilised within the limited cobalt examples of SABRE may enable polarisation 
transfer, as although this complex requires the formation of a dihydride 
species, the change in ligand may serve to stabilise the complex. The 
investigation of a mixed iridium/rhodium system would also prove useful to 
confirming the source of SABRE currently reported by Koptug et al., though 
they state it was hard to differentiate which species was responsible for 
polarisation transfer. The utilisation of 13C SABRE should enable 
differentiation of the polarisation transfer species as there is a characteristic 
JRhC coupling observed within the rhodium complexes synthesised here which 
would only be visible in rhodium-mediated 13C SABRE. 
 
Figure 103. Structure of Rapasudil. 
This work has demonstrated the potential for 19F SABRE, however, a range of 
other potential ligands would be of interest, including other clinically approved 
medication with structures potentially amenable to SABRE such as Rapasudil, 
the structure of which is shown in Figure 103. The high chemical shift 
sensitivity of 19F may also enable a range of potential applications of utilising 
fluorinated pyridyl tags for the hyperpolarisation, and detection, of complex 
molecules. For instance previously reported tagging of oxytocin with 
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perfluorohetroaromatic groups may enable a hyperpolarisation based 
detection method for a range of polypeptides.22 
The capacity for silica-based scavenging of the metal components from 
solution has been demonstrated herein. However, the scope of scavengers 
utilised was limited by the initial project design focusing on the formation of a 
HET-SABRE catalyst. Within literature, the utilisation of sulphur-based 
scavengers has proven to be advantageous over nitrogen based analogues.23 
Therefore, the combination of the most successful scavengers tested within 
this work with sulphur containing heterocycles represents a promising avenue 
for future work. The implementation of a solid-based metal scavenger into an 
automated system for the production of a metal depleted bolus, from which a 
hyperpolarised signal may still be measured, would demonstrate a significant 
step towards production of a clinically relevant technique developing from the 
work reported here. 
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8. Experimental 
8.1. Chemicals 
All materials for experimental synthesis were sourced from Acros Organics, 
Sigma-Aldrich, Fisher Scientific or Apollo chemicals. ICP standards were 
purchased from SCP science. Iridium and rhodium chloride salts were sourced 
from Precious Metals Online, www.precmet.com.au. All materials were used 
as received unless stated within the experimental procedure. Solvents were 
purchased from Fisher Scientific and were of general use or HPLC grade 
unless specifically stated. Where the use of dry ethyl acetate is stated this was 
dried over anhydrous potassium carbonate. TLC analysis made use of 
aluminium backed silica gel 60 F254 plates (Merck Millipore). Silica gel 
chromatography was performed with geduran silica gel 60 (Merck Millipore). 
Deuterated solvents were sourced from Sigma Aldrich with ≥99.8% deuterium 
labelling. 
8.2. Instrumentation 
All NMR spectra for characterisation of synthesised compounds were 
collected on a JEOL ECS-400 FT NMR in the solvent described with chemical 
shifts (δ) quoted in ppm and coupling constants (J) quoted in hertz (Hz). 
Spectra were collected at a frequency of 400.14 MHz for 1H spectra, 101 MHz 
for 13C spectra and 376 MHz for 19F spectra. SABRE NMR spectra were 
collected on an Oxford Instruments Pulsar benchtop at a frequency of 59.8 
MHz for 1H spectra and 56 MHz for 19F spectra. NMR analysis was carried out 
making use of MestReNova version 11.0.4. Measurements making use of a μ-
magnetic shield utilised a LakeShore cryogenics model 4065 zero gauss 
chamber. Measurements making use of a mixing field outside of the 
spectrometer above earth’s field made use of a custom electromagnet 
produced by Siga Transformers (sigatransformers.co.uk) within which a 
vertical magnetic field of up to 150 G could be generated. A Hirst Magnetic 
Instruments Ltd GM07 gaussmeter with transverse (Hirst magnetic 
instruments ltd, serial #10620) and axial (RS components ltd, stock number 
212-736) hall probes were used to determine the exact magnetic field for 
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measurements which involved polarisation transfer occurring under SABRE 
conditions. 
Hydrogen was generated using a Peak scientific PH200 hydrogen generator 
set to 3.5 bar. Where parahydrogen was required this was generated through 
the immersion of a charcoal packed coil into liquid nitrogen to generate ~50% 
enriched parahydrogen. SABRE measurements were made utilising GPE 
scientific, 5mm, 7’’ long, 400 MHz, Norell select series Young’s tubes. 
Mass spectrometry was performed using an Agilent technologies 6540 UHD 
Accurate-Mass Q-TOF LC/MS system. Where needed, LC separation prior to 
MS was performed on an Agilent technologies 1260 infinity series LC system. 
EDX measurements were acquired on a ZEISS GeminiSEM system equipped 
with an Ametek EDX attachment. Data was analysed utilising SmartSEM and 
EDX genesis software. 
Microwave reactions made use of an Anton Parr monowave 300 microwave 
reactor.  
Samples requiring sonication made use of a 475H Langford Sonomatic 
ultrasonic cleaner.  
ICP-OES samples were prepared where stated making use of a VWR 
Microstar12 centrifuge and VWR digital vortex mixer. Deionised water was 
purified with a Merck Millipore gradient A10 water purification system or a 
Merck Millipore Milli-Q Integral water purification system. Deionised water was 
stored after purification in a Merck Millipore polyethylene storage tank. 
Analysis was performed using a Thermo Scientific iCAP 6000 series ICP-OES 
utilising Qtegra software.  
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8.3. SABRE hyperpolarisation 
8.3.1. Enhancement calculations 
The calculation of enhancement factors made use of Equation 3 
𝐸𝑛ℎ𝑎𝑛𝑐𝑒𝑚𝑒𝑛𝑡 (𝜀) =
𝑆ℎ𝑦𝑝
𝑆𝑡ℎ𝑒𝑟𝑚𝑎𝑙
 
Equation 3. Equation for the calculation of enhancement factors where Shyp is 
the integral of a set region after hyperpolarisation and Sthermal is the integral of 
the same region without hyperpolarisation. 
The same sample was used for the collection of Sthermal and Shyp, however, 
Sthermal was allowed to fully relax in the measurement field (typically 1.4 T, see 
section 8.2) before data acquisition. Reference and polarised spectra were 
collected using identical acquisition parameters, including the use of heating 
and cooling of the sample prior to acquisition where specified. The raw 
integrals of the relevant resonances in the polarised and unpolarised spectra 
were used to determine the enhancement level. The same chemical shift 
region was selected for integrals to ensure a fair comparison – in all cases 
each spectrum was properly referenced to the solvent used.  
Where stated in the results, some enhancements were calculated making use 
of signal magnitude. These were collected as described above but made use 
of Equation 4. 
𝐸𝑛ℎ𝑎𝑛𝑐𝑒𝑚𝑒𝑛𝑡 (𝜀) =
|𝑆ℎ𝑦𝑝|
|𝑆𝑡ℎ𝑒𝑟𝑚𝑎𝑙|
 
Equation 4. Equation for the calculation of enhancement factors where |Shyp| 
is the integral of a set region after hyperpolarisation and |Sthermal| is the integral 
of the same region without hyperpolarisation. 
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8.3.2. Sample preparation 
8.3.2.1. SABRE sample preparation 
Unless otherwise specified, a sample of ligand (L) was solvated in 600 μL of 
deuterated solvent with 2 mg of the SABRE pre-catalyst, [Ir(IMes)(COD)Cl]. 
The ratio of ligand to pre-catalyst was, as specified, typically within the range 
of 4-20 equivalents ligand:pre-catalyst. The sample was shaken to ensure full 
ligand and pre-catalyst solvation before transfer into a Young’s capped NMR 
tube. The sample was then freeze-thaw degassed making use of the 
procedure outlined in section 8.3.3 for the solvent used. The sample was then 
activated by shaking for 30 seconds following the introduction of parahydrogen 
into the head space of the tube. 
8.3.2.2. SABRE-RELAY sample preparation  
Unless otherwise specified a sample of ligand (L) was solvated in 500 μL D2O 
(Sigma Aldrich, 99.9% deuterated) and 100 μL ammonia (Fisher scientific, 
35% in H2O) with 2 mg of the SABRE pre-catalyst, [Ir(IMes)(COD)Cl]. The ratio 
of ligand to pre-catalyst was 4 equivalents ligand:pre-catalyst. The sample was 
shaken to ensure full ligand and pre-catalyst solvation before transfer into a 
Young’s capped NMR tube. The sample was then freeze-thaw degassed 
making use of the procedure outlined in section 8.3.3 for the solvent used. The 
sample was then activated by shaking for 30 seconds following the 
introduction of parahydrogen into the head space of the tube. 
8.3.2.3. Mirfentanil-heroin mix SABRE sample 
preparation 
174.9 mg of heroin, was dissolved in 3.6 mL of d4-methanol and sonicated for 
~30 seconds. For the lowest concentration (81.2 μM) 1.1 mg of mirfentanil and 
0.5 mg of the SABRE pre-catalyst, [Ir(IMes)(COD)Cl] were added to this stock 
and sonicated for 30 seconds. Following this a 0.6 mL aliquot was transferred 
to a Young’s capped NMR. The sample was then freeze-thaw degassed 
making use of the procedure outlined in section 8.3.3 for d4-methanol before 
parahydrogen was introduced into the head space of the tube. SABRE was 
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then performed with polarisation transfer at both earth’s magnetic field and 65 
G by shaking the tube for 10 seconds in the polarisation transfer field before 
rapid transfer and acquisition at 1.4 T. Parahydrogen within the headspace of 
the tube was then replenished prior to additional measurements. 
The aliquot was then returned to the stock solution and additional mirfentanil 
added in steps of 1.1 mg, 2.3 mg and 2.4 mg respectively to give four total 
concentrations. Alongside these mirfentanil additions 1.0 mg of 
[Ir(IMes)(COD)Cl] was added at each concentration step up. Following the 
addition of more mirfentanil and [Ir(IMes)(COD)Cl], the stock was sonicated 
for 30 seconds before removal of a fresh aliquot and acquisition repeated in 
this way for the total four concentrations (81.2, 162.3, 332.0 and 509.1 μM 
mirfentanil). 
8.3.3. Freeze-thaw degassing methods 
8.3.3.1. d4-methanol 
The Young’s capped NMR tube was submerged in an acetone/dry ice bath 
before a vacuum was applied to the head space until the pressure was below 
6 mbar. The tube was then removed from the acetone/dry ice bath and shaken 
for a minimum of 20 seconds before repeating the degassing step a further 
twice. 
8.3.3.2. D2O 
The Young’s capped NMR tube was submerged in a liquid nitrogen bath 
before a vacuum was applied to the head space until the pressure was below 
6 mbar. The tube was then carefully removed from the liquid nitrogen, while 
acetone was run down the length of the tube, and shaken for a minimum of 20 
seconds before repeating the degassing step a further twice. 
8.3.4. Magnetic Field Measurements 
Where SABRE measurements were carried out at a field above Earth’s 
magnetic field, a Siga Transformers hollow tube coil was utilised within which 
a vertical magnetic field of up to 150 G could be generated (Figure 104). The 
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sample was then rapidly inserted in to the NMR spectrometer and a 1H NMR 
spectrum acquired.  
 
Figure 104. Magnetic field produced in response to voltage applied to the 
hollow tube coil used for SABRE hyperpolarisation transfer. 
8.3.5. Variable temperature SABRE 
All SABRE measurements were conducted at room temperature unless 
otherwise specified. Where specified parahydrogen was added to the 
headspace of the Young’s capped NMR tube and not shaken until after being 
submerged within a water bath heated or cooled to the specified temperature 
for 2 minutes prior to rapid transfer into the measurement field and sample 
interrogation. Where SABRE occurred the specified enhancements are 
compared with a thermal spectrum acquired at the same temperature following 
the same procedure. 
8.4. Exchange Rate Spectroscopy 
A sample of ligand (L) was solvated in 600 μL of deuterated solvent with 
between 6-10 mg of the SABRE pre-catalyst, [Ir(IMes)(COD)Cl]. The ratio of 
ligand to pre-catalyst was 4:1. The sample was shaken to ensure full ligand 
and pre-catalyst solvation before transfer into a Young’s capped NMR tube. 
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The sample was then freeze-thaw degassed making use of the procedure 
outlined in section 8.3.3 for the solvent used. 
Exchange data was collected by running a series of NOESY experiments at 
temperatures between 268 – 305 K. Data was collected at six temperatures. 
At each temperature a series of mixing values typically ranging from 0.005 s 
to 1 s were used to establish the rate constants for hydride and bound-ligand 
loss. These values were then used to create Eyring-Polanyi plots in order to 
obtain ∆G300 K, ∆H and ∆S for each exchange process. 
8.5. Use of controlled substances 
All controlled drug standards were either prepared in-house or obtained, under 
UK Home Office licence (No. 550460), by authorised personnel and in 
compliance with both the UK Misuse of Drugs Act (1971) and UK Misuse of 
Drugs Regulations (2001). Test samples (street samples) were provided by 
Greater Manchester Police (GMP) personnel, in accordance with the 
legislation and under the approved protocol operating between the 
MANchester DRug Analysis and Knowledge Exchange (MANDRAKE) and 
GMP. All controlled/restricted materials were stored, transferred, used and 
destroyed in compliance with the UK Misuse of Drugs Act (1971) and UK 
Misuse of Drugs Regulations (2001). 
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8.6. Chemical Synthesis 
A range of compounds were synthesised over the course of this work, specifics 
are detailed below. 
8.6.1. N,N'-bis(2,4,6-trimethylphenyl)ethanediimine, 1 
 
A solution of glyoxal (7.3 mL, 40% in water, 64 mmol) in methanol (25 mL) was 
added with stirring to a warmed (50°C) solution of 2,4,6-trimethylaniline (13.79 
g, 100 mmol), acetic acid (0.05 mL, 1 mmol) and methanol (25 mL). Upon 
addition of the glyoxal, the desired material began to crystallise out of solution. 
The mixture was left to stir o/n and the resulting orange suspension filtered. 
The solid was washed with methanol (20 mL) before drying overnight (o/n) 
under reduced atmosphere. This yielded 1 as a yellow solid (11.88 g, 39%); 
1H NMR (400 MHz, CDCl3) δ 8.19 (s, 2H, ArH), 6.90 (s, 4H, Mes), 2.28 (s, 6H, 
Me), 2.15 (s, 12H, Me). 13C NMR (101 MHz, CDCl3) δ 147.50, 136.65, 136.57, 
134.36, 129.07 (Caromatic), 20.87, 18.31 (CMe). HRMS expected for C20H24N2 
m/z=293.2012, found m/z=293.2009. 
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8.6.2. 1,3-bis(2,4,6-trimethylphenyl)-imidazolium 
hydrochloride, 2 
 
1 (1.00 g, 3.42 mmol) and paraformaldehyde (115.4 mg, 3.8 mmol) were 
dissolved in dry ethyl acetate (10 mL) and heated to 70°C. Trimethylsilyl 
chloride (0.52 mL, 4 mmol) was added dropwise over 45 mins and the reaction 
was stirred o/n. The reaction was then cooled to 5°C. After an hour of stirring 
at low temperature the solution was filtered and a cream solid obtained. This 
was washed with ethyl acetate (30 mL) and left to dry o/n under reduced 
atmosphere. This yielded 2 as a cream solid (0.83 g, 79%); 1H NMR (400 MHz, 
CDCl3) δ 10.89 (s, 1H, NCHN), 7.51(s, 2H, Imidazole), 6.97 (s, 4H, Mes), 2.28 
(s, 6H, Me), 2.13 (s, 12H, Me). 13C NMR (101 MHz, CDCl3) δ 141.50, 140.16, 
134.17, 130.68, 130.06, 124.25(Caromatic), 21.26, 17.80(CMe). HRMS expected 
for C21H24N2 m/z=305.2017, found m/z=305.2018. 
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8.6.3. [Ir(COD)Cl]2, 3 
 
Argon was bubbled through a solution of IrCl3.xH2O (0.50 g, 1.6 mmol 
anhydrous) in distilled water (8 mL) and propan-2-ol (12 mL). After 30 min, 
cyclooctadiene (COD), (2.7 mL, 20.4 mmol) was added and the mixture was 
heated to 90°C under argon. After 2-3 h, a brick red solution was formed and 
the reaction was cooled to room temperature. The precipitate was then filtered 
and washed with cold methanol (20 mL) and dried under reduced pressure to 
yield 3 as an orange solid (0.21 g, 18% based on anhydrous IrCl3); 1H NMR 
(400 MHz, CDCl3) δ 5.59 (s, 8H, CH), 2.37 (s, 16H, CH2). 13C NMR (101 MHz, 
CDCl3) 128.76 (CH), 28.10 (CH2).  
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8.6.4. [Ir(IMes)(COD)Cl], 4 
 
A solution of 2 (0.20 g, 66 mmol) and potassium tert-butoxide (0.08 g, 0.71 
mmol) in dry tetrahydrofuran (8 mL) was stirred under argon for 30 mins. A 
solution of 3 (0.2 g, 0.30 mmol) in dry tetrahydrofuran (8 mL) was added to this 
solution. The reaction was then left to stir o/n. The solution was then 
concentrated under reduced pressure before purifying with silica gel 
chromatography (8:1 DCM:acetone). The yellow fraction was collected and 
dried under vacuum. The product was triturated with diethyl ether (5 mL), and 
after removal of the solvent under reduced pressure, this yielded 4 as a golden 
solid (0.27 g, 71%); 1H NMR (400 MHz, d4-MeOD) δ 7.23 (s, 2H, Imidazole), 
7.03 (d, 4H, JHH= 6.46, ArH), 4.00 (m, 2H, CH of COD), 3.08 (m, 2H, CH of 
COD), 2.36 (s, 6H, CH3), 2.29 (s, 6H, CH3), 2.18 (s, 6H, CH3), 1.67 (m, 4H, 
COD), 1.33 (m, 4H, COD). 13C NMR (101 MHz, d4-MeOD) 180.65, 139.93 
(CAr), 138.24 (CAr), 137.58, 135.94, 130.34, 129.35, 125.28, 82.82, 53.21, 
34.38, 29.81, 21.17, 19.98, 18.56. HRMS expected for IrClN2C29H36 
m/z=639.2246, found m/z (M-Cl)= 603.2484, found m/z=603.2460. 
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8.6.5. [Rh(COD)Cl]2, 5 
 
Argon was bubbled through a solution of RhCl3.xH2O (0.5068 g, 2.4 mmol) in 
propan-2-ol (20 mL). After 30 min, cyclooctadiene (COD) (1.1 mL, 9 mmol) 
was added and the mixture was heated to 80°C under argon. After 2-3 h the 
reaction was cooled to room temperature, then the solution is left to stand o/n. 
The precipitate was then filtered and washed with cold methanol and dried 
under reduced pressure to yield compound 8 as an orange solid [Rh(COD)Cl]2 
(0.2972 g, 50% yield based on anhydrous mass of RhCl3); 1H NMR (400 MHz, 
CDCl3) δ 4.21 (s, 4H), 2.48 (m, 4H), 1.74 (q, 4H, JHH= 7.90). 13C NMR (101 
MHz, CDCl3) 78.79 (d, JCRh= 14.40 Hz, CH), 30.96 (CH2). HRMS expected for 
C16H24Cl2Rh2 m/z=491.9365, found m/z=252.0258, HRMS expected for 
[Rh(COD)(MeCN)]= 252.0215. 
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8.6.6. [Rh(IMes)(COD)Cl], 6 
 
A solution of 2 (277 mg, 0.9 mmol) and potassium tert-butoxide (100 mg, 0.9 
mmol) in dry tetrahydrofuran (7 mL) was stirred under argon for 30 mins. A 
solution of 8 (248 mg, 0.5 mmol) in dry tetrahydrofuran (5 mL) was added to 
this solution. The reaction was then left to stir o/n. The solution was then 
concentrated under reduced pressure before purifying with silica gel 
chromatography (8:1 DCM:acetone). The yellow fraction was collected and 
dried under vacuum. The product was triturated with diethyl ether, and after 
removal of the solvent under reduced pressure, 9 was obtained as a golden 
solid (374.4 mg, 88%); 1H NMR (400 MHz, CDCl3) δ 7.23 (s, 2H, Imidazole), 
7.08 (s, 4H, ArH), 4.38 (m, 4H, COD), 3.42 (m, 4H, COD), 2.39 (s, 6H, Mes), 
2.32 (s, 3H, Mes), 2.16 (s, 2H, Mes), 1.86 (s, 4H, COD), 1.58 (s, 4H, COD). 
13C NMR (101 MHz, d4-MeOD) 181.48, 140.03 (CAr), 138.40 (CAr), 137.77, 
135.93, 130.51, 129.45, 125.54, 96.89 (d, JCRh= 7.95), 69.79 (d, JCRh= 14.61), 
33.62, 29.27, 29.04, 21.19, 20.11, 18.50. HRMS expected for RhClN2C29H36 
m/z=550.1622, found m/z (M-Cl)=515.1934. 
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8.6.7. [Rh(ImNPri2)(COD)Cl], 7 
 
A solution of ImNPri2.Cl (152 mg, 0.80 mmol) and potassium tert-butoxide (126 
mg, 11.2 mmol) in dry tetrahydrofuran (10 mL) was stirred under argon for 1 
hour. A solution of 8 (197 mg, 0.4 mmol) in dry tetrahydrofuran (10 mL) was 
added to this solution. The reaction was then left to stir o/n. The solution was 
then concentrated under reduced pressure before purifying with silica gel 
chromatography (8:1 DCM:acetone). The yellow fraction was collected and 
dried under vacuum. The product was triturated with diethyl ether, and after 
removal of the solvent under reduced pressure, 10 was obtained as a bright 
yellow solid (253.9 mg, 79%); 1H NMR (400 MHz, CDCl3) δ 6.87 (s, 2H, 
Imidazole), 5.79-5.68 (septet, J=6.85, 2H, aliphatic CH), 4.98 (s, 2H, COD), 
3.31 (s, 2H, COD), 2.39 (m, 4H, COD), 1.93 (d, J= 9.02, 4H, COD). 13C NMR 
(101 MHz, CDCl3) 181.54, 116.87, 98.09 (d, JCRh= 7.38), 67.55 (d, JCRh= 
14.43), 52.64, 33.09, 28.99, 24.36, 23.42. HRMS expected for RhClN2C17H28 
m/z=398.0997, found m/z (M-Cl)=363.1300.  
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8.6.8. [Rh(ItBu)(COD)Cl], 8 
 
A solution of ItBu BF4 (111 mg, 0.41 mmol) and potassium tert-butoxide (105 
mg, 0.94 mmol) in dry tetrahydrofuran (5 mL) was stirred under argon for 2 
hours. A solution of 8 (101 mg, 0.2 mmol) in dry tetrahydrofuran (5 mL) was 
added to this solution. The reaction was then left to stir o/n. The solution was 
then concentrated under reduced pressure before purifying with silica gel 
chromatography (8:1 DCM:acetone). The yellow fraction was collected and 
dried under vacuum. The product was triturated with diethyl ether, and after 
removal of the solvent under reduced pressure, 11 was obtained as a bright 
yellow solid (72.8 mg, 37.8%); 1H NMR (400 MHz, CDCl3) δ 7.11 (s, 2H, 
Imidazole), 4.91 (m, 2H, COD), 3.15 (s, 2H, COD), 2.38 (s, 4H, COD), 2.08  
(s, 18H, Me), 1.75 (m, 4H, COD). 13C NMR (101 MHz, CDCl3) 179.93, 119.97, 
67.87, 33.01, 32.25, 28.74. 19F NMR demonstrated no BF4 starting material 
was still present within the product. HRMS expected for RhClN2C19H32 
m/z=428.1461, found m/z (M-Cl)=391.1614.  
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8.6.9. [Rh(ICy)(COD)Cl], 9 
 
A solution of ICy BF4 (140 mg, 0.44 mmol) and potassium tert-butoxide (108 
mg, 0.96 mmol) in dry tetrahydrofuran (5 mL) was stirred under argon for 2 
hours. A solution of 8 (103 mg, 0.2 mmol) in dry tetrahydrofuran (5 mL) was 
added to this solution. The reaction was then left to stir o/n. The solution was 
then concentrated under reduced pressure before purifying with silica gel 
chromatography (8:1 DCM:Acetone). The yellow fraction was collected and 
dried under vacuum. The product was triturated with diethyl ether, and after 
removal of the solvent under reduced pressure, 11 was obtained as a bright 
yellow solid (77.1 mg, 38.6%); 1H NMR (400 MHz, CDCl3) δ 6.82 (s, 2H, 
Imidazole), 5.33 (ddt, J= 11.9, 7.7, 3.7, 2H, ICy), 4.99 (s, 2H, COD), 3.28 (s, 
2H, COD), 2.36 (m, 4H, COD), 2.00 (m, 4H, ICy), 1.94 (d, J= 8.00, 4H, COD), 
1.62 (m, 4H), 1.36 (td, J= 12.3, 3.8, 2H, ICy). 13C NMR (101 MHz, CDCl3) 
182.96, 117.31, 97.80 (d, JCRh= 7.23), 67.31 (d, JCRh= 14.51), 60.39, 34.39 (d, 
JCRh= 5.51), 33.25, 29.11, 26.30, 26.00, 25.60. 19F NMR demonstrated no BF4 
starting material was still present within the product. HRMS expected for 
RhClN2C23H36 m/z=478.1617, found m/z (M-Cl)=443.1931.  
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8.6.10. 3-Fluoropyridine-N-oxide, 10 
 
3-fluoropyridine (1.34 mL, 13.65 mmol), hydrogen peroxide (30%, 2.7 mL, 46 
mmol) and acetic acid (8.1 mL, 141.6 mmol) were heated to 80°C. The solution 
was left to stir for 26 hours before being reduced to a small volume (5 mL) 
under vacuum. The resulting solution was neutralised with potassium 
carbonate and dried with sodium sulfate before chloroform (30 mL) was added. 
The solution was then filtered and the filtrate concentrated under reduced 
pressure to yield 5 as a pale yellow solid (1.46 g, 83%); 1H NMR (400 MHz, 
D2O) δ 8.27-8.20 (m, 1H), 8.08-8.01 (m, 1H), 7.49-7.40 (m, 2H). 13C NMR (101 
MHz, D2O) δ 160.36 (d, JCF= 252.31, CF), 135.93 (Cortho), 129.67 (d, JCF= 
36.99, Cortho), 127.39 (d, JCF= 9.51, Cmeta), 119.78 (d, JCF= 19.16, Cpara). 19F 
NMR (376 MHz, CDCl3) δ -119.86. HRMS expected for C5H4NFO 
m/z=114.0350, found m/z=114.0353. 
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8.6.11. 3-Fluoropyridine-N-oxide-d4, 11 
 
5 (8, 0.2571 g, 2.27 mmol), potassium carbonate (0.1682 g, 1.22 mmol) and 
D2O (1.7 mL) were reacted in a microwave for 3 hours at 190°C. The volume 
of the reaction mixture was reduced, additional D2O added (5 mL) and 
microwaved at 190°C, this was repeated 9 times, until >98% deuteration was 
obtained through 1H NMR monitoring. The solution was then concentrated 
under reduced pressure to yield 6 as a yellow solid (0.24 g, 90%); 13C NMR 
(101 MHz, D2O) δ 165.49 (d, JCF= 252.31, CF), 135.93 (Cortho), 129.67 (d, JCF= 
36.99, Cortho), 127.39 (d, JCF= 9.51, Cmeta), 119.78 (d, JCF= 19.16, Cpara). 19F 
NMR (376 MHz, CDCl3) δ -121.95. HRMS expected for C5D4NFO 
m/z=117.0528, found m/z=117.0534.  
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8.6.12. 3-Fluoropyridine-d4, 12 
 
6 (0.12 g, 1.02 mmol) was dissolved in dichloromethane (25 mL) before 
addition to PCl3 (0.2 mL, 2.3 mmol) at 0°C. The solution was then heated to 
45°C for 2 hours before cooling and the addition of 10 ml deionised water at 
0°C. The resulting solution was neutralised with a saturated potassium 
carbonate solution (15 mL) before separation and the organic layer being 
concentrated under reduced pressure to yield 7 as a white solid (0.05 g, 48%); 
13C NMR (101 MHz, D2O) δ 165.48, 135.58 (t, JCF= 26.45), 129.43 (t, JCF= 
27.55), 127.11 (d, JCF= 8.32), 119.50. 19F NMR (376 MHz, CDCl3) δ -121.99. 
HRMS expected for C5D4NFO m/z=117.0528, found m/z=117.0534.  
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8.6.13. Potential HET-SABRE Catalysts 
8.6.13.1. 3-Aminopropyl-functionalised silica gel 
(S1) 
A dry flask was charged with 4 (34.5 mg, 0.05 mmol) and 3-aminopropyl 
functionalised silica gel (199 mg). A vacuum was applied for 30 mins before 
addition of dry toluene (5 mL) and TEA (3 drops). The reaction was left o/n 
before filtering and washing with methanol until the eluent ran clear. 183 mg 
of the pale yellow product was collected. 
8.6.13.2. 3-(ethylenediamino)propyl-
functionalised silica gel (S2) 
A dry flask was charged with 4 (34.1 mg, 0.05 mmol) and 3-
(ethylenediamino)propyl functionalised silica gel (199 mg). A vacuum was 
applied for 30 mins before addition of dry toluene (5 mL) and TEA (3 drops). 
The reaction was left o/n before filtering and washing with methanol until the 
eluent ran clear. 168 mg of the pale yellow product was collected. 
8.6.13.3. 3-(diethylenetriamino)propyl-
functionalised silica gel (S3) 
A dry flask was charged with 4 (34.2 mg, 0.05 mmol) and 3-
(diethylenediamino)propyl functionalised silica gel (199 mg). A vacuum was 
applied for 30 mins before addition of dry toluene (5 mL) and TEA (3 drops). 
The reaction was left o/n before filtering and washing with methanol until the 
eluent ran clear. 185 mg of the pale yellow product was collected. 
8.6.13.4. 3-(Imidazole-1-yl)propyl-functionalised 
silica gel (S4) 
A dry flask was charged with 4 (34.4 mg, 0.05 mmol) and 3-(imidazole-1-
yl)propyl functionalised silica gel (200 mg). A vacuum was applied for 30 mins 
before addition of dry toluene (5 mL) and TEA (3 drops). The reaction was left 
o/n before filtering and washing with methanol until the eluent ran clear. 181 
mg of the pale yellow product was collected. 
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8.6.13.5. 2-(2-pyridyl)ethyl - functionalised silica 
gel (S5) 
A dry flask was charged with 4 (34.8 mg, 0.05 mmol) and 2-(2-pyridyl)ethyl 
functionalised silica gel (200 mg). A vacuum was applied for 30 mins before 
addition of dry toluene (5 mL) and TEA (3 drops). The reaction was left o/n 
before filtering and washing with methanol until the eluent ran clear. 58 mg of 
the pale yellow product was collected. 
8.6.13.6. Ethylenediamine, polymer-bound (S6) 
A dry flask was charged with 4 (34.9 mg, 0.05 mmol) and polymer bound 
ethylenediamine (201 mg). A vacuum was applied for 30 mins before addition 
of dry toluene (5 mL) and TEA (3 drops). The reaction was left o/n before 
filtering and washing with methanol until the eluent ran clear. 192 mg of the 
yellow product was collected. 
8.6.13.7. (Aminomethyl)polystyrene (S7) 
A dry flask was charged with 4 (2.9 mg, 0.005 mmol) and polymer bound 
ethylenediamine (17 mg). A vacuum was applied for 30 mins before addition 
of dry toluene (5 mL) and TEA (3 drops). The reaction was left o/n before 
filtering and washing with methanol until the eluent ran clear. 5 mg of the 
yellow product was collected. 
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8.7. Characterisation of SABRE complexes 
8.7.1. NMR characterisation data for [Ir(IMes)(H)2(L3)3]Cl 
(17-fold excess to 5 mM of 1 in MeOD) at 245 K. 
 
Resonance 
number 
1H (ppm) 13C (ppm) 19F (ppm) 
1  180.65  
2 7.23 122.71  
3  137.00  
4  135.00  
5 6.62 128.32  
6  138.45  
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7 2.07 17.62  
8 2.22 19.60  
9 -22.85   
10 8.42 149.13  
11    
12 7.38 126.23  
13 7.72 123.74  
14 8.00 144.22  
15   -124.2 
16 7.94 151.38  
17    
18 7.08 126.67  
19 7.64 123.93  
20 8.25 144.51  
21   -124.5 
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8.7.2. NMR characterisation data for [Ir(IMes)(H)2(L5)3]Cl 
(17-fold excess to 5 mM of 1 in MeOD) at 245 K. 
 
Resonance 
number 
1H (ppm) 13C (ppm) 19F (ppm) 
1  148.3  
2 7.27 122.94  
3  136.8  
4  135.1  
5 6.78 128.4  
6    
7 2.09 17.59  
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8 2.25 19.67  
9 -23.22   
10,14 8.19   
11,13  159.6  
12 7.88 112.72  
15   -124.35 
16,20 8.21 141.48  
17,19    
18 7.77 112.02  
21   -124.77 
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NMR characterisation data for [Ir(IMes)(H)2(L5)2(MeOD)]Cl (17-fold excess to 
5 mM of 1 in MeOD) at 245 K. 
 
Resonance 
number 
1H (ppm) 13C (ppm) 19F (ppm) 
1  150.05  
2 7.06 121.92  
3  138.33  
4  135.5, 135.9  
5 6.86, 6.77 128.18, 128.25  
6    
7 2.25 17.84  
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8 2.22, 2.20 17.68, 17.50  
9 -23.94, d 8.3 Hz   
10,14 8.18 139.65  
11,13  159.0, 159.3  
12 7.60 110.2  
15   -124.16 
16,20 8.66 140.53  
17,19  159.0  
19 7.62 111.8  
21   -124.9 
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8.8. ICP-OES methodology 
8.8.1. Calibration series 
A commercially available 1000 ppm iridium stock solution was diluted with 
deionised water to produce a 10 ppm standard which was then diluted further 
to produce a range of standards ranging from 10 ppb to 10 ppm, all standards 
were stabilised with 3% HCl. 
8.8.2. Organic content testing 
For monitoring the effect of organic species present in solution, an organic 
stock of 160 µL pyridine in 100 mL MeOH was produced to simulate the 
organic mixture present in a typical SABRE sample (4 eq pyridine relative to 
4). The iridium standard solutions were prepared a further three times In which 
the level of the organic stock was varied to give 1%, 0.4% and 0.2% organics. 
All four sets of standards were tested making use of the iridium 224.268 nm 
line in both axial and radial view.  
A further test varying the radio frequency utilised to induce the plasma made 
use of axial view with radio frequency values of 1050 W and 1150 W. 
8.8.3. Iridium capture with solid supports 
2.4 mL of d4-methanol was added to a 7 mL sample vial (non-sterile) 
containing 45.3 mg of 4 and 0.25 mL pyridine. This was repeated without 
iridium added for method blanks (A, B and C) and with iridium for triplicate 
measurements (D, E and F). This gave two stock vials. Both vials were 
sonicated for ~1 min to ensure homogeneity.  
0.8 mL stock blank and 0.8 mL iridium stock were added to new Young’s tubes 
and degassed as in section 8.3.3.1 – though due to the high liquid quantities 
in the tubes each was degassed 4 times. This was repeated for the three blank 
(A-C) and three iridium (D-F) containing samples. 
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Hydrogen (3 bar) was added to the tube before 1.5 mins manual shaking 
commenced. Hydrogen was refilled 20 mins later and shaken for a further 1 
min. Tubes were then left o/n. 
Tubes were then shaken for a further 1 min each before being reduced to 
dryness under reduced pressure (an additional ~0.3 mL methanol was used 
to wash out Young’s tubes and ensure complete sample transfer). The 
resulting residue was reconstituted with 8.5 mL deionised water and this bolus 
was divided into 8 centrifuge tubes (1 mL per tube). 10 mg of scavengers S1 – 
S1 was added to tubes 1 – 7 and no solid was added to tube 8. Subsequently 
this each tube was vortexed for 10 seconds at a speed setting of 1500 rpm. 
This produced a series of samples A-F 1-8, as shown in Table 35. 
Table 35. Tabular representation of the ICP-OES samples examined for the 
assessment of support iridium sequestering. 
 1 2 3 4 5 6 7 8 
A A1 A2 A3 A4 A5 A6 A7 A8 
B B1 B2 B3 B4 B5 B6 B7 B8 
C C1 C2 C3 C4 C5 C6 C7 C8 
D D1 D2 D3 D4 D5 D6 D7 D8 
E E1 E2 E3 E4 E5 E6 E7 E8 
F F1 F2 F3 F4 F5 F6 F7 F8 
The solutions were then centrifuged for 2 minutes at 4000 RPM.  0.1 mL of 
each filtered solution was diluted with 9.9 mL of 3% HCl in de-ionised water to 
give a total volume of 10 mL for each sample.  
Following the removal of an aliquot, the tube was then vortexed again for 10 
seconds as above and a wait time t was applied before centrifuging again and 
removal of another aliquot. 
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8.8.4. Calculation of iridium remaining from data 
extrapolation 
Iridium remaining in the sample was calculated via extrapolation of data in 
5.3.3 using the formula below: 
𝑦 = 𝑚𝑒−𝑛𝑥 
𝐿𝑛 (
𝑦
𝑚)
−𝑛
= 𝑥 
Equation 5 Equation utilised for the extrapolation of scavenger quantity 
needed to remove enough iridium to match the value measured for deionised 
water x. 
The average iridium concentration detected in n=5 deionised water blanks run 
before the experiments described in section 8.8.3 was 0.2126 ppb.  
For all time points y = 1708.7e-nx therefore the value of 𝐿𝑛 (
𝑦
𝑚
) does not change 
from -8.99194. 
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